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ABSTRACT 
Manganese is a prominent heavy metal within the earth’s crust and a micro mineral essential for 
biological function, however, high level exposure may lead to neurological defects. Industrial 
activities allow elevated manganese (Mn2+) to enter air and waterways. The Environmental 
Protection Agency (EPA) implements secondary standards for aesthetics in drinking water at 
0.05 ppm Mn2+, although evidence indicates levels at, or below this concentration negatively 
impact aquatic life. Crayfish (Procambarus clarkii) were exposed to environmentally relevant 
Mn2+ concentrations for 6 months, while the control group was kept in reconstituted fresh water 
for the same time period. During this time, crayfish were placed in a novel environment weekly 
and videotaped for 20 minutes. Control crayfish continually increased time and distance moved 
throughout the 6 months while remaining mostly in border regions, but freely exploring the 
novel environment. Animals treated with lower Mn2+ concentrations moved lesser time and 
distances, while darting between zones. The highest concentration Mn2+ treatment continually 
moved elevated time and distances while remaining concealed within the border throughout the 
experiment. When threat-avoidance behaviors were analyzed over the weeks, control crayfish 
continually increased stopping behavior and reduced escape behavior.  Mn2+ treated crayfish 
displayed suppressed tail-flip frequencies indicating neurological impact; however, in later 
weeks, they increased tail-flip and startle response frequencies compared with the control group. 
Based upon my data, I suggest manganese exposure at levels below EPA standards may lead to 





Manganese is a prominent component of the earth’s crust and is essential for biological 
function in trace amounts. The Environmental Protection Agency (EPA) implements secondary 
standards for aesthetics in drinking water at 0.05 ppm manganese (U.S EPA 2017); however, 
anthropogenic exposure to manganese concentrations at, and below, 0.05 ppm have been 
associated with negative health effects in aquatic life (Antonsen and Chandi 2018; Antonsen et 
al. 2018). Crayfish are useful indicator species due to their widespread geographic location 
(Hobbs et al. 1989) and sensitivity to metal contamination (Reynolds and Souty-Grosset 2012; 
Fernandez-Cisnal et al. 2018). Furthermore, invertebrates provide simplified neural networks 
allowing investigation of cellular changes which may be shared throughout taxa (Krasne and 
Edwards 2002). The current study investigates chronic effects of manganese (0.0014 ppm Mn2+, 
0.0028 ppm Mn2+, 0.014 ppm Mn2+) on Procambarus clarkii behavior. 
Routes of Exposure  
Manganese ores comprise 0.1% of the earth’s crust (ATSDR 2012) where natural erosion 
and volcanic eruptions make it more readily available to organisms (WHO 2004). Manganese is 
spread throughout the environment where it is commonly present in natural waterways below 0.2 
ppm (Reimer 1999) and in the air below 0.07 μg/m3 (WHO 1999). Despite the environmental 
abundance of manganese, the primary intake route for organisms is via dietary sources (Aschner 
and Aschner 2005). Various nutritional sources composing typical diets including rice, nuts, 
green vegetables, tea, and chocolate allow humans to adequately reach the recommended levels 
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of 1.8-2.3 mg/day (ATSDR 2012) for proper neurological, enzymatic, and metabolic functions 
(Aschner and Aschner 2005; Santamaria 2008). 
Common sources of elevated manganese exposure that may lead to toxicity include the 
gasoline additive methyl cyclopentadienyl manganese tricarbonyl (MMT), fertilizers, cosmetics, 
magnetic resonance imaging (MRI) techniques, and nutritional supplements including total 
parenteral nutrition (TPN) and baby formulas (Aschner and Aschner 2005; Chen et al. 2016). 
The Food and Drug Administration (FDA) implements minimum nutritional requirements for 
infant formula, but has not established maximum nutritional standards. While physicians 
recommend consumption of 3 µg Mn2+/day, formula may expose infants to 17x the daily 
recommendation (O'Neal and Zheng 2015). Due to manganese’s essentiality in brain 
development, toxicity is of high concern during the 1st week of life. Premature newborns are 
especially at risk when receiving TPN as manganese bypasses the GI tract, leading to 100% 
retention entering the blood stream (Aschner and Aschner 2005). Prenatal and postnatal exposure 
to elevated manganese levels are linked to increased mortality (Spangler and Spangler 2009) and 
birth defects (Kilburn 1987). 
Toxicity 
In humans, elevated manganese exposure may cause a Parkinsonian-like condition, 
known as manganism (Perl and Olanow 2007). Although both disorders target the basal ganglia, 
Parkinson’s disease is characterized by dopaminergic neurodegeneration within the substantia 
nigra pars compacta (Lees et al. 2009) while manganese preferentially accumulates within 
globus pallidus neurons (Guilarte 2010). Manganism’s biphasic symptoms involve initial 
psychiatric decline including memory loss, emotional disturbance, and compulsive behaviors 
followed by motor deficits including postural instability and muscle rigidity (Calne et al. 1994). 
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Both disorders disrupt cellular mechanisms resulting in oxidative stress, excitotoxicity, 
mitochondrial dysfunction, and apoptosis which are often manifested through bradykinesia, 
dystonia (prolonged muscle contraction) and hypokinesia (decreased bodily movement) 
(Barbeau 1984). Symptomatic resemblance between Parkinson’s disease and manganism may be 
due to each disease directly or indirectly altering basal ganglia chemicals including dopamine, 
GABA (gamma-Aminobutyric acid), or glutamate levels responsible for sensory feedback, 
voluntary movement control, procedural learning, postural stability, and other cognitive 
functions (Kwakye et al. 2015); slight disruption of one of these chemicals may lead to 
dyshomeostasis of the entire network. 
Concern for manganese toxicity first arose in 1837 following examination of manganese 
ore factory workers who exhibited Parkinson-like symptoms (Couper 1837). Since then, 
workplace manganese toxicity has become a widespread research topic, with specific focus on 
welders who are regularly exposed to welding fumes which were recently classified as 
carcinogenic (Guha et al. 2017). Inhaled fume particles, typically MnO2, can result in pulmonary 
inflammation (ATSDR 2012) where macrophages phagocytose and solubilize the foreign 
particles. Soluble particles may cross the pulmonary epithelial lining and enter the blood stream 
(Quintanar 2008). Smaller particles not trapped within respiratory mucus are readily taken up via 
the olfactory tract, bypassing the blood-brain barrier (BBB) and traveling directly to sensory 
areas of the brain (Elder et al. 2006; Quintanar 2008; ATSDR 2012).  
The Occupational Safety and Health Administration (OSHA) implements airborne 
standards at 5 mg/m3 manganese per 8-hour workday although subclinical symptoms including 
impaired eye-hand coordination and decreased neurobehavioral test scores have been observed in 
workers chronically exposed to manganese concentrations near 0.07 mg/m3 manganese  (ATSDR 
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2012). Decreased neurobehavioral performance of manganese-exposed workers have been 
correlated with significant globus pallidus and cerebellum volume reductions (Chang et al. 
2013). 
The EPA implements secondary standards for aesthetics and cosmetics in drinking water 
at 0.05 ppm manganese stating that manganese concentrations at, or around these standards may 
cause reduced water clarity and unfavorable bitter taste (U.S EPA 2017). Manganese is not 
currently considered threatening to human health at the secondary standard maximum 
contaminant level (U.S EPA 2017). However, U.S regions with high levels of industrial 
manganese discharge are correlated with elevated rates of manganese-induced Parkinsonism 
(Chen et al. 2014). Communities surrounding industries that use or release manganese are often 
exposed to both airborne and manganese contaminated water, considered safe by EPA secondary 
standards, correlated with motor impairment and other neurobehavioral symptoms (ATSDR 
2012; Peres et al. 2016). Residents near the Eramet Marietta, Inc (Marietta, OH) ferromanganese 
refinery exhibited postural instability significantly associated with manganese exposure (Rugless 
et al. 2014).    
While there have been substantial advancements in understanding the potential threats of 
industrial manganese exposures and consumption of contaminated drinking water in humans, 
environmental impacts on other organisms, especially invertebrates, remain largely unexplored. 
Most mammalian studies focus on elevated manganese levels well above the threshold for 
manganism, while recent studies suggest that chronic low-level exposure may cause behavioral 
and motor dysfunction in addition to cognitive deficits. Evidence has recently arisen indicating 
neurotoxicity in invertebrates as result of low-level manganese contamination, expanding the 
focus of manganese toxicity beyond mammalian models. Behavioral and cellular impacts have 
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been observed in Caenorhabditis elegans worms, fruit flies, honeybees (Ben-Shahar 2018) and 
aquatic organisms including starfish (Sköld et al. 2015) and crustaceans (Tunca et al. 2013; 
Ponzoni 2017). Consequently, long-term low-level manganese exposure may adversely impact 
animal physiology with potentially detrimental effects in the ecological community expanding 
beyond the immediate focus of human health. 
Environmental Impacts 
Manganese Chemistry 
Manganese may transition between eleven oxidation states and is capable of forming 
solid and soluble compounds (Pinsino et al. 2012). In aquatic systems, manganese most often 
oscillates between Mn2+ and Mn4+, with the former being the most bioavailable (WHO 2004). 
While Mn3+ may also be present, it is inherently instable and transitions to Mn2+ or Mn4+ 
(Armstrong 2008). Redox conditions and pH determine the chemistry of manganese with anoxic 
(Middelburg and Levin 2009) and low pH environments, observed in acid mine drainage 
(AMD), favoring soluble manganese (Mn2+) while higher pH favors water- insoluble manganese 
(Mn4+) (LaZerte and Burling 1990).  
When present in the divalent form, manganese pairs with oxygen, chloride, sulfate, or 
bicarbonate (ATSDR 2012). Mn2+, in the presence of aerobic environments, portrays complex 
oxidation/precipitation reactions that render the manganese biologically unavailable as MnO2. 
Mn2+ oxidation processes occur at a much slower rate in water (Zaw and Chiswell 1999) ranging 
from days to years depending on water conditions (Stokes et al. 1988). Microorganisms are 
primary factors in aquatic chemical cycling, catalyzing otherwise slow manganese redox 
reactions within anoxic sediments and releasing solubilized Mn2+ into the water column (Fig. 1) 
(Pinsino et al. 2012). Oxidation back into insoluble manganese most often occurs within oxic 
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water layers where Mn2+ combines with oxygen to form precipitates observed as dark, dusty 

































Figure 1. Aquatic Manganese Cycle 
Aquatic manganese reduction occurs within the sediment (anoxic) while oxidation occurs at a 
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Anthropogenic manganese impacts are worldwide due to global utilization in dry-cell 
battery production, fertilizers, brick and paint colorant, and gasoline additives (Chen et al. 2016). 
Major Appalachian industries including steel production (Haynes et al. 2010; ATSDR 2012; 
Rugless et al. 2014) and mining (Hartman et al. 2005; ATSDR 2012) expose people, as well as 
the surrounding environment to elevated manganese levels they would not typically encounter. 
Sixteen million tons of manganese ore is annually extracted worldwide with little regulation on 
manganese release and waste disposal (Cannon et al. 2017). Approximately 90% of U.S 
imported manganese is used in steel production resulting in release of 6,185 tons of manganese 
and over 73,000 tons of manganese-containing compounds (U.S EPA 2011B). According to the 
U.S Geological Survey, manganese ore is most often imported to plants concentrated in
midwestern and eastern United States (USGS 2017; ATSDR 2012) where it is converted to 
ferromanganese for later use as a deoxidizer and strengthener in steel (Canno 2014). Throughout 
this conversion process small manganese particles are released into the air, eventually settling 
and depositing into soil (Canno 2014; ATSDR 2012). The longest operating ferromanganese 
refinery in the country (Eramet Marietta, Inc.- Marietta, OH) releases over 100,000 pounds of 
manganese annually (Rugless et al. 2014). There are over 3,000 manganese-releasing facilities 
across the country with nearly 500 located in Ohio and Pennsylvania emphasizing the specific 
concern for the Appalachia region (Fig. 2) (ATSDR 2012).  
Mountaintop removal is a surface mining technique where sediment over coal seams is 
removed to unearth underlying coal. Explosives are utilized to remove as much as 300 vertical 
meters of mountain-top (U.S EPA 2011) exposing pyrite and manganese ores deep within the 
earth’s crust which then often become deposited into waterways. When pyrite, an iron sulfide, is 
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exposed to water and aerobic bacteria, it is oxidized to form strong acidic components of acid 
mine drainage (Stumm and Morgan 1996); these low pH environments favor manganese 
reduction to its more bioavailable form (Mn2+) (LaZerte and Burling 1990). 
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Figure 2. Central Appalachia Industry 
Overlapping areas of central Appalachia active coal fields (U.S EPA 2003; U.S EPA 2005) and 
steel industrialization (U.S EPA 2016) in relation to Huntington, WV. 
Steel Industry 
Central Appalachia Coal Fields 
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Waterways downstream of mountain-top removal sites are often acutely lethal to standard 
invertebrate toxicity models and likely contribute to decreased biota (Turner et al. 2013). It is 
common for mine effluent to contain manganese levels ranging from 5 to 10 ppm, reaching more 
than 50 ppm in extreme cases (Johnson and Hallberg 2005). While manganese is a main 
component of acid mine drainage (Johnson and Hallberg 2005), mine effluent contains many 
environmental contaminants, so it cannot be determined if manganese is the main toxicity source 
(U.S EPA 2011). A ten-year study (1992-2002) estimated that 12 million acres of coalfields were 
responsible for contaminating over 1,944 km, or nearly 2% of stream miles within central 
Appalachia with projections indicating the mining footprint to have doubled in recent years (U.S 
EPA 2011).  
Furthermore, there are often natural manganese-rich sediment nodules along benthic 
marine regions (Bonatti and Nayudu 1965; Wang et al. 2011). Increasing water temperatures and 
eutrophication, due to anthropogenic activity (IPCC 2013), may compound toxic effects of 
aquatic Mn2+ waste by decreasing dissolved oxygen and favoring bioavailable manganese release 
from benthic stores (Bertone et al. 2016). These conditions reduce manganese oxidation 
efficiency, breaking the typical interconversion cycle and releasing excess Mn2+ into the water 
column (Fig. 3) (Middelburg and Levin 2009; Bertone et al. 2016).  
As suboxic conditions escalate, there is little benthic manganese cycling, and trace metals 
drastically decline due to source metal depletion within sediment reservoirs (Lenz et al. 2015). If 
dissolved oxygen levels eventually restabilize, trace metal oxidation occurs much slower than 
reduction, allowing Mn2+ to remain in the water column for several weeks following the hypoxic 
event (Krang and Rosenqvist 2006). High manganese-oxide reduction rates combined with slow 
oxidation may lead to 1,000-fold increase in soluble manganese (Trefry et al. 1984; Aller 1994). 
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Figure 3. Changes in Manganese Cycle via Anthropogenic Activity 
Elevated manganese concentrations may be released directly into waterways, or into the air as 
particulate matter pairing with oxygen where it eventually falls to the ground. Global 
anthropogenic activity leading to increasing water temperatures and organic load may reduce 
oxygen availability, further elevating Mn2+ within the aquatic ecosystem. Escalating suboxic 
conditions favor manganese Mn2+ dissolution into the water column with little-to-no occurrence 
of benthic recycling. Acidic environments are a compounding effect of anthropogenic activity 
which strongly favor Mn2+ further dysregulating the manganese cycle. Elevated bioavailable 
manganese may then be taken up by aquatic organisms, used by plants, and may contaminate 
human drinking water (Middelburg and Levin 2009).  
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Mechanisms of Toxicity 
Manganese is essential in minute concentrations for many physiological functions 
(ATSDR 2012), while elevation above an unknown threshold may deregulate manganese-
dependent and manganese- independent mechanisms resulting in neural damage, lung 
inflammation, and immune dysfunction (Keen et al. 2013). Effects of elevated manganese 
levels may be compounded by its essentiality in a multitude of biological pathways. Each 
pathway tolerates manganese differently depending on form, exposure route, and concentration, 
resulting in complex concentration-independent changes for any system. 
Transporters 
Several mechanisms are critical for movement of manganese throughout the body, 
although elevated exposure may exploit these pathways often rendering their proper biological 
function ineffective. Mn2+ is found within blood plasma as freely dissolved ions, or bound to 
albumin and β-globulin proteins (O'Neal and Zheng 2015). Mn2+ uptake from blood plasma and 
transport into target cells predominantly occurs via divalent metals transporter-1 (DMT1) 
(Aschner et al. 2007). DMT1, primarily responsible for iron, calcium and zinc movement, is 
highly expressed within iron-rich regions of the central nervous system (Burdo et al. 2001). 
DMT1 activity is regulated by iron levels, although it binds Mn2+ with relatively higher affinity, 
making their metabolism interdependent (Garrick et al. 2006, Thompson et al. 2007). For this 
reason, it is postulated that DMT1 may be an important mechanism behind neurodegeneration as 
increased expression is often observed in Parkinson’s disease (Salazar et al. 2008) and 
manganese toxicity (Molina et al. 2011). DMT1 expressed within BBB capillary endothelial cells 
are responsible for Mn2+ transport into the central nervous system (CNS) (Quintanar 2008) 
where Mn2+ may be directly imported into neurons (Peres et al. 2016).  
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Manganese typically remains as Mn2+ unless bound to ligands which favor Mn3+ and 
Mn4+ oxidative states (Armstrong 2008). The otherwise unstable Mn3+ mirrors iron, forming 
transferrin complexes for transportation to target tissues (O'Neal and Zheng 2015). When 
transferrin receptors (Peres et al. 2016) expressed in neurons, astrocytes, and BBB endothelial 
cells (Michalke and Fernsebner 2014) recognize the complex, the cell membrane folds inward 
forming an endocytic vesicle (Peres et al. 2016). Ferrireductase, released by DMT1, may also 
reduce Mn3+ to Mn2+, thereby mediating manganese-transferrin dissociation (Tuschl et al. 2013) 
and allowing influx via DMT1. 
It has recently been discovered that Mn2+ structurally mimics endogenous molecules of 
numerous transporters within the DMT1 family in order to transverse cell membranes. This 
transporter family is highly conserved among taxa ranging from yeast to humans (Bozzi et al. 
2016). Manganese-specific transporters have yet to be identified providing reasoning behind use 
of calcium, iron and other metal-transport systems (Chen et al. 2015).  
Of these metal-specific transporters, zinc transport proteins (ZIP 8 and ZIP 14) are of 
particular importance (Chen et al. 2014). Zip 8 and Zip 14 are expressed within the nasal 
respiratory epithelium where they are influential in the passage of inhaled manganese across the 
epithelial lining and into the blood stream (Genter et al. 2009). Furthermore, expression within 
olfactory neurons could lead to inhaled manganese being directly transported to the brain (Genter 
et al. 2009), as is common when exposed to welding fumes. 
It is possible that elevated manganese exposure can alter crayfish behavior through 
similar physiological pathways. Crustacean gills contain metal transporters similar to the 
mammalian DMT1, providing a main site of Mn2+ influx (Ponzoni 2017) through the gill 
epithelium and directly into the hemolymph. Manganese binds to hemolymph, without 
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substituting for copper, to be carried throughout the body where it may influence the function of 
numerous tissues (Fig. 4) (Baden and Neil 1998). 
Additionally, crayfish have a glial perineurium, which has analogous protective roles as 
the vertebrate BBB (Butt et al. 1990). Similar to how inhaled manganese may bypass fish (Tjalve 
et al. 1995) and other vertebrate BBB (Elder et al. 2006; Quintanar 2008), manganese may enter 
crustacean chemoreceptor organs located on the antennules providing a direct neuronal path to 
the supraesophageal ganglion (brain) (Baden and Neil 1998; Krang and Rosenqvist 2006). In 
manganese-exposed fish, manganese may also compete for chemosensory receptor binding sites 
(Rehnberg and Schreck 1986), while Mn4+ precipitates may cover chemoreceptive hairs, thereby 






























Figure 4. Manganese Exposure Routes in Crayfish 
Dissolved manganese potentially may enter via gills or antenna, and non-soluble forms are 
precipitated on the exoskeleton or may be consumed via diet. The combination of these exposure 
routes allows manganese to target nerve tissue and spread throughout the body via hemolymph to 
affect muscle contraction, exoskeletal formation, hepatopancreas integrity, and even immune 
function (Baden and Neil 1998). 














Additionally, manganese uses membrane transport proteins, responsible for chemical 
messenger movement, for neural influx (Erikson et al. 2005). While few detailed studies on 
crayfish dopamine active transporters (DAT) have been conducted, all bilaterian animals retain 
the DAT gene; substrate selectivity of the fruit fly parallels that of mammalian DAT, suggesting 
an evolutionary conserved mechanism (Pörzgen et al 2001). In mammalian models, DAT are 
highly expressed in substantia nigra, globus pallidus and striatum neurons for inducing 
presynaptic dopamine reuptake (Chen et al. 2015). Chronic manganese exposure has been 
associated with decreased DAT density and activity indicating that manganese toxicity plays a 
direct role in dopamine movement (Chen et al. 2015). Additionally, manganese can induce 
dopamine autoxidation, via similar mechanisms observed in Parkinson’s disease, resulting in 
reactive oxygen species (ROS) production and apoptosis (Lloyd 1995). 
In comparison, manganese neurotoxicity may alter the expression of GABA transporter 
proteins in rats receiving manganese contaminated drinking water (Anderson et al. 2008). The 
sodium-dependent presynaptic GABA transporter 1 (GAT1), and extra-synaptic GABA 
transporter 3 (GAT3) are responsible for astrocytic GABA reuptake (Kersanté et al. 2012). GAT 
are in the same transporter family as DAT, suggesting manganese may have similar binding 
affinity for each (Fordahl and Erikson 2014). GABA transporters, similar to mammalian GAT, 
have been discovered in the tobacco hornworm (Mbungu et al. 1995) and cabbage lopper (Gao et 
al. 1999) further indicating GABA transport may be similarly impacted by Mn2+ exposure across 
taxa. 
There are only four identified mammalian pathways capable of exporting manganese to 
successfully maintain the tightly regulated homeostatic environment. Of these four mechanisms, 
solute carrier family 30 member 10 (SLC30A10) proteins are particularly interesting because a 
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recessive mutation within SLC30A10 is associated with manganese-induced Parkinson’s disease 
(Tuschl et al. 2013). Being that this protein is highly expressed within both the liver and basal 
ganglia, this mutation may lead to excretion failure and manganese retention within the brain 
(Quadri et al. 2012). 
Chemical Disruption 
Although manganese accumulation has been extensively studied in several vertebrate and 
invertebrate Parkinsonism models, absence of Lewy bodies (characteristic of Parkinson’s 
disease) (Perl and Olanow 2007) and lack of recovery after levodopa treatment (therapeutic drug 
to treat early Parkinson’s disease) (Pal et al. 1999) suggest a differing dopaminergic 
pathophysiology for manganese toxicity. Dopamine is the most abundant catecholamine in 
crustaceans (Fingerman and Kulkarni 1993) functioning as a neurotransmitter and neurohormone 
within hemolymph (Elofsson et al.1982), pericardial organs, and the X-organ-sinus gland (Cooke 
and Sullivan 1982; Elofsson et al. 1977) where it modulates locomotion, cognition, 
osmoregulation (Tierney et al. 2003), sexual maturation and courtship display (Wood et al. 
1995). Dopamine’s diverse range of physiological effects within the crustacean nervous system, 
not only signifies its importance, but indicates numerous mechanisms that manganese may 
influence. When neotropical freshwater crabs were exposed to Manganese (II) chloride (MnCl2) 
for 72 hours, Mn2+ accumulation within cerebral ganglion resulted in reduced catecholamine 
signaling (Ponzoni 2017). Effects of manganese toxicity in crustaceans may also reflect 
dopamine interaction in higher organisms, as this biogenic amine is widely conserved across taxa 
and abundant in vertebrate nervous systems. How metal toxicity impacts invertebrate cell 
integrity may provide information on cellular mechanisms underlying manganism and 
Parkinsonian-like syndromes.  
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The serotonergic system is also affected by exposure to excess Mn evidenced by reduced 
5-HT in the brain of rats fed a high-manganese diet (Kimura et al. 1978) and significant 5-HT 
reductions in several brain regions of Mn-exposed rhesus monkeys (Struve et al. 2007). 
Serotonin (5-HT) is a neurotransmitter, modulator, and hormone that influences memory and 
avoidance learning in snails (Han et al. 2010), increases heart and locomotion rate in aplysia 
(Marinesco et al. 2004), and regulates the master clock (Medanic and Guillette 1992), mood, 
appetite, memory, and learning in higher organisms (Mohammad-Zadeh et al. 2008). Serotonin 
has modulatory roles within neural circuitry of crayfish Lateral Giant command fibers (Antonsen 
and Edwards 2007), the crayfish neuromuscular junction (Wang and Zucker 1998), P. clarkii 
circadian rhythm correlated with motor and sensory activity (Galeano 1976), crayfish aggression 
(Tierney et al. 2004), and is important for the crayfish stress response (Fossat et al. 2015).  
The crayfish neuroendocrine system, the X- organ/sinus gland, consists of 
neuroendocrine cells that synthesize, store, and secrete crustacean hyperglycemic hormone 
(cHH) as a stress response. Serotonin controls cHH secretion which ultimately increases 
hemolymph glucose levels as fight/flight preparation (Loredo-Ranjel et al. 2017); dopamine 
(Sarojini et al. 1995) and GABA (Perez-Polanco et al. 2011) are also suggested to partially 
regulate cHH release. Hyperglycemia is common after exposure to environmental stressors 
including manganese contamination (Lorenzon et al. 2005). Previous studies within the 
Antonsen lab have discovered that low-level MnCl2 exposure disrupts 5-HT levels within the 
crayfish ventral nerve cord (Antonsen et al. 2018). Furthermore, chronic stress (Fossat et al. 
2015), possibly via elevated manganese exposure, and social stress (Bacque-Cazenave et al. 
2017) may induce prolonged 5-HT elevations within the P. clarkii brain that are correlated with 
anxiety-like behavior. Elevated 5-HT within the glial perineum may be a direct result of stress 
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(Fossat et al. 2015). Analyzing how environmental contamination may indirectly influence cHH 
levels and the underlying modulatory mechanisms may provide useful information on the 
manganese-induced stress response of aquatic organisms.  
GABA, the main inhibitory neurotransmitter in crustaceans, is released at the motor 
synapse (Horwitz and Orkand 1980) and may function to regulate x-organ stress hormone release 
(Perez-Polanco et al. 2011). While it is postulated crayfish exhibit GAT similar to mammalian 
models, Mn2+ impacts on crustacean GABA remain mostly unexplored and are not completely 
understood. In humans, it is believed manganism differs from Parkinson’s disease, in that 
manganese preferentially targets the GABA-rich globus pallidus and substantia nigra pars 
reticulata (Fig. 5) (Yamada et al. 1986; Guilarte et al. 2006; Bowman et al. 2011) rather than 
damaging dopaminergic neurons within the substantia nigra pars compacta (Perl and Olanow 
2007). Improper GABA levels in humans are associated with psychiatric disorders that resemble 
early manganism including bipolar disorder, anxiety, and schizophrenia (Torrey et al. 2005). 
Symptomatic resemblance further suggests that GABA dysfunction contributes to the onset of 
manganese toxicity. 
In vivo studies have reported conflicting results as to whether GABA concentrations 
increase or decrease after manganese exposure. Rats receiving sub-toxic manganese exposure, 
displayed a dose-dependent increase in extracellular GABA, prior to changes in dopamine levels, 
resulting in a 30-60% reduction in motor levels (Gwiazda et al. 2002). These results were 
consistent with earlier rodent observations (Bonilla 1978; Lipe et al. 1999) while other studies 
discovered reduced GABA levels after exposure to elevated manganese thereby complicating 
matters (Brouillet et al. 1993; Seth et al. 1981). Regardless of underlying changes, GABA 
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imbalance may dysregulate major inhibitory signaling throughout mammalian (Sigel and 















































































Figure 5. Basal Ganglia Circuitry 
Simplified representation of the basal ganglia circuitry that illustrates the hypothesized primary 
manganese toxicity targets being the globus pallidus, and to a lesser degree, the substantia nigra. 
Green arrows represent glutamatergic (excitatory) input, red arrows represent GABAergic 
signaling (inhibition), and purple arrows represent dopaminergic signaling. Globus pallidus 
neurodegeneration may lead to decreased GABA causing overstimulation of downstream 
circuitry, as well as, dopamine dysregulation (Fitsanakis and Aschner 2005). Due to the 
neurotransmitters within the basal ganglia circuitry being interrelated, manganese impact on one 
















Manganese toxicity is associated with glutamate metabolism disruption leading to 
changes in excitatory cellular communication. Glutamate is a prominent neurotransmitter within 
the crustacean ventral nerve cord where it is used as an excitatory signaler between neurons and 
muscle fibers (Kawagoe et al. 1981; Schneider et al. 2018). It is believed glutamate also mediates 
axon-glia communication in both crayfish and squid (McKinnon et al. 1995). It is believed that 
enzymatic reactions comparable to the vertebrate system interconvert glutamate and glutamine 
within crayfish giant nerve fibers (McKinnon et al. 1995).  
In a normally functioning vertebrate system, glutamate is removed from the synapse by 
astrocytes where glutamine synthetase, responsible for synaptic termination and metabolic 
regulation of glutamate, converts it into glutamine (Tholey et al. 1987). Glutamine is then 
available for reuptake by glutamatergic cells, or GABAergic neurons as a precursor for GABA 
production (Tholey et al. 1987; Fitsanakis and Aschner 2005). Chemical uptake from the 
synaptic cleft as well as this interconversion mechanism must be highly regulated to prevent 
over-excitation. Similar to mammals, crustacean glutamine synthetase is localized within glial- 
like cells whereas glutaminase is distributed between these cells and axons (Engler et al. 2002). 
Exposure to elevated manganese may, therefore, similarly impact crustacean glutamine 
synthetase, as well as, glutamate and GABA function. 
Manganese is an important co-factor for metalloenzymes, especially glutamine 
synthetase, which contains approximately 80% of manganese available in the brain (Wedler 
1994). Improper manganese homeostasis may inhibit glutamate reuptake from the synaptic cleft 
leading to excitotoxicity. In the brain, excessive glutamate levels may compromise the striatum 
due to its dense glutamatergic input from the cerebral cortex (Fitsanakis and Aschner 2005). A 
13-week study exposing rats to MnCl2 contaminated drinking water revealed no tissue damage, 
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but the number, intensity, and activity of glutamate synthetase expressing cells were decreased 
(Morello et al. 2007). Elevated Mn2+ concentrations strongly inhibit glutamate synthetase 
activity (Tholey et al. 1987) while manganese deficiency reduces glutamine synthetase activity 
(Wedler and Denman 1984). These data suggest glutamine synthetase properly functions under 
strict conditions that may be regulated by Mn concentration.  
Additionally, non-human primates exposed to elevated Mn2+ exhibited reduced cerebral 
cortex N-acetyl-aspartyl glutamate (NAAG) metabolite levels which are important for 
glutamatergic neurotransmission (Guilarte and Chen 2007). NAAG interacts with N-methyl-d-
aspartate (NMDA) receptors which have roles in learning/memory. NMDA receptors have 
divalent cation binding sites which typically allow magnesium (Mg2+) to modulate activity, 
although Mn2+ may directly inhibit these channels at a much lower inhibitory constant (Ki) 
(Guilarte and Chen 2007). Therefore, exposure to elevated manganese levels may lead to 
synaptic plasticity reduction and learning/memory impairments. Furthermore, communication 
between striatal dopamine D1 and ionotropic glutamate NMDA receptors are important for long-
term memory consolidation. Manganese exposure, however, may decrease both D1 and NMDA 
receptor expression (Song et al. 2016). 
Although attention towards the cholinergic system is scarce, it may provide useful 
insights to the pathophysiology of manganese toxicity. In crustaceans acetylcholine (ACh) 
modulates swimmeret movements (Mulloney and Hall 2007), activates coordinating interneurons 
(Schneider et al. 2018), and is a neurotransmitter used by sensory neurons (Braun and Mulloney 
1993). Limited research has been conducted on elevated manganese concentrations influencing 
ACh in crustacean models, although impacts on other invertebrate models may provide 
information on how crustacean ACh mechanisms may be influenced. 
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Within vertebrates and invertebrates, choline acetyltransferase (ChAT) synthesizes ACh 
within nerve terminals, while acetylcholinesterase (AchE) is responsible for transmission 
termination. AchE inhibition may lead to tetanic neuromuscular paralysis, while AchE 
overstimulation results in suppressed neuromuscular performance. Starfish exposed to MnCl2 for 
two weeks displayed a 50% reduction in turnover capacity which was believed to be due to 
elevated AchE activity (Sköld et al. 2015). Turnover capacity was not restored even after two 
weeks of recovery (Sköld et al. 2015). In vertebrate models, acetylcholine is a basal ganglia 
chemical (Santos et al. 2012B), as well as the main excitatory neurotransmitter at the 
neuromuscular junction and synapses of the visceral motor system (Purves 1970). Juvenile rats 
receiving MnCl2 showed no changes in AchE activity (Lai et al. 1984) while treated adult rats 
displayed an increase in AchE activity (Lai et al. 1992) indicating that manganese differently 
impacts AchE depending on developmental stages.  
Calcium Homeostasis 
Calcium (Ca2+) is the most abundant mineral in the body, essential for intracellular 
communication governing functions including bone health (Zhang et al. 2014), neurotransmitter 
release (Sudhof 2012), muscle contraction (Szent-Gyorgyi 1975), metabolism (Haydon and 
Carmignoto 2006), and is crucial in second messenger cascades with wide-ranging physiological 
roles (James and Butt 2002; Clark et al. 2008). Specialized homeostatic mechanisms within 
neurons and glia ensure Ca2+ levels are tightly regulated at very low concentrations allowing 
slight Ca2+ elevations to efficiently activate nearby pathways for proper cellular function. 
However, excessive Ca2+ accumulation may exceed the capacity of these regulatory mechanisms 
leading to inapt activation of Ca2+ pathways and potential excitotoxicity. Abnormal Ca2+ 
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signaling is a common factor within neurodegenerative disorders due to its homeostatic 
importance in neural viability (Bezprozvanny 2009; Liu et al. 2015).  
Manganese binds to Ca2+ sites with high affinity, typically outcompeting calcium (Gunter 
et al. 2010) and can use voltage-gated and store-opened Ca2+ channels for cellular influx 
(Crossgrove and Yokel 2004). It is possible that manganese may impact any Ca2+ dependent 
chemical release including the aforementioned neurotransmitters as well as signal cascades. Ca2+ 
ions are vital components of crustacean physiology important for metabolic activity, exoskeletal 
formation, and glutamatergic release at the crayfish neuromuscular junction (Kupchik et al. 
2008). At rest, soluble NSF attachment receptor (SNARE) proteins and synaptotagmin 
machinery are tonically inhibited by a presynaptic inhibitory G protein-coupled autoreceptor. 
Upon depolarization, the autoreceptor goes through a conformational change and uncouples from 
the machinery to relieve the tonic block. Proper functioning machinery along with Ca2+, that 
enters via voltage-gated channels, allows for neurotransmitter release (Kupchik et al. 2008) and 
binding to receptors on the sarcolemma required for muscle depolarization (Fatt and Ginsborg 
1958). Mn2+ accumulation may suppress muscle membrane depolarization and decrease 
neuromuscular performance via direct competition at sarcolemmal Ca2+ channels (Fatt and 
Ginsborg 1958). Norway lobsters exposed to MnCl2 for three weeks displayed inefficient muscle 
contraction leading to a 40% reduction in tail-flip extension (Holmes et al. 1999). All synapses, 
including inhibitory GABA release at the crayfish neuromuscular junction (Harris-Warrick 2005) 
and cholinergic signaling at vertebrate neuromuscular junction (Parnas and Parnas 2007), operate 




In crustaceans, proper Ca2+ concentrations are crucial in post-molt exoskeletal 
calcification. The crayfish exoskeleton serves as a protective barrier consisting of hardened, 
calcified layers (Nagasawa 2012).  The rigid exoskeleton confines crayfish to discontinuous 
growth and thus must be shed for development to occur (Calhoun and Zou 2016). Prior to 
crayfish molting, exoskeletal Ca2+ is excreted via gills, or resorbed into two disc-like calcium 
carbonate structures known as gastroliths (Wheatly and Gannon 1995). During post-molt, both 
gastrolith remobilization and environmental Ca2+ uptake form carbonate salts essential for mouth 
part, carapace, chelipeds, and dactyl hardening. While the most prominent carbonate salt formed 
is calcium carbonate, increased presence of other metal ions may replace Ca2+ thereby preventing 
proper mineralization. Proper calcification is needed to resume feeding, locomotion, and to 
sustain overall survival (Wheatly and Gannon 1995). Crayfish living in acidic waters (pH 5.4-
5.6), comparable to AMD, exhibited a three-fold increase in carapace manganese correlated with 
decreased carapace rigidity compared with crayfish from unaffected lakes (France 2011). Due to 
manganese’s ability to impact Ca2+ homeostasis, Mn2+ may displace Ca2+ at multiple sites and 
become incorporated into calcified regions of the exoskeleton thereby decreasing survivability 
(Eriksson and Baden 1998). 
Under normal physiological conditions, bones contain about 40% of the body’s total 
manganese (ICRP 1972) with oral exposure often leading to long-bone manganese accumulation 
(O’Neal and Zheng 2015). In theory, humans diagnosed with manganism could exhibit decreased 
bone density due to reduced Ca2+ and zinc absorption. Zinc-related proteins may increase bone 
formation by stimulating cell proliferation and suppressing osteoclast function (Cerovic et al. 
2007). Therefore, it is possible that nutritional zinc deficits would negatively influence bone 
health. In addition to competing at zinc transporter sites and reducing Ca2+ absorption, elevated 
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manganese inhibits alkaline phosphatase, a crucial enzyme in proper bone formation (Epstein 
1988). This evidence suggests manganese may have multidimensional abilities in disrupting 
bone formation-resorption equilibrium.  
Ca2+ is widely used as a regulatory second messenger within signal cascades with 
principal components conserved among plants and animals (Nagata et al. 2004). Manganese may 
reduce the second messenger activator, calmodulin, which responds to miniscule changes in Ca2+ 
for metabolism, learning and memory, immune response, and apoptosis regulation (Liu et al. 
2015). Further studies on rat learning and memory provide strong evidence that high manganese 
levels may produce cognitive deficits (Liang et al. 2015). Hippocampal signaling, specifically 
the cyclic adenosine 30, 50-monophosphate (cAMP) pathway and its downstream effectors, are 
essential for learning processes and memory consolidation (Liang et al. 2015). Manganese-
treated rats exhibited significant dose-dependent reductions in hippocampal cAMP levels which 
are strongly related to cognitive deficits (Liang et al. 2015). Reduced cAMP signaling may 
dysregulate downstream effectors such as protein kinase A and brain derived neurotrophic factor 
(BDNF) leading to improper hippocampal function and memory formation (Liang et al. 2015). In 
relation to cAMP reductions, rats also exhibited significant reductions in spatial learning and 
memory consistent with previous studies (Liang et al. 2015). The relationship between Ca2+ 
homeostasis and manganese concentrations provides strong evidence that key components of 
manganese toxicity are linked to calcium movement. 
Mitochondrial Dysfunction 
Manganese toxicity induces oxidative stress, alters mitochondria function and promotes 
apoptosis in both crayfish (Fernandez-Cisnal et al. 2018) and higher organisms (Malecki 2001; 
Chen et al. 2016) via multiple sources due to manganese’s wide range of biological activity. 
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Manganese-superoxide dismutase (Mn-SOD), a metalloenzyme located within mitochondria, is 
essential in detoxifying reactive oxygen byproducts of oxidative phosphorylation (Lindenau et al. 
2000). Rats receiving low-level manganese exposure displayed significant reductions in Mn-
SOD positive cell number and intensity, as well as glutamine synthetase activity, within the 
striatum and globus pallidus indicating that manganese toxicity acts in a region-specific manner 
(Morello et al. 2007).  
Neural dendrites are highly susceptible to manganese toxicity due to high mitochondrial 
density and elevated Mn-SOD concentrations needed for the high energy maintenance of Na+/K+ 
gradients and cellular communication (Gunter 2016). Additionally, astrocytes may be a target of 
manganese toxicity due to elevated oxygen requirements needed for ATP generation and proper 
brain function. Manganese induced Ca2+ inhibition may alter astrocytic communication 
responsible for regulating synaptic communication and cerebral blood flow (Gunter 2016). 
Toxic effects of increased ROS include induction of mitochondrial permeability 
transition (MPT) which increases mitochondrial permeability leading to electrochemical gradient 
loss. The reasoning behind MPT is not well understood, but it is thought to be an apoptotic 
method for controlling injured ROS-producing cells. In addition to ROS production and 
electrochemical gradient loss, Mn2+ readily binds transporters of the Electron Transport Chain 
(ETC), thus inhibiting several steps of oxidative phosphorylation contributing loss of energy 
production (Fig. 6) (Gunter and Sheu 2009; Gunter 2016).  
Direct Mn2+ inhibition of sodium dependent and independent Ca2+ efflux mechanisms 
(Gavin et al. 1999), as well as loss of energy production and electrochemical gradient may 
dysregulate the sodium-calcium exchanger, further increasing intracellular Ca2+ levels. Elevated 
intracellular Ca2+ exacerbates the effects of MPT by binding mitochondrial transition pore 
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(mPTP) activation sites on the inner mitochondrial membrane and generating additional free 
radicals (Gunter and Sheu 2009). Ultimately, exposure to elevated manganese levels may cause 
neurodegeneration via mitochondrial disruption that inhibits energy production and induces ROS 






































































Figure 6. Manganese Toxicity Impacts on Mitochondria 
Representation of the mitochondrial metabolic pathway including the electron transport chain 
and the citric acid cycle. All sites of possible manganese inhibition as listed by Gunter (2016) are 
bolded and underlined. Sites include transporters of the Electron Transport Chain including 
Complex I (Galvani et al. 1995) and Complex II (Gunter et al. 2010),  both F1 and F0 ATP 
synthase subunits (Gunter et al. 2010), glutamate-aspartate exchanger (Gunter et al. 2010), and a-
ketogluterate dehydrogenase (Gunter et al. 2010) within mitochondria of various cell types. 
Other mitochondrial components that may be impacted include intramitochondrial Mn-SOD, and 
disruption of the cell homeostasis via mitochondrial permeability transition pores (mPTP) within 






Chronic stress is typically associated with immune system suppression causing increased 
illness susceptibility (Segerstrom and Miller 2004). Immune-based regenerative mechanisms, 
including phagocyte function, may be dysregulated with chronic stress. In lobsters exposed to 20 
mg/l Mn2+ for 10 days, haemocytes (phagocytes within hemolymph) were reduced by 60% 
(Hernroth et al. 2004). Stem cell maturation into haemocytes were also suppressed, providing 
further evidence of manganese-induced immune dysfunction. Immune suppression may be the 
basis behind microbial exoskeleton infections associated with elevated manganese 
concentrations within blue crab (Weinstein et al. 1992) as well as the high parasite frequency in 
lobsters exposed to elevated manganese (Field et al. 1992; Baden and Neil 1998). Although 
limited research has been conducted on the etiology of shell disease, similar results observed in 
vertebrate models suggest manganese-induced immune suppression as a potential etiology. Birds 
exposed to MnCl2 for three months exhibited immune system oxidative damage (Liu et al. 2013) 
increasing susceptibility to disease and stress-induced illness.  
Analyzing induced immune dysfunction may provide further information on toxic 
mechanisms of manganese in invertebrates, as well as, vertebrates. Alveolar macrophages, which 
serve as the main guardian against foreign respiratory bodies, are of particular interest for 
inhaled manganese dust as these particles may pass directly to the brain (Bergstrom 1977; 
Broug-Holub et al. 1998). Like other macrophages types, alveolar macrophages specialize in 
immune surveillance as homeostatic contributors to the inflammatory process. MnCl2 exposure 
significantely altered rabbit alveolar macrophages, reducing both cell number and viability 
(Waters et al. 1975). Compromised activity, therefore, not only has implications on pulmonary 
health, but the entire immune system. 
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Reflexes and Behavior 
Neural Components of Escape 
Large, accesible neurons comprise pathways of various fast reflex escape behaviors seen 
in the crayfish tail-flip (Wine and Krasne 1972; Herberholz et al. 2004), jump take-off in flies 
(Lima and Miesenböck 2005) and the C-start in fish (Tabor et al. 2014). There are additional 
non-stereotyped mechanisms within the vertebrate and invertebrate behavioral reperotire that do 
not involve these pathways (Peek and Card 2016). When presented with an immediate threat, 
crayfish respond by activating one of three distinct tail-flip escape pathways. Two of these neural 
circuits are mediated by the large axons known as giant fibers. Bilateral giant fibers receive 
convergent input from primary afferent and sensor interneurons which relay excitatory signals to 
giant motor neurons (GMN). GMN command effector muscles to rapidly flex specific abdomen 
segments in order to tailflip (Edwards et al. 1999). Sufficient tail-fan mechanosensory hair 
stimulation provides excitatory signals to Lateral Giant (LG) fibers that thrust the crayfish 
upward into the water column (Antonsen and Edwards 2007; Herberholz et al. 2004), which is 
useful when a predator attacks from behind. Rostrally located threats stimulate visual and 
antennule sensory fibers that send excitatory signals towards Medial Giant (MG) fibers to bend 
all abdomen segments for a backwards thrust (Edwards et al. 1999; Herberholz et al. 2004; Wine 
and Krasne 1972). Both reflex mechanisms are highly stereotyped and occur very quickly. The 
Segmental Giant (SG) allows MG and LG to recruit an additional group of motoneurons known 
as the fast flexor motoneurons. When stimulation is not sufficient to activate giant fiber escape, 
fast flexor motoneurons are solely utlized. Non-giant escape is characterized by longer latencies 
attributed to ability to adjust tail-flip angle and direction prior to execution (Edwards et al. 1999; 
Herberholz et al. 2004).  
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Threat Avoidance Behavior 
Analyzing behavioral output gives insight on the complex interplay between 
environmental stressors and internal factors. This allows us to understand changes in cellular 
components behind behaviors that may be a result of poor environmental quality. This 
information may then be used to evaluate potential threat to human health. 
Juvenile crayfish live in shallow water ecosystems where they often encounter predators 
that attack from above including fish, birds, and mammals (Correia 2001). Animals survive 
predation by effectively producing prompt escape, freezing to avoid detection, or fighting to 
increase chances of survival. Escape is appropriate behavior for immediate threats, while 
freezing is often used for distant threats (Ydenberg and Dill 1986). Freezing or fighting may also 
be used during inescapable situations in order to either remain concealed, or as a last resort of 
defense (Lima and Dill 1990). When near a potentially threatening stimulus, such as a shadow 
passing over, crayfish respond with one of the above distinct behaviors. Depending on context, a 
specific response pathway is excited for appropriate behavior (Wine and Krasne 1972).  
Threat avoidance behavior is essential for all organisms and is believed to be molded by 
evolution (Law and Blake 1996) in order to achieve the highest degree of survival. For this 
reason, many cellular components including 5-HT, GABA, ACh, Dopamine, and their neural 
networks are often conserved between taxa, potentially allowing information from crustacean 
behavior to shed light onto higher organisms.  
Impacts of Stress 
A reflex, a defensive automatic response to a stimulus, either precedes, or is a component 
of threat avoidance. Short latency startle reflex, which is a response to a surprising stimulus to 
prepare the body to fight/flight, is observed across taxa. Its interruptive properties clear ongoing 
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motor, cognitive, and autonomic activity to reorient maximal neural processing towards the 
stimulus (Blumenthal 2015), immediately followed by threat avoidance behavior. Reflexes and 
behavior are correlated with an organism’s health, so deviation from stereotyped, or typical 
behavior, suggests a stressor is impacting the nervous system (Walker 1990). Environmental 
stressors may sensitize or reduce reflex actions with both hypoactive and hyperactive reflexes 
indicating neurological pathway disturbances. Both physiological and psychological stress may 
be manifested in behavior as organisms try to cope with sickness and facilitate healing. 
The stress response is essential for survival as it physiologically prepares the organism 
for fight or flight. Once the immediate stressor is gone, the body enters a resistance phase where 
it begins to repair itself by demobilizing stress hormones, resorbing mobilized energy sources, 
and normalizing heart-rate until the body is back to its pre-stress state (Selye 1950); however, 
chronic stress does not allow the body to heal and leads to physical and psychological 
exhaustion. Signs of exhaustion include fatigue and anxiety (Selye 1950) which may weaken the 
immune system and increase predation risk.  
Anxiety is exhibited in humans, while similar behavior has been observed in primates 
(Coleman and Pierre 2014) and zebrafish (Blaser and Rosemberg 2012). Fossat et al. (2015) 
suggest that crayfish exhibit similar context-independent anxiety-like behavior. Furthermore, a 
study on mice revealed olfactory manganese exposure leads to anxiety-like behavior (Ye and 
Kim 2015), while zinc deprived rats (Takeda et al. 2007) exhibit similar behavior. Perhaps there 
is a link between manganese exposure, which alters zinc homeostasis, and anxiety-like behavior. 
Additionally, elevated manganese exposure is often associated with hyperactivity and 
inattention. Interestingly anxiety disorder in humans commonly co-occurs with attention-
deficit/hyperactivity disorder (ADHD) likely due to symptom overlap (Grogan et al. 2018). 
36 
Farias et al. 2010 discovered that elevated blood manganese levels were associated with 
significantly increased rates of ADHD in children. People with ADHD often have higher 
exposure rates to environmental contaminants (Shih et al. 2018) further suggesting that elevated 
manganese exposure may influence the pathogenesis of anxiety-like and ADHD behaviors. 
Crayfish as a Model for Toxicity 
Invertebrates, such as crayfish, exhibit stereotyped reflexes homologous to vertebrates, 
but offer experimental advantages including large, accessible neurons (giant fibers) and 
decreased complexity (Edwards and Herberholz, 2005; Huber et al. 2011). These simplified 
properties, along with similar basic cellular components as vertebrates, give the ability to 
investigate mechanisms behind behaviors shared throughout taxa. 
Crayfish are known to alter behavior, including reflexes, when exposed to environmental 
changes in such a manner that may decrease anti-predatory success. Previous studies within the 
Antonsen lab have discovered that two- day manganese exposure impacted crayfish tail-flip 
angle trajectory, while two- week treatment increased other aspects of behavioral variability 
including number of tail flips performed (Lefevre et al. 2015). While additional tail flips may 
increase distance from the initial attack, this may expose the crayfish to other predators in close 
proximity and may be an expenditure of excess energy. In addition, crayfish exposed to elevated 
manganese exhibit changes in hepatopancreas histopathology (Antonsen and Chandi 2018), 
motility (Antonsen et al. 2018), growth and survivability (Antonsen et al. 2018), and serotonin 
distribution (Lefevre et al. 2015; Antonsen et al. 2018). Furthermore, ancient genes conserved 
throughout evolution code the proteins behind Ca2+ movement (Gao and Wheatly 2004). 
Therefore, understanding how invertebrate gene expression underlying Ca2+ movement may be 
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influenced by elevated manganese exposure may provide insight on mechanisms that involve 
Ca2+ dysregulation within humans (Gao and Wheatly 2004).  
Toxicity tests often focus on lethal contaminant concentrations, but sublethal levels may 
still influence an organism’s physiology and behavior (Kleerekoper 1976; Schober and Lampert 
1977; Hernroth et al. 2004; Rugless et al. 2014; Ponzoni 2017). Exposure to realistic manganese 
concentrations have shown to accumulate in crustacean nervous tissues, hemolymph, and 
muscle, (Baden and Neil 1998), neotropical freshwater crab (Dilocarcinus pagei) gill and 
hepatopancreas (Ponzoni 2017), and starfish tubefeet (Sköld et al. 2015). 
Omnivores, such as crayfish, are useful bio-indicators due to dietary intake of vegetation 
and other invertebrates which both contribute to metal accumulation (Goretti et al. 2016; 
Schilderman et al. 1999). Crayfish are keystone species in both aquatic and terrestrial food webs 
across the world, making them a manganese trophic-transfer source (Suarez-Serrano et al. 2010). 
Vertebrates (Aschner and Aschner 2005) and invertebrates (Ben-Shahar 2018) alike utilize 
manganese as a co-factor for various essential enzymatic reactions. Crayfish are valuable models 
for neuroscientists because they can provide information on neuronal mechanisms behind 
reflexes and value-based behavioral decisions (Liden et al. 2010). Studying chronic effects of 
elevated manganese on P. clarkii may provide information that can be applied towards the 
cellular and behavioral impacts on other organisms. My work has continued to expand 
knowledge of the effects of elevated manganese exposure by specifically answering how 
chronic, low-level exposure impacts motility, threat avoidance, and other behavioral aspects that 
may increase predation susceptibility.         
 





Laboratory-bred crayfish (P. clarkii) (30 females, 16 males) 3-5 cm in length (rostrum to 
telson) were selected for behavioral analysis. A total of 46 crayfish were used throughout 
experimentation, with 32 being analyzed as complete data sets (n=8 for each treatment). All 
crayfish were in good health upon selection and any adverse health effects that occurred 
throughout experimentation, specifically due to molting difficulty, were documented.  
Animals were kept in a 12-hour light/ dark cycle and assigned 1.2 L aquaria containing 
new substrate and a small shelter. Naturalistic pebble substrate (Estes’ spectrastone, Fairfield, 
NJ) used was similar to substrate found within P. clarkii habitat to decrease the presence of 
additional stressors. This substrate was easily maintained compared with finer substrates, while 
still providing a natural burrowing habitat.  
Individual housing aquaria limited social interaction to visual contact only. Crayfish 
primarily communicate via olfaction but may also interact through touch and visual cues. In P. 
clarkii, two of the three sensory inputs are required to establish dominance. A social hierarchy 
could not be established between the housing tanks, and therefore could not influence behavior 
(Callaghan et al. 2012).  All animals acclimated to this housing environment for one week before 
experimentation. Crayfish were fed Ocean Nutrition- Formula One medium pellets (Essen, 
Belgium) weekly to maintain a healthy weight and to limit mortality risk associated with 
excessive molting (Taugbol and Skurdal 1992). 
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Manganese 
Manganese (II) chloride tetrahydrate (MnCl₂·2H₂O) was obtained from a commercial 
supplier (Sigma-Aldrich, St. Louis, MO) and stored in desiccant at room temperature prior to 
use. Reconstituted fresh water was made by mixing one tablespoon all-natural freshwater 
aquarium salt (Mars Fish care North America, Inc., Chalfont, PA) with 20 liters reverse osmosis 
(RO) water; each housing tank was filled with one liter of water. A total dissolved solid (TDS) 
(HM Digital, Inc., Redondo Beach, CA) meter calibrated in sodium chloride (NaCl) ensured 
TDS within the reconstituted fresh water were between 140-150 ppm which mimicked TDS of a 
natural environment and provided adequate mineral and nutrient availability. The World Health 
Organization (2003) reports various rivers worldwide naturally containing chloride, a standard 
anion in fresh water, at concentrations higher than in the MnCl2 used in this experiment.   
Drastic TDS fluctuations may be harmful to aquatic organisms due to changes in water 
salinity and ionic composition that organisms cannot endure. However, increasing salinity daily 
by 5% intervals did not appear to stress crayfish or modify locomotion even after seawater 
salinity was reached (Bissattini et al. 2015). Sharfstein and Chafin (1979) determined that P. 
clarkii survival was not influenced by short-term elevated salinity. P. clarkii display adaptive 
behavior likely due to their ability to live in coastal environments subject to salinity variation 
(Sharfstein and Chafin 1979). This evidence supports chloride concentration fluctuation between 
MnCl2 treated water in housing aquaria and reconstituted freshwater used for experimentation 
were negligible. Treatment groups were exposed to MnCl2 (0.0014 ppm Mn
2+, 0.0028 ppm 
Mn2+, or 0.014ppm Mn2+) dissolved in the reconstituted fresh water for 6 months to investigate 
chronic effects of elevated Mn2+ while control crayfish were housed in reconstituted fresh water 
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for the same time-period. An inductively coupled plasma mass spectrometry (ICP-MS) 
determined reconstituted fresh water Mn2+ concentrations were at 0.00032 ppm Mn2+.  
Experimental Preparations 
A random number generator was used to avoid bias when assigning test days and 
treatment groups. Housing aquaria were labeled with treatment group, treatment start date, 
crayfish sex, and corresponding identification number. Crayfish were dried and marked on the 
cephalothorax with Liquid Paper Correction Fluid (Newell Brands Inc, Atlanta, GA). The 
painted region was then marked with fluorescent paint marker to ensure contrast with the 
carapace for accurate software tracking. These methods were essential for proper behavioral 
tracking; however, painting may have induced stress leading to exoskeleton molting which may 
directly impact metabolic pathways underlying locomotion, feeding, and may increase risk of 
molting-associated death. To avoid unnecessary stress that may influence behavior, crayfish 
were marked at least 48 hours prior to scheduled video recording.  
A novel 1.2L test aquarium filled with reconstituted freshwater was illuminated from 
above with an LED spectral aquarium light (Kessil Lighting- A80 Tuna Sun, Richmond, CA) 
which simulated natural sunlight (Fig. 7). Lighting was roughly equivalent to overcast daylight 
which provided sufficient illumination for recording without being an additional stressor (Judd et 
al. 1964). A camera (Canon Inc., Tokyo, Japan) was positioned on a tripod above the tank 
allowing all aquarium zones to be captured (Fig. 8). High definition recording at 30 frames per 
second (60i) captured all movements including high-speed tail-flip behavior. The tripod was 
wall-tethered for additional stability, and camera view settings were fully zoomed so that the 
field of view was confined to the aquarium. 
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A meter stick with a foam sheet (18cm x 4cm) adhered to its distal end was attached to a 
DC electric motor. When the shadow generating apparatus was manually activated, the foam 
sheet passed the light’s path casting a shadow. Shadow velocity was measured daily so that 
movement was consistently at 28 cm/s to simulate an actively searching predator. This was the 
maximum speed achievable that did not disrupt water surface and compromise video quality. 
Foam pads under the motor and tripod feet absorbed vibrations while a pedestal fan created 
interference to dampen noise outside the experimentation room. The filtered DC motor 
effectively suppressed any electromagnetic interference, and any currents that were caused by 
the motor remained consistent throughout each trial. 
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Figure 7. Experimental Set-up 
The novel aquarium was illuminated, and video recorded from directly above. An electric motor 
placed 1 meter from the arena allowed the attached arm to pass directly through the light’s path 
thereby casting a shadow. 
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Figure 8. Novel Arena Zones 
A detailed overhead view of the novel aquarium’s four border zones (Shadow origin, Top 
perimeter, Bottom perimeter, and Shadow end) and one center zone. Border zones measurements 




Crayfish acclimated in their housing aquarium for one week prior to video recording. 
Animals were recorded on a consistent weekly basis to minimize temperature fluctuation, diurnal 
bioamine variation, and other physiological parameters which could influence behavior patterns 
(Castanon-Cervantes et al. 1999). Crayfish were removed from isolated housing aquaria via a 
small aquarium fishing net and placed into the novel tank filled with reconstituted fresh water 
(Fig. 9). Recording began as crayfish were placed into the tank and lasted for twenty minutes; ten 
to twenty minutes was sufficient acclimation time (Liden and Herberholz 2008; Liden et al. 
2010).  
Threat avoidance behavior was studied by presenting a moving shadow stimulus modeled 
to resemble a passing predator. When crayfish were oriented towards shadow origin after the 
initial 20-minute acclimation, the shadow generating apparatus was manually activated to cast a 
shadow. Once the shadow was triggered, another 10 minutes were recorded to capture 
subsequent behaviors. The movement criteria ensured crayfish were all moving in the same 
direction and allowed behaviors such as stopping and tail-flipping to be scored. Crayfish had up 
to one hour to meet the described criteria due to other studies suggesting approximately 40 
minutes being enough time for crayfish to transcend the exploratory phase (Tierney and Andrews 
2013). Instances occurred where crayfish ceased total movement for an entire hour and never 
met shadow movement criteria. It was not possible to score behavior for crayfish that did not 
meet criteria, so additional crayfish were treated in order to obtain equivalent sample sizes 
throughout the 6-month experiment.  
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Figure 9. Experimental Procedure 
Experimentation consisted of video recording weekly for 6 months followed by water changes 




Week 0 was baseline testing for pre-treatment behavior comparison. Treatment consisted 
of 6 days Mn2+ exposure with video recording occurring on the 7th day. Behavior was observed 
on a computer monitor from behind a curtain to ensure experimenter was not visually detected. 
Weekly water changes for housing aquarium were completed after recording cessation by 
pipetting (Labnet International Inc., Edison, NJ) respective MnCl2 concentrations from 10ppm 
solution into 1L reconstituted freshwater using a stir bar. Control subjects received new 
reconstituted fresh water after each recording, and cross contamination was limited by rinsing the 
experimental tank between trials. Room temperature was recorded daily, and husbandry steps 
were carried out weekly until test cessation. 
Total crayfish for each treatment varied due to mortality although each contained a 
complete data set (n=8). Crayfish that died before experiment cessation or did not meet shadow 
criteria were replaced by another crayfish, so the sample sizes were consistent between 
treatments. Potential causes of death included molting, or physiological stress due to chronic 
Mn2+ experimentation. 
Dissection and Storage 
Crayfish were placed into an ice bath for 20-30 minutes to induce anesthesia. The nerve 
cord near the brain was cut to terminate input, followed by dorsal exoskeleton removal to expose 
intact gills and musculature. Crayfish were pinned dorsal side up in a petri dish filled with clear 
silicone elastomer (Dow Corning-Sylgard, Midland, MI) and bathed in buffered 1x crayfish 
saline (concentrations in mM: 202 NaCl, 5.37 KCl, 13.53 CaCl2, 2.6 MgCl2, and 2.4 HEPES, pH 
7.4). Gills, hepatopancreas, and abdomen musculature were excised, and nerves were cut at the 
furthest point from each ganglion to minimize nerve cord damage during removal. Tissues were 
labeled and stored separately in 5mL 4% paraformaldehyde (Electron Microscopy Sciences- 
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paraformaldehyde prills, Hatfield, PA) with 1x crayfish saline at 4 °C for 12 hours. Tissues were 
rinsed with 0.1M phosphate buffer (pH 7.4) and stored in 5mL 30% sucrose (Fisher Scientific 
Company, Pittsburgh, PA) with 0.05% sodium azide (Millipore Sigma, Burlington, MA) 
solution. Sucrose is a cryoprotectant to prevent ice crystal formation while sodium azide 
functions as a bacteriostatic agent to inhibit bacterial growth. 
Behavior Analysis 
Videos were entered into Ethovision XT 11 behavioral tracking software (Noldus 
Information Technology Inc., Leesburg, VA) to analyze parameters which may be affected by 
Mn2+ exposure including distance moved, time spent in specific arena zones, zone crossings, tail-
flip latencies, and mobility states. Distance moved, mobility state, and place preference provide 
useful information on foraging, mate-finding, and overall fitness impacts of elevated Mn2+ 
exposure. Center zone latency, zone transition, and time spent per zone provides information on 
whether treated crayfish are rapidly entering exposed areas after a potential predation scenario, 
or whether they are remaining concealed within the border zones. A Lowess (Locally weighted 
scatter plot smoothing) filter was used to exclude movement noise due to gait, tracking outliers, 
or system noise. A Minimum Distance Moved filter was also added to exclude small jitter 
movement less than 1 pixel in size which sometimes occurred when crayfish were immobile. 
Raw videos were also analyzed for threat avoidance behavior and data were entered into 
a behavioral matrix. Classes were created based on the observed behavior, and each observation 
was categorized by zone and timestamp of occurrence. Observing how treated crayfish respond 
to shadow movement provides information on whether the proper contextual anti-predatory 
behavior is being exhibited. All variables recorded were compared to control subjects and 
baseline week 0 results to determine impacts of elevated manganese on P. clarkii behavior.  
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Statistical Analysis 
Data were organized into Excel spreadsheets and statistics analysis was performed using 
R software (R Foundation for Statistical Computing, Vienna, Austria) with all data being 
presented as mean and standard deviation (mean ± s.d) except for boxplots. Any data that could 
be influenced by animal size were length normalized before statistical measures were completed. 
Due to some data not meeting parametric assumptions, non-parametric alternatives were used 
throughout. An individual’s behavior is highly contextual, and sometimes deviated from ongoing 
trends making it difficult to accurately interpret weekly changes. Sturges rule (grDevices 
package, nclass.Sturges function) (R Core Team 2018) was used to determine number of classes 
to properly bin data by week which gave a better representation of overall trends. 
The Shapiro-Wilk test (STATS package, shapiro.test function) (R Core Team 2018), one 
of the most powerful normality tests useful for analyzing small sample sizes (Razali and Yap 
2011), determined normality while the Bartlett test (STATS package, bartlett.test function) (R 
Core Team 2018) determined homoscedasticity. The Kruskal Wallis Rank Sum test (STATS 
package, kruskal.test function) (R Core Team 2018) was used to analyze differences between 
manganese treated crayfish and multiple pairwise comparisons were performed via Dunn’s test 
(DescTools package, dunnTest function) (Signorell 2019). Analysis goal was to determine if 
treatment concentration significantly influenced behavior compared with controls. 
Repeated measures ANOVA was not suitable for motility data that failed normality and 
homoscedasticity, or categorical threat avoidance behavior, so the Friedman test (STATS 
package, friedman.test function) (R Core Team 2018) and Pairwise Wilcoxon Rank Sum tests 
(STATS package, pairwise.wilcox.test function) (R Core Team 2018) were conducted to analyze 
differences between weekly dependent data. Repeated measures analysis goal was to determine 
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if behavioral change was dependent on exposure time which would indicate whether exposure to 
Mn2+ concentrations below EPA standards impact behavior. One-way ANOVA (STATS 
package, aov function) (R Core Team 2018) was completed for percentage change in total length 
data, as well as, length-carapace ratio data. Change-in-length data were specific to crayfish 
which completed behavioral analysis (n=8 for each treatment). Being that death-temperature data 
did not meet normality assumptions, correlation was investigated using a Kendall rank test 
(STATS package, cor.test function) (R Core Team 2018) which is effective in determining 




Crayfish motility within the novel environment was analyzed to understand effects of 
elevated manganese exposure on exploratory behavior. Exploration of a new environment is a 
critical component in searching for food resources and assessing potential threats. During the 20-
minute acclimation period, crayfish were able to freely move throughout all zones (center and 
perimeter regions) of the novel environment. Examining metrics including motility and place 
preference (whether crayfish spent more time in the open center zone or attempted to remain 
concealed within the border regions) provides useful information on the behavioral impacts of 
manganese that may affect crayfish survivability. The second phase of this research involved the 
passing of a shadow stimulus to determine the impacts of manganese on danger recognition and 
response. Like the initial acclimation period, crayfish were able to freely move throughout all 
zones of the novel environment while threat avoidance and subsequent behaviors were recorded. 
Threat-avoidance response and the behaviors that follow it are important for the survival of prey 
species.  
Behaviors were analyzed weekly for six months to monitor the exposure time needed for 
low-level manganese to cause behavioral change. Data were then binned to remove interference 
of weekly noise allowing a clearer representation of overall trends. Line plots were used to 
visualize weekly changes, while boxplots provided information on each group’s data 
distribution. Additionally, within-video observations were used to analyze behavior trends 
throughout the 10-minute recordings. 
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Weekly Behavior Analysis Over 6 Months-Before Shadow Stimulus 
Before-Shadow Distance Traveled 
Distances moved for the initial 10-minute acclimation in the novel environment prior to 
shadow stimulus was analyzed weekly for 6 months (Fig. 10A). During weeks 1-4, control 
crayfish immediately traveled further distances compared with baseline levels, continually 
increasing for the next eight weeks. A plateau occurred during weeks 9-12, although it was only 
temporary as gradual weekly increases resumed thereafter (+35.8% from baseline). 0.0014 ppm 
Mn2+ treated crayfish reduced distances traveled during the first four weeks (-15.4%), recovering 
back to baseline values at weeks 5-7 and remaining steady until weeks 17-20. 0.0028 ppm Mn2+
treated crayfish repeatedly traveled further distances until week 16, where they became the first 
group to display consistent reductions. The two lower Mn2+ concentration treatment groups 
regularly traveled lesser weekly distances than the control group in addition to being the only 
groups to reduce distances during the last four weeks. In contrast, 0.014 ppm Mn2+ treated 
crayfish significantly increased distances from baseline within the first five weeks and continued 
rapidly climbing for the next seven weeks thereafter (+65.8%). This group displayed the largest 
increase from baseline of any group throughout the entire experiment.  
Observation of distances moved among the center and border zones revealed that crayfish 
traveled further distances in the border rather than center zone. Therefore, distances traveled 
within the border zone followed similar trends to the overall distance moved within the entire 
novel environment (Fig. 10B). Control crayfish exhibited a positive trend, repeatedly traveling 
further border distances except for a reduction during weeks 21-24. 0.0028 ppm Mn2+ treated 
crayfish gradually moved further border distances throughout the experiment being the only 
group that did not show any signs of reduction. In comparison, 0.014 ppm Mn2+ treated crayfish 
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rapidly increased weekly distance traveled within the border, but as weeks 13-16 approached 
they tended to travel further within the center. Although control crayfish reduced border 






































B- Border Distance Traveled
Week
Week
Figure 10. Distances Moved Over Time-Before Shadow 
All groups, with exception of 0.0014 ppm Mn2+ treatments began moving further distances from 
baseline, displaying larger differences from the control group as weeks progressed. (A) The 
control group increased distances moved over time. Lower Mn2+ treated crayfish increased 
smaller distances each week, while 0.014 ppm Mn2+ treated crayfish displayed the fastest 
percentage increase from baseline throughout the experiment (Control: Friedman p-value=0.004; 
0.0014 ppm Mn2+: Friedman p-value= 0.08; 0.0028 ppm Mn2+: Friedman p-value= 0.1; 0.014 
ppm Mn2+: Friedman p-value = 0.2). (B) Pre-shadow distance moved within the border over the 
course of the 6 months showed similar trends as overall distance traveled for the first sixteen 
weeks. During weeks 13-16, 0.014 ppm Mn2+ treated crayfish reduced border distances traveled, 
while the control group followed suit during weeks 17-20. At this time, 0.0028 ppm Mn2+ 
continued moving further border distances (Control: Friedman p-value=0.004; 0.0014 ppm Mn2+: 
Friedman p-value= 0.91; 0.0028 ppm Mn2+: Friedman p-value= 0.01; 0.014 ppm Mn2+: Friedman 
p-value = 0.004).
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Dispersion comparison during the entire 10-minute stretch following introduction to the 
novel environment, but before shadow stimulus did not indicate large distributional abnormality 
within baseline results (Fig. 11A). Boxplots shows that all groups were generally distributed 
similarly, although the lower 25% of data within the control group were condensed leaving a 
single outlier below the lower limit. Even with the outlier present, dispersion of the control 
group’s data was closely related to the other groups’ dispersions. Furthermore, the elevated 
distance moved within 0.0014 ppm Mn2+ treated crayfish during baseline testing was not 
influenced by abnormal distribution or outliers. 
Little distributional change occurred among Mn2+ treated crayfish after one-week 
exposure. By week 4, control group distribution still closely resembled their baseline results with 
slight elevation in central tendency (Fig. 11B). Most noticeable differences observed were 
among 0.0014 ppm Mn2+ treated crayfish as their range doubled and central tendency decreased. 
Upper and lower outliers also appeared within 0.0028 ppm Mn2+ treated crayfish resulting in a 
larger spread, as well. 
Weeks 1-4 boxplot supports the notion that exposure to Mn2+, at these concentrations, 
does not immediately manifest within distances traveled as large changes between treatment 
groups were not present, although more prominent differences arose during weeks 9-12 (Fig. 
11C). While the spread of data within the control group increased from previous weeks, 0.014 
ppm Mn2+ treatment data displayed the largest distribution of any group, with variance 
increasing by 113% from baseline. Crayfish within the upper limit traveled the furthest of any 
group, although elevated distances were highly variable. During weeks 21-24, the control group 
displayed a distribution consistent with weeks 9-12 (Fig. 11D). As in previous weeks, variability, 
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specifically within 0.014 ppm Mn2+ treatment data, remained elevated compared with the control 




Figure 11. Before-Shadow Distribution Comparison of Distance Traveled.  
Distributional comparison of data within each treatment group did not reveal large changes until 
midway through the experiment. Treatment groups are represented on the x-axis and distance 
traveled is on the y-axis with each graph showing a progression of results from different weeks 
throughout the experiment. (A) While baseline medians differed between treatments, data 
displayed minimal distribution differences (Kruskal-Wallis test: p-value = 0.079). (B) Data for 
weeks 1-4 pre-shadow distances traveled showed small distributional changes from baseline 
(Kruskal-Wallis p-value = 0.25). (C) During weeks 9-12, behavioral change became more 
prominent with Mn2+ treatment data increasing ranges more so than the control group (Kruskal 
Wallis p- value= 0.07). (D) Distances traveled during weeks 21-24 revealed that 0.0028 ppm 
Mn2+ treated crayfish moved significantly shorter distances than the control group (Kruskal 
Wallis p-value= 0.01; Dunn’s test: control-0.028 ppm p-value= 0.03). Additionally, 0.014 ppm 
Mn2+ treated crayfish displayed the largest variability of any group. 
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Baseline distributions for border distance moved were similar to overall distance moved 
due to absence of large skews or outliers (Fig. 12A). Again, immediate week 1 changes were not 
prominent, but by weeks 9-12, all groups’ distributions had increased while continuing to 
generally resemble each other (Fig. 12B). In contrast to overall distance moved, 0.014 ppm Mn2+ 
treated crayfish displayed the smallest distribution during this time while the control group 
contained the most variable data. By weeks 21-24, this trend completely changed with the 
control group data displaying the smallest variability, while Mn2+ treatment data were more 
dispersed (Fig. 12C). 
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Figure 12. Before-Shadow Distribution Comparison of Border Distance Traveled 
Overall, all groups displayed similar distributional characteristics within the border zone. 
Treatment groups are represented on the x-axis and border distance traveled on the y-axis with 
each graph showing results from different weeks throughout the experiment. (A) Baseline 
distances traveled within the border zone were similar to baseline results for overall distance 
moved (Kruskal Wallis p-value = 0.09). (B) Week 9-12 results for border distance moved 
showed all data retaining similar distributions, although slightly larger (Kruskal Wallis p-value = 
0.07). (C) Week 21-24 results showed that Mn2+ treated crayfish displayed larger distributions 
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One-minute time-bins of distance moved throughout the acclimation to the novel 
environment were analyzed to understand activity within the 10-minute video recording. 
Baseline recording revealed all groups moved further distances when first placed into the novel 
environment which decreased by the end of recording (Fig. 13A). Control crayfish moved 
shorter distances over each minute compared to when first introduced into the novel 
environment. 0.0014 ppm Mn2+ treated crayfish moved the furthest distance of any group when 
initially placed into the novel environment but exhibited the steepest negative trend as minutes 
progressed. 0.0028 ppm Mn2+ and 0.014 ppm Mn2+ treated crayfish displayed similar trends to 
each other over the 10-minutes with the largest reduction occurring the last minute. Comparison 
of distances moved within week 12 (Fig. 13B) and week 24 (Fig. 13C) recordings revealed that 
control crayfish exhibited a stronger negative trend as weeks progressed, moving further 
distances within the first five minutes. As weeks proceeded, 0.0014 ppm Mn2+ treated crayfish 
continued displaying strong negative trends with the largest decrease in all groups occurring in 
the last minute. 
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Figure 13. Distance Moved Within the Initial 10-Minute Acclimation 
Time in minutes is represented on the x-axis and distance traveled is on the y-axis. (A) Baseline 
distances moved where all groups displayed a negative trend (Kruskal Wallis: Minute 1 p-value 
= 0.01, Dunn’s test 0.028-0.014 ppm p-value = 0.02; Minute 5 p-value = 0.11; Minute 10 p-value 
= 0.82). (B) Week 12 distances moved where all groups still displayed a negative trend, while 
moving further during the first two minutes (Kruskal Wallis: Minute 1 p-value = 0.21; Minute 5 
p-value = 0.32; Minute 10 p-value = 0.08). (C) Week 24 distances moved showed that all groups
displayed similar trends again; however, trends were more constant until the last minute where a
large reduction in distances occurred (Kruskal Wallis: Minute 1 p-value = 0.09; Minute 5 p-value





































































Before-Shadow Time Occupying Center vs Border Zones 
Time spent within the center and border zones were compared to better understand the 
impacts of manganese on place preference. Throughout six months of treatment, all groups spent 
over 85% of their time within the border zone during the initial 10-minute acclimation (Fig. 14). 
For the first four weeks, control crayfish reduced time in the border, spending more time in the 
center. This reduction was only temporary, as the control group increased border time thereafter 
and continued increasing until weeks 13-16. Control crayfish reduced border time again during 
the last eight weeks ending with a 4% increase from baseline, the largest increase from baseline 
of any group. 
0.0014 ppm Mn2+ treated crayfish spent the most time in the border during baseline with 
increasing trends until weeks 9-12. After week 12, they continually spent less time in the border 
resulting in a 0.4% elevation from baseline. 0.0028 ppm Mn2+ treated crayfish exhibited the 
lowest baseline time spent in the border, so it was expected that this trend may continue 
throughout the experiment; however, they displayed the strongest increase of any group over the 
first four weeks. Border time fluctuated throughout the remaining weeks, with reductions 
occurring between weeks 5-8 and again at weeks 17-20. By the end of the experiment, they had 
only increased by 1.5% compared with baseline. 0.014 ppm Mn2+ treated crayfish began 
spending more time in the border within the first four weeks where their numbers leveled off 
until week 12, abruptly increasing again from weeks 13-20. Elevated time in the border was 
short-lived, as 0.014 ppm Mn2+ treated crayfish reduced their border time the last 4 weeks 
(+2.5% from baseline). 
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Figure 14. Before-Shadow Time Occupying Border.  
All groups displayed an increase in border time with the control group showing the greatest 
increase from baseline and the two lower Mn2+ concentrations showing the smallest increase. 
Weeks are presented on the x-axis with percent of time on the y-axis. Over 85% of the time, 
crayfish from each group occupied the border region, with the most fluctuation occurring among 
0.0028 ppm Mn2+ treated crayfish (Control Friedman p-value = 0.25; 0.0014 ppm Mn2+ 



























When analyzing distributions of baseline results for time spent in the border, the control 
group displayed slightly large inner quantile variability. While all groups were negatively 
skewed, 0.014 ppm Mn2+ treated crayfish presented a single outlier that spent 53% of its time in 
the border (Fig. 15A). During weeks 1-4, the distribution of control group remained the same, 
but all Mn2+ treated crayfish now presented outliers on the lower limit (Fig. 15B), becoming 
more extreme by weeks 9-12 and giving reason behind the low amount of time spent within the 
border compared with the control group (Fig. 15C). During the last four weeks, the control group 
had reduced inner quantile range compared with their baseline results, while 0.0028 ppm Mn2+ 
and 0.014 ppm Mn2+ treatment inner quantile range increased. Outliers within Mn2+ treatment 
data were more abundant than previous weeks, as well (Fig. 15D). 
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Figure 15. Before-Shadow Time in Border Distribution Comparison  
Figures are presented to compare distribution of data within each treatment group to control and 
baseline results. All groups displayed similar distributions early on, with Mn2+ treatments 
retaining a higher percentage of outliers as weeks progressed. Groups are represented on the x-
axis and percent of time spent within the border zone on the y-axis with each graph showing a 
progression of results from different weeks throughout the experiment. (A) Baseline percentages 
of time spent within the border with small distributional differences occurring between groups 
(Kruskal-Wallis p-value = 0.45). (B) During weeks 1-4, slight differences began to emerge with 
Mn2+ treated crayfish all containing outliers (Kruskal-Wallis p-value = 0.04; Dunn’s test 
Control-0.0014 ppm p-value = 0.03). (C) During weeks 9-12, behavioral change between control 
and Mn2+ treatment data became more prominent with outliers becoming more extreme (Kruskal 
Wallis p- value = 0.09). (D) The presence of outliers, specifically within Mn2+ treatments, were 
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Before-Shadow Center Zone Crossing Frequency 
Zone crossing frequency was analyzed and compared with time spent per zone to 
determine if crayfish freely moved throughout the arena, or if they actively avoided entering the 
center zone. Analyzing crossing between center and border zones during the before-shadow 
video recording determined that by week 24, control crayfish reduced zone crossing frequency 
by 26.7% from baseline (Fig. 16). Control crayfish were the only group to continually decrease 
crossing frequency between the center and border zones. After the initial reduction in 0.0014 
ppm Mn2+ crayfish zone crossing frequency during the first four weeks (-35.4% from baseline), 
an increasing trend presented itself thereafter. By weeks 13-16, 0.0014 ppm Mn2+ crayfish began 
crossing into the center zone more frequently than the control group, especially during the last 
eight weeks.  
0.0028 ppm Mn2+ and 0.014 ppm Mn2+ treated crayfish displayed similar trends for the 
first sixteen weeks, slightly increasing initially and then decreasing crossing frequency back to 
baseline levels. During weeks 17-20, 0.0028 ppm Mn2+ treated crayfish increased crossing by 
26.3%, reducing again thereafter. 0.014 ppm Mn2+ treated crayfish displayed opposing results, 
decreasing below baseline frequencies during weeks 17-20 and then increasing again. 
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Figure 16. Before-Shadow Center Zone Crossing Over Time.  
Frequency of crossing between border and center zones during the recording prior to shadow 
stimulus with treatment week on the x-axis and count center zone crossing on the y-axis. As 
weeks progressed, the control group repeatedly reduced crossing frequency, while the two lower 
Mn2+ concentrations showed large increases during the last eight weeks (Control: Friedman p-
value = 0.4; 0.0014 ppm Mn2+: Friedman p-value = 0.47; 0.0028 ppm Mn2+: Friedman p-value = 












Baseline testing determined that the dispersion of crossing frequency between control 
crayfish and 0.014 ppm Mn2+ treated crayfish were similar, but slightly larger than other groups. 
The control group contained an outlier crossing the center zone an abnormally high amount, 
although it did not seem to drastically skew the data (Fig. 17A). During weeks 1-4, the 
distribution of the control group decreased, while all Mn2+ treatments increased from baseline, 
with these changes continuing to become more prominent by weeks 9-12 (Fig. 17B). By weeks 
21-24, variability within the control group’s data increased due to an upper outlier crossing (Fig.
17C). This was primarily responsible for the increase in crossing frequency during the last four 
weeks. 0.0028 ppm Mn2+ treated crayfish also displayed a lack of symmetry, with several 
outliers positively skewing the data. Regardless of outliers, median analysis determined this 
treatment still displayed the highest tendency of zone crossing during the last four weeks. 
Although the control group had a large range due to its outlier, all Mn2+ treatments, especially 
the two highest Mn2+ treatment concentrations, exhibited larger interquartile spreads suggesting 
the central 50% of values within the dataset were more dispersed.  
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Figure 17. Before-Shadow Center Zone Crossing Distribution Comparison 
While all distributions were similar during baseline testing, Mn2+ treatments contained larger 
interquartile distributions by weeks 24. (A) Baseline count of number of times crayfish crossed 
the center zone with data distributions being similar (Kruskal-Wallis test: p-value = 0.46). (B) 
During weeks 9-12, 0.014 ppm Mn2+ treated crayfish showed the most change from baseline due 
to increased variability among crayfish behavior in the upper limit (Kruskal Wallis p-value = 
0.19). (C) All groups’ distributions increased from baseline during weeks 21-24, with 0.0028 
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Before-Shadow Time Spent Moving 
When observing time spent moving during the acclimation before shadow exposure, 
baseline results between groups largely differed. Although pre-treatment differences were 
present, deviation from baseline results over the next twenty-four weeks still provided important 
information on how elevated Mn2+ exposure impacts crayfish behavior. During the first four 
weeks, control subjects increased by 5.8% (Fig. 18). For the next twelve weeks, control subjects 
spent an average 80.25 % of their time moving, increasing to 84.8% for the last eight weeks (a 
total of +10.9% from baseline). 0.0014 ppm Mn2+ treated crayfish displayed a sharp, temporary 
drop in time moving during weeks 1-4 (-11.6%). Activity returned to baseline levels during 
weeks 5-8, although a steady decline reemerged thereafter.  
While 0.0028 ppm Mn2+ treated crayfish did not increase time moving during week 1-4 
to the same degree as the control, they displayed similar trends throughout much of the 
experiment, increasing by 7.1%. However, 0.0028 ppm Mn2+ treated crayfish largely reduced 
time moving during the last four weeks. While all groups reduced movement time during weeks 
21-24, this was the most extreme. 0.014 ppm Mn2+ treated crayfish sharply increased movement
time by 11.7% during the first week. Thereafter, 0.014 ppm Mn2+ treated animals consistently 
spent the most time moving until control crayfish surpassed them week 17. Even though control 
and 0.014 ppm Mn2+ treated crayfish moved similar times at the end of experimentation, 0.014 
ppm Mn2+ treated crayfish displayed elevated movement within the first week; it took control 
crayfish 17 weeks to reach comparable levels.  
70 
Figure 18. Time Spent Moving During Initial Acclimation. 
Comparison of time spent moving between treatment groups over 6 months with weeks being 
represented on the x-axis and percent of time moving on the y-axis. Control crayfish gradually 
increased time moving over each week, while 0.0014 Mn2+ treated crayfish reduced time 
moving, and 0.014 ppm Mn2+ treated crayfish displayed elevated time moving compared with 
the control group (Control: Friedman p-value = 0.2; 0.0014 ppm Mn2+: Friedman p-value = 0.27; 
0.0028 ppm Mn2+: Friedman p-value = 0.04; 0.014 ppm Mn2+: Friedman p-value = 0.56). 























Distributional analysis showed relatively large baseline deviation between groups evident 
by the large differences in Figure 19 (Fig. 19A). The control group contained the smallest 
interquartile distribution, but also presented an outlier on each limit. By weeks 1-4, all groups 
exhibited similar interquartile spreads, although Mn2+ treated crayfish each had several outliers 
spending an abnormally low amount of time moving (Fig. 19B). Outliers became more severe by 
weeks 9-12 with ranges doubling that of the control group’s (Fig. 19C). During weeks 21-24, 
interquartile ranges of all groups remained similar to each other (Fig. 19D). However, outliers 
spent even less time moving, leading to the large reduction in movement time from 0.0014 ppm 
Mn2+ and 0.0028 ppm Mn2+ treatments. 
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Figure 19. Before-Shadow Time Spent Moving Distribution Comparison 
Strong negative outliers were present among the two lower Mn2+ concentration treatments 
throughout much of the experiment, leading to a lesser amount of time spent moving compared 
to the control group. (A) Baseline results greatly differed between groups with distributions 
increasing by treatment (Kruskal-Wallis p-value = 0.35). (B) Data for weeks 1-4 showed the 
presence of outliers began to emerge in Mn2+ treated crayfish spending very little time moving 
(Kruskal-Wallis p-value = 0.23). (C) During weeks 9-12, outliers became more abundant in Mn2+ 
treated crayfish (Kruskal Wallis p- value = 0.24). (D) Outliers were still present in Mn2+ 
treatments, which also displayed larger interquartile distributions than the control group (Kruskal 




















































































































Before-Shadow Border Time Spent Moving 
Border time moving was analyzed to determine activity within the most frequently 
occupied zone. When analyzing time spent within the border during the initial 10-minute 
recording, trends resembled overall time spent moving within the entire arena (Fig. 20). The 
most prominent difference occurred in 0.014 ppm Mn2+ treatments, where after the initial 
increase during weeks 1-4, a gradual decreasing trend became present. 
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Figure 20. Border Time Spent Moving During Initial Acclimation. 
Comparison of border time spent moving between treatment groups with weeks presented on the 
x-axis and percent of time spent moving within the border on the y-axis. Only the control group
continually increased time spent moving over time, while although all Mn2+ treated crayfish
increased periodically, they displayed negative trends by the end of the trial (Control: Friedman
p-value = 0.16; 0.0014 ppm Mn2+: Friedman p-value = 0.19; 0.0028 ppm Mn2+: Friedman p-






















When analyzing distributions of data, control crayfish spent a median of 83% time 
moving in the border during baseline testing with a small negative skew present due to an outlier 
moving only 52% of the time (Fig. 21A). Mn2+ treatment interquartile distributions were similar, 
while 0.014 ppm Mn2+ treated crayfish tended to spend less time moving in the border during 
baseline testing. Control crayfish continually reduced spread throughout the entire experiment, 
with less extreme outliers being present by week 24 (Fig. 21B, Fig. 21C, Fig. 21D). Within the 
first four weeks, 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ treatment ranges increased due to 
influence of outliers which remained present throughout the experiment, doubling the 
distribution size of these groups. During the last four weeks, interquartile distributions of all 
Mn2+ treatments were larger than the control group, increasing by treatment concentration. The 
large spreads and outliers present among Mn2+ treated crayfish were responsible for reduction in 















Figure 21. Before-Shadow Border Time Moving Distribution Comparison 
As weeks progressed, Mn2+ treatments, specifically 0.014 ppm Mn2+ treated crayfish, displayed 
large increases in interquartile variability. Treatment groups are represented on the x-axis and 
percent of time moving in the border is on the y-axis. Each graph shows a progression of results 
from different weeks throughout the experiment. (A) Baseline distributions among each group 
were similar, although central tendency for each group differed (Kruskal-Wallis p-value = 0.09). 
(B) During weeks 1-4, central tendency of Mn2+ treated crayfish were similar to the control 
group, although outlier severity increased (Kruskal-Wallis p-value = 0.3). (C) During weeks 9-
12, the control group’s interquartile range decreased from baseline, while more outliers became 
present in Mn2+ treated crayfish (Kruskal Wallis p- value = 0.55). (D) By weeks 21-24, all Mn2+ 
treated crayfish displayed larger interquartile distributions than the control group, and their 
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Within-video analysis of the 10-minute recording before shadow stimulus revealed that 
control crayfish and 0.0014 ppm Mn2+ treated crayfish immediately spent less time moving after 
one minute in the novel environment (Fig. 22A). While both groups spent less time moving as 
minutes progressed, control crayfish continually reduced movement time the most. The two 
higher Mn2+ treated crayfish groups initially spent more time moving during the first minute and 
did not display clear reductions throughout the recording as the control group did. 
During week 12, control crayfish spent less time moving within the first minute 
compared with baseline and continued decreasing until the fourth minute where a more constant 
trend appeared thereafter (Fig. 22B). Mn2+ treated crayfish differed by spending more time 
moving within the first four minutes. By week 24, the control group spent a more constant time 
moving throughout the video as the strong initial reduction was not present (Fig. 22C). While 
Mn2+ treatment trends mirrored the control group during week 24, 0.0014 ppm Mn2+ treated 
crayfish differed the most. However, large differences were not present within this parameter 
throughout the entire experiment. 
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Figure 22. Time Spent Moving Within Initial 10-Minute Acclimation 
While observing this parameter over the weeks, large differences between treatments were not 
observed. (A) Baseline time moving over the 10-minute video showed that all groups except 
0.014 ppm Mn2+ treated crayfish reduced time moving as minutes progressed (Kruskal Wallis: 
Minute 1 p-value = 0.09; Minute 5 p-value = 0.59; Minute 10 p-value = 0.47). (B) During week 
12, all groups again displayed negative trends while 0.014 ppm Mn2+ treated crayfish displayed 
the most constant trend (Kruskal Wallis: Minute 1 p-value = 0.01, Dunn’s test Control-0.0014 p-
value = 0.02; Minute 5 p-value = 0.34; Minute 10 p-value = 0.23).  (C) Week 24 time moving 
over the 10-minute video showed that groups displayed similar negative trends, with 0.0028 ppm 
Mn2+ treated crayfish differing the most (Kruskal Wallis: Minute 1 p-value = 0.78; Minute 5 p-









































































Weekly Behavior Analysis Over 6 Months-After Shadow Stimulus 
After-Shadow Distance Traveled 
Distance moved was analyzed during the 10-minute recording After-Shadowexposure to 
determine influence of predatory clues on manganese-exposed crayfish motility and behavior. 
Trends between overall distance moved and border distance moved After-Shadow stimulus were 
identical with over 90% of total distances traveled being in the border zone. All groups moved 
similar baseline distances and exhibited a moderately positive trend throughout the first four 
weeks (Fig. 23). During weeks 5-8, the control group increased substantially (+101.3% from 
baseline) after which they gradually decreased movement by 26%. The lowest Mn2+ 
concentration treatment moved similar weekly distances with a gradual increase during weeks 5-
8. By week 12, 0.0028 ppm Mn2+ treated crayfish increased by 23.9%, but declined back to
baseline levels in the remaining weeks. While moving similar distances as the control group for 
the first eight weeks, 0.014 ppm Mn2+ treated crayfish continued significantly moving further 
distances until week 17, surpassing all other groups (+111.8% from baseline). This treatment 










Figure 23. After-Shadow Distance Moved 
Overall distance moved for the 10-minute video After-Shadow stimulus showed that 0.0028 ppm 
Mn2+ treatments moved lesser distances while 0.014 ppm Mn2+ treatments moved elevated 
distances compared to the control group. (Control: Friedman p-value = 0.002; 0.0014 ppm Mn2+: 
Friedman p-value = 0.07; 0.0028 ppm Mn2+: Friedman p-value = 0.47; 0.014 ppm Mn2+: 






















Baseline comparison of group distributions showed that slight skews were present among 
all groups, although overall distributions were relatively similar. 0.0014 ppm Mn2+ treated 
crayfish had the smallest interquartile range while being heavier tailed (Fig. 24A). Immediate 
week 1 changes in distribution were minimal and by weeks 9-12, all distributions except 0.0028 
ppm Mn2+ treated crayfish closely resembled each other (Fig. 24B).  
When observing weeks 21-24, control crayfish moved similar distances as weeks 9-12, 
with a reduction in interquantile variability (Fig. 24C). Most noticeably, 0.014 ppm Mn2+ treated 
crayfish displayed the largest dispersion of data, doubling the range of baseline results. A strong 
positive skew was attributed to crayfish in the upper quartile moving further, highly variable 
distances. Reductions in Mn2+ treatment distances moved during the last four weeks was not due 
to distribution abnormalities, but instead all Mn2+ treated crayfish reduced central tendency more 
so than the control group.  
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Figure 24. After-Shadow Distribution Comparison of Distance Traveled 
By the end of the experiment, the 0.014 ppm Mn2+ treated crayfish had increased their 
interquartile range the most from baseline similar to observations from other parameters. (A) 
Baseline distributions were similar among most groups with that of 0.0028 ppm Mn2+ treated 
crayfish being slightly smaller (Kruskal-Wallis p-value = 0.83). (B) Distributions of weeks 9-12 
pre-shadow distances traveled were all very similar, with the interquartile range of 0.0028 ppm 
Mn2+ treated crayfish being smaller (Kruskal-Wallis test: p-value = 0.23). (C) During weeks 21-
24, distributional variability among 0.014 ppm Mn2+ treatment data increased the most from 
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Distance moved within the 10-minute baseline video showed that control crayfish 
reduced traveling by 50% throughout the video with the sharpest decline occurring during the 
eighth minute (Fig. 25A). All Mn2+ treated crayfish displayed positive trends by increasing 
distance moved as the recording progressed until the eighth minute where all groups decreased 
distances. During week 12, control crayfish continually increased distances until the last minute 
where they dropped by 24% below baseline. All groups displayed slightly increasing trends until 
minute 9, where they drastically reduced movement (Fig. 25B). By week 24, control crayfish 
moved lesser distances within the first minute compared with other groups, but increased 
distance traveled by 497% thereafter (Fig. 25C). While Mn2+ treated crayfish began moving 
further for the first several minutes compared with baseline, none increased by the same 
percentage as the control group. 
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Figure 25. Distance Moved Within the 10-Minute After-Shadow Recording 
Time in minutes is represented on the x-axis and distance moved on the y-axis with each graph 
showing a progression of results from different weeks throughout the experiment. (A) Baseline 
time moving over the 10-minute video with all groups displaying similar trends (Kruskal Wallis: 
Minute 1 p-value = 0.21; Minute 5 p-value = 0.94; Minute 10 p-value = 0.02, Dunn’s test 
0.0028-0.014 p-value = 0.02). (B) Week 12 distances traveled comparison does not show much 
change between groups (Kruskal Wallis: Minute 1 p-value = 0.95; Minute 5 p-value = 0.93; 
Minute 10 p-value = 0.96). (C) During week 24, control crayfish moved the least distances over 
the first three minutes, thereafter increasing and resuming trends similar to Mn2+ treated crayfish 
(Kruskal Wallis: Minute 1 p-value = 0.03, Dunn’s test Control-0.0014 p-value = 0.05; Minute 5 








































































After-Shadow Time Occupying Center vs Border Zones 
When comparing After-Shadow time spent in the border to before-shadow recording, all 
groups generally spent more time in the border during the initial acclimation period throughout 
the entire 6-month experiment. Baseline results for time spent in the border After-Shadow 
exposure revealed that control crayfish spent an average of 85.5% of their time within the border 
whereas all Mn2+ treated crayfish spent less than 80% in the border (Fig. 26). Therefore, it was 
anticipated for all Mn2+ treated crayfish to spend less time in the border than control crayfish 
which was the case for much of the experiment. 
Control crayfish increased time spent in the border until weeks 5-8, thereafter plateauing 
and slightly decreasing by week 24 (+3% from baseline). Although Mn2+ treated crayfish 
displayed lower baseline levels, they all greatly increased their time spent in the border during 
the first four weeks. 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ treated crayfish both increased 
until weeks 13-16, thereafter reducing border time. 0.014 ppm Mn2+ treated crayfish exhibited 
the largest increase in border time of any group during the first four weeks, continuing to 
increase until weeks 17-20, and then displaying the most drastic decline of any group during the 
last 4 weeks. 
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Figure 26. Time Spent Within Border Zone After Shadow 
Treatment weeks is presented on the x-axis while percent of time spent within the border zone is 
on the y-axis. The control group slightly increased border time throughout each week compared 
with baseline, while all Mn2+ treated crayfish displayed large increases during the first four 
weeks, remaining elevated for the rest of the experiment (Control: Friedman p-value = 0.89; 
0.0014 ppm Mn2+: Friedman p-value = 0.12; 0.0028 ppm Mn2+: Friedman p-value = 0.24; 0.014 




















Distributional observations showed that all Mn2+ treated crayfish contained larger 
baseline spreads than the control group (Fig. 27A). Reductions in Mn2+ treatment interquartile 
ranges were immediately present during weeks 1-4 (Fig. 27B), however, 0.014 ppm Mn2+ treated 
crayfish still maintained the largest distribution with several outliers spending an abnormally low 
time within the border. All interquartile ranges decreased by weeks 9-12 with each group 
showing similar distributions and central tendencies (Fig. 27C). By weeks 21-24, distributions of 
all groups increased from weeks 9-12, with 0.0014 ppm Mn2+ and 0.014 ppm Mn2+ treated 
crayfish again displaying the largest interquartile ranges (Fig. 27D). While the central tendency 
of all groups remained near 95%, each group displayed negative skews responsible for the 
reduction in average time moving during the last four weeks. 0.0014 ppm Mn2+ and 0.014 ppm 




Figure 27. After-Shadow Time Spent in Border Distribution Comparison 
Figures are presented to compare distribution of data within each Mn2+ treatment to control and 
baseline results. Treatment groups are represented on the x-axis and percentage of border time is 
on the y-axis with each graph showing a progression of results from different weeks throughout 
the experiment. (A) Baseline border time indicated large distributional differences between 
groups, specifically among the control group and 0.0014 ppm Mn2+ and 0.014 ppm Mn2+ treated 
crayfish (Kruskal-Wallis test: p-value = 0.66). (B) Weeks 1-4 data shows immediate reductions 
in each Mn2+ treatments’ interquartile ranges (Kruskal Wallis p- value = 0.77). (C) Data for 
weeks 9-12 shows a reduction in interquartile spread of all groups with outliers present in each 
(Kruskal-Wallis p-value = 0.65). (C) During weeks 21-24, outliers within the control group 
became more abundant, but outliers within Mn2+ treated crayfish became more extreme. Like 
baseline testing, the control group contained the smallest interquartile range (Kruskal Wallis p- 
value = 0.98). 
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After-Shadow Center Zone Crossing Frequency 
Baseline testing determined that control crayfish crossed the center zone the most once 
exposed to the shadow stimulus. Control crayfish displayed an overall negative trend resulting in 
a 43.9% decrease, with a peak in zone crossing frequency during weeks 5-8 (Fig. 28). 0.0014 
ppm Mn2+ treated crayfish increased frequency by 57% until week 12, and then decreased back 
to their baseline numbers. 0.014 ppm Mn2+ treated crayfish resembled control group trends for 
the first twelve weeks where they then reduced crossings at a faster rate than control crayfish 
followed by an increase for the last eight weeks. Mn2+ treatment center crossing frequencies were 
lower than control group frequencies throughout experimentation until weeks 9-12. In latter 
weeks, Mn2+ treated crayfish began crossing into the center zone at a higher frequency than the 
control group. 
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Figure 28. After-Shadow Center Zone Crossing Frequency 
Crossing frequency between center and border zones After-Shadow exposure for the 6-month 
experiment with weeks presented on the x-axis and count of zone crossings on the y-axis. Except 
for 0.0028 ppm Mn2+ treatments, all groups decreased crossing frequency over time, with the 
control group showing the largest reduction from baseline (Control Friedman p-value = 0.007; 
0.0014 ppm Mn2+ Friedman p-value = 0.25; 0.0028 ppm Mn2+Friedman p-value = 0.42; 0.014 











During baseline testing, control crayfish exhibited the largest distribution with a range of 
1-25 times, while Mn2+ treated crayfish distributions were smaller and similar to each other (Fig.
29A). 0.014 ppm Mn2+ treated crayfish contained an outlier resulting in a positive responsible for 
the elevated baseline crossing frequency. Distributional changes within the control group were 
minimal over the first twelve weeks as they retained a similar central tendency and spread as 
baseline results. Mn2+ treatments, however, all presented upper outliers within the first four 
weeks which greatly increased their range (Fig. 29B) while becoming more prominent by weeks 
9-12 (Fig. 29C). Mn2+ treated crayfish displayed a lower median crossing frequency than the
control group, although outliers were more extreme than weeks prior. 
By the end of experimentation, control crayfish crossed center zone the least even though 
they exhibited the highest baseline frequency. Control crayfish variability also decreased the 
most out of any group from baseline results (Fig. 29D). While all groups exhibited similar 
spreads during weeks 21-24, Mn2+ treatment distributions increased from baseline. While their 
median continued to decrease throughout week 24, there was an abundance of outliers among the 
upper limit.  
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Figure 29. After-Shadow Center Zone Crossing Frequency Distribution Comparison 
Figures are presented to compare distribution of data within each treatment group to control and 
baseline results. Treatment groups are represented on the x-axis and count of times the center 
zone was entered is on the y-axis with each graph showing a progression of results from different 
weeks throughout the experiment. (A) Baseline center crossing frequency in which control 
crayfish exhibited the largest baseline distribution (Kruskal Wallis p-value = 0.95). (B) Data for 
weeks 1-4 where dispersion among Mn2+ treatment data increased while the control group 
decreased (Kruskal-Wallis test: p-value = 0.46). (C) During weeks 9-12, spread became more 
prominent in Mn2+ treatment data with outliers crossing more often than prior weeks (Kruskal 
Wallis p- value = 0.56). (D) During the last four weeks of experimentation, 0.014 ppm Mn2+ 
treatment data displayed the largest variability among all groups (Kruskal Wallis p-value = 0.72). 
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After-Shadow Time Spent Moving 
Control crayfish increased time moving over the first eight weeks, peaking and slightly 
decreasing thereafter (Fig. 30). 0.0014 ppm Mn2+ and 0.014 ppm Mn2+ treated crayfish followed 
a similar trend, although not increasing to the same degree as control crayfish. 0.014 ppm 
Mn2+ treated crayfish only increased 39% by week 24, compared with the control group which 
increased by 59%. By week 24, all subjects except 0.0028 ppm Mn2+ treated crayfish spent more 
time moving as weeks progressed compared with baseline results. 0.0028 ppm Mn2+ treated 
crayfish were the only group to repeatedly spend lesser time moving. 
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Figure 30. Overall Time Spent Moving After Shadow Stimulus   
With exception from 0.0028 ppm Mn2+ treatments, all groups spent more time moving compared 
with baseline as weeks progressed, with other Mn2+ treated crayfish decreasing during the last 
four weeks. Overall movement time during the 10-minute video that occurred after the shadow 
stimulus passed. Weeks are presented on the x-axis while percent of time spent moving is on the 
y-axis (Control: Friedman p-value =0.008; 0.0014 ppm Mn2+: Friedman p-value = 0.09; 0.0028 




















During baseline testing, the control group exhibited the smallest interquartile spread of 
any group (Fig. 31A). 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ treated crayfish displayed 
negatively skewed distributions, while 0.014 ppm Mn2+ treated crayfish displayed a positive 
skew. Within the first four weeks, all groups exhibited increased behavioral variability, with 
0.014 ppm Mn2+ treatments containing the largest (Fig. 31B). During weeks 9-12 (Fig. 31C), the 
control group’s dispersion remained relatively the same while 0.0028 ppm Mn2+ and 0.014 ppm 
Mn2+ treatment dispersions increased the most from baseline. The 0.014 ppm Mn2+ treatment 
distribution became negatively skewed due to two outliers moving less than 10% of the After-
Shadow recording, although this did not greatly impact the average time moving. 0.014 ppm 
Mn2+ treatment variability continued to increase throughout week 24 and continually displayed 














Figure 31. After-Shadow Time Moving Distribution Comparison  
Figures are presented to compare distribution of data within each treatment group to control and 
baseline results. Treatment groups are represented on the x-axis and percent of time moving is on 
the y-axis with each graph showing a progression of results from different weeks throughout the 
experiment. (A) Baseline results showed that all groups displayed large, relatively similar 
spreads, although all Mn2+ treated crayfish displayed skewness. (Kruskal-Wallis p-value = 0.56). 
(B) During weeks 1-4, all spreads increased, with 0.014 ppm Mn2+treated crayfish distribution
being the largest (Kruskal-Wallis p-value = 0.25). (C) During weeks 9-12, 0.0028 ppm Mn2+
0.014 ppm Mn2+ treated crayfish showed similar distributions slightly larger than the control
group’s (Kruskal Wallis p- value = 0.23). (D) Weeks 21-24 showed that 0.014 ppm Mn2+
treatment’s distribution spans virtually the entire y-axis while the control group displayed the
smallest range (Kruskal Wallis p-value = 0.1).
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When observing border movement After-Shadow exposure, control crayfish peaked at 
weeks 5-8, thereafter decreasing border time moving until falling just below baseline levels (-
1.1% below baseline) (Fig. 32). 0.0014 ppm Mn2+ treated crayfish again followed a similar 
pattern until weeks 9-12, where they decreased at a faster rate than the control group for the next 
eight weeks. For the last 4 weeks they spent elevated time moving within the border, surpassing 
the control group. Like overall time moving, 0.014 ppm Mn2+ treated crayfish displayed a sharp 
rate of increase during the first four weeks, although decreasing movement time for the 
remaining weeks (7.4% below baseline). 0.0028 ppm Mn2+ treated crayfish differed the most in 
that they did not increase border time moving within the first eight weeks, and never surpassed 
their baseline results throughout the entire experiment. 
98 
Figure 32. Border Time Spent Moving After Shadow Stimulus   
The control group increased border time moving until weeks 5-8 and then reduced border time 
moving for the remainder of the experiment. 0.0028 ppm Mn2+ treated crayfish showed little 
reduction throughout the experiment while increasing during the last four weeks similar to 
0.0014 ppm Mn2+ treated crayfish. Weeks are presented on the x-axis with percent of time 
moving within the border zone on the y-axis (Control: Friedman p-value = 0.73; 0.0014 ppm 
Mn2+ Friedman p-value = 0.001;0.0028 ppm Mn2+ Friedman p-value = 0.99; 0.014 ppm Mn2+ 






















During baseline border time moving, 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ treated 
crayfish displayed similar interquartile variability to the control group, although control crayfish 
spent the highest median time moving within the border (Fig. 33A). Immediate differences were 
not observed, however, by weeks 9-12 control crayfish increased border time moving while 
decreasing overall range (Fig. 33B). 0.0014 ppm Mn2+ and 0.014 ppm Mn2+ treated crayfish 
followed similar trends as the control, while 0.0028 ppm Mn2+ treated crayfish were the only 
group that increased dispersion with several crayfish moving abnormally small percentages of 
time. Weeks 21-24 revealed opposing trends, as the control group increased variability the most 
of any group while exhibiting a strong negative skew (Fig. 33C). 0.014 ppm Mn2+ treated 
crayfish displayed a similar, but larger distribution, increasing the most of any group from 
previous weeks.  
100 
Figure 33. After-Shadow Distribution Comparison of Border Time Moving 
Treatment groups are represented on the x-axis and percent of time moving on the y-axis. (A) 
Baseline results showed that all groups displayed similar distributions although each contained 
different severity of skewness (Kruskal-Wallis: p-value = 0.8). (B) During weeks 9-12, 0.0028 
ppm Mn2+ treated crayfish were the only group that did not decrease in range (Kruskal Wallis p- 
value = 0.006; Dunn’s test: Control-0.014 ppm p-value = 0.02, 0.0014 ppm-0.014 ppm p-value = 
0.04). (C) During weeks 21-24, the control group distribution greatly increased, while 0.014 ppm 















































































When analyzing time spent moving within the After-Shadow baseline recording, all 
groups spent shorter time moving when the shadow initially passed, increasingly spending more 
time moving as time progressed; all groups exhibited the sharpest increase during the first two 
minutes (Fig. 34A). After the initial two minutes, the control group plateaued, spending 
relatively the same amount of time moving for the remainder of the video. In contrast, Mn2+ 
treated crayfish continually increased time moving until minute 8. 
During week 12, all groups spent more time moving immediately after the shadow sweep 
and continued to display positive trends as the recording progressed (Fig. 34B). During week 24, 
control crayfish weighted their movement towards the end of the video with reduced movement 
during the first five minutes (Fig. 34C). All Mn2+ treatments, in comparison, spent more time 
moving than the control group within the first several minutes, similar to week 12. 
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Figure 34. Time Moving Within the 10-Minute After-Shadow Recording 
Time in minutes is represented on the x-axis and percent of time spent moving on the y-axis. (A) 
Baseline time moving over the 10-minute video with all groups displaying positive trends, with 
the control group plateauing early on (Kruskal Wallis: Minute 1 p-value = 0.06; Minute 5 p-
value = 0.55; Minute 10 Kruskal Wallis p-value = 0.08). (B) Week 12 time moving over the 10-
minute video showed all groups displaying similar increasing trends (Kruskal Wallis: Minute 1 
p-value = 0.87; Minute 5 p-value = 0.94; Minute 10 p-value = 0.86). (C) During week 24, the
control group initially differed by increasing time moving at a faster rate than any other group 









































































Before-Shadow Stimulus Motility Discussion 
Control crayfish and Mn2+ treated crayfish often exhibited different baseline results. 
While differing pre-treatment behavior may seem strange, every crayfish has a different state 
dependence that contributes to behavioral variance. Additionally, animals in captivity are 
believed to increase behavioral variance (McPhee 2004) which may further contribute to the 
differing baseline results. For this reason, observing trends over time in addition to treatment 
concentration is very important. Exploring and processing information about a novel 
environment is essential under natural conditions for foraging, predator detection and overall 
survival, so it is no surprise that information gathering is deeply embedded even within captive 
bred crayfish behavior. 
Distance and Time Moving 
Observations of pre-shadow behavior over the 6-month experiment revealed that control 
crayfish increased distance moved each week, traveling mainly in the border zone, with the 
strongest increases occurring before weeks 5-8. I had expected elevated manganese exposure to 
be associated with motility deficits, as well as impacts in decision making ability due to evidence 
from previous studies indicating Mn2+ exposure may affect these pathways (Bakthavatsalam et 
al. 2014; Sköld et al. 2015). For the first twelve weeks, 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ 
treated crayfish increased weekly distances traveled, but at a lesser rate of increase than the 
control group, with each decreasing distance traveled thereafter. In comparison, 0.014 ppm Mn2+ 
treated crayfish began moving further distances after the 1st week of Mn2+ exposure, continuing 
to increase at high rates throughout weeks 9-12, and moving the furthest distances of any group 
for the remainder of the experiment. When analyzing the distribution of each group’s distance 
traveled, 0.014 ppm Mn2+ treatment data displayed the largest increase in variability beginning 
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weeks 9-12, continually becoming progressively larger. While the control group’s distribution 
also increased, it occurred in smaller increments. 
Comparing distance traveled and time moving provides information on the rate of 
movement. For the control group, time spent moving was positively related to their distance 
traveled. Control crayfish gradually increased time moving, with a sharper increase during weeks 
17-20, similar to their distance moved; a slight decrease was present in both thereafter for the
remaining weeks. 0.0028 ppm Mn2+ treated crayfish displayed the most similar trends to the 
control group, as they increased distance traveled and time moving, but to a smaller degree, with 
larger reductions during the last four weeks. In comparison, as weeks progressed 0.0014 ppm 
Mn2+ treated crayfish moved constant distances until weeks 21-24, where a reduction in distance 
and time spent moving occurred. 0.014 ppm Mn2+ treated crayfish appeared hyperactive early on, 
spending a higher percentage of time moving during weeks 1-4 than the control group did 
throughout the entire experiment. Increased time moving was positively related to the elevated 
distances traveled by this group. The continual weekly increases in distance moved compared to 
the time spent moving indicates that 0.014 ppm Mn2+ treated crayfish were moving at 
increasingly high velocities. 
Place Preference 
For zone crossing frequency, the control group spent little time crossing into the center 
zone until the last four weeks. There was a consistent negative trend present, with a slight 
increase during weeks 21-24 mainly due to a single outlier. However, control crayfish did 
increase tendency to move throughout zones suggesting they were becoming more familiar and 
comfortable with their environment. 0.0014 ppm Mn2+ treated crayfish initially decreased zone 
crossing frequency by 35.4%, the most of any group, while remaining concealed within the 
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borders; however, they presented an increasing trend thereafter crossing zones at a higher 
frequency then the control group by weeks 9-12. 0.0028 ppm Mn2+ and 0.014 ppm Mn2+ treated 
crayfish increased zone crossing frequency, crossing more than the control group by weeks 5-8. 
Mn2+ treated crayfish displayed elevated zone crossing compared with the control during weeks 
21-24, with more movement between zones. “Darting” movements were observed, primarily
within 0.0014 ppm Mn2+ treated crayfish during these last four weeks, as crayfish temporarily 
entered the border, but immediately reentered the center zone. These movements consisted of 
unpredictable movement patterns consisting of abrupt episodes of progression and periodic 
immobile phases. When analyzing the distribution of data within each group, the control group’s 
distribution was the largest during baseline testing, although it continually decreased each week. 
Variability of zone crossing behavior within all Mn2+ treated crayfish increased to similar size of 
the control group by weeks 9-12, continuing to become larger by weeks 21-24. 
Examining data by zone showed that all groups spent over 85% of their time within the 
border during the pre-shadow recording, although differing trends were present between groups. 
Control crayfish increased their time spent in the border until weeks 17-20, where they displayed 
an increasing preference for the center zone. 0.0014 ppm Mn2+ treated crayfish initially displayed 
a similar trend as the control group during the first eight weeks, deviating thereafter with a 
reduction of time spent in the border. While 0.0028 ppm Mn2+ treated crayfish initially increased 
border time the most of any group during weeks 1-4, they displayed periodic highs and lows 
without one clear trend being present. However, after weeks 1-4, they never spent as much time 
in the border as the control group, remaining in the center zone more than any other group. 
In opposition, 0.014 ppm Mn2+ treated crayfish continued spending more time within the 
border with steeper elevations beginning weeks 13-16 and continuing until weeks 17-20. While 
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all groups displayed positive trends for border time, the control group continually spent the most 
time within the border. Similar to observations in other parameters, the control group’s 
distribution decreased from baseline and remained this way for a majority of the experiment. 
Variability of time moving for Mn2+ treated crayfish opposed this trend, as they increased from 
baseline, surpassing the control group by weeks 5-8. 
Within-video Analysis 
Within-video analysis of distance traveled, and time spent moving within the pre-shadow 
recordings showed that each group displayed relatively similar periods of activity within the 10-
minute recordings as weeks progressed. Analyzing distance moved and time moving within the 
baseline 10-minute video revealed all groups habituated to the new environment, decreasing 
motility throughout each minute during both week 12 and week 24. 
Before-Shadow Behavioral Overview 
Overall observations of pre-shadow behavior over the 6-month experiment revealed that 
control crayfish increased distance moved throughout the experiment, with the strongest 
increases occurring before weeks 5-8, while spending more time moving, specifically in the 
border zone. During the last eight weeks, however, they reduced overall movement, while 
spending more time exploring the center zone. There was a continual reduction in zone crossing 
frequency, although a small increase was present at the end of the experiment indicating that 
while crayfish were spending most of their time exploring the center zone, they were moving 
freely and still crossing into the border. 
During weeks 1-4, 0.0014 ppm Mn2+ treated crayfish reduced distances traveled and 
frequency of zone crossing resulting in very little movement while remaining within the border 
zone. By weeks 9-12, 0.0014 ppm Mn2+ treated crayfish had only displayed a 1.9% increase in 
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distance moved from baseline compared with a 29.3% increase from the control group. While 
zone crossing frequency remained the lowest of any group until weeks 13-16, there was an 
increased prevalence of zone crossings. Throughout the experiment, they continually decreased 
distance moved and time moving with most drastic reductions occurring during weeks 21-24. 
During the last four weeks, this treatment displayed its lowest motility remaining mostly in the 
center zone. 0.0014 ppm Mn2+ treated crayfish were mostly remaining within the open center 
zone while darting into and out of the border. 
Similar to 0.0014 ppm Mn2+ treatments, 0.0028 ppm Mn2+ treated crayfish spent weeks 
1-4 within the border displaying low motility. Distance traveled increased until weeks 13-16,
although at a lesser rate of increase than the control group (+22.2%) with crayfish activity 
concentrated in the border zone. While distance decreased thereafter, time spent moving 
continued to increase until weeks 17-20 and zone crossing frequency increased the largest 
percentage of any group, indicating restless behavior. During weeks 21-24, 0.0028 ppm Mn2+ 
treated crayfish reduced motility while remaining in the center zone and displaying darting 
behavior like 0.0014 ppm Mn2+ treatments. The two lower Mn2+ treatment concentrations spent 
more time within the center zone while moving lesser distances than the control group. 
When examining each experimental parameter that was tested, 0.0014 ppm Mn2+ and 
0.0028 ppm Mn2+ treated crayfish typically retained similar results, while exposure to the highest 
Mn2+ treatment concentration often led to contrasting trends. 0.014 ppm Mn2+ treated crayfish 
increased time moving within the first four weeks by 11.7% while control crayfish did not 
increase by this percentage until weeks 17-20. 0.014 ppm Mn2+ treated crayfish continually spent 
an elevated amount of time moving, while also increasing weekly distances traveled throughout 
the experiment. They increased 60% by weeks 9-12 and continued to move the furthest distances 
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of any group for the remainder of the experiment. While time moving remained constant after 
weeks 1-4, distance continued to increase indicating these crayfish were moving at higher 
velocities each week. While they remained mostly in the border until weeks 17-20, a small 
reduction occurred weeks 21-24 with an increased prevalence of crossing frequency.  
Furthermore, increased variability among Mn2+ treatment behaviors compared with 
baseline testing and the control group reoccurred throughout several parameters. This most often 
occurred among 0.0028 ppm Mn2+ and 0.014 ppm Mn2+ treatments, with the highest Mn2+ 
concentration typically being the most severe and worsening over time. Chronic stress may cause 
difficulty in regulating homeostatic mechanisms resulting in psychological and behavioral 
abnormalities. Crayfish exposed to such stressors may display a reduced ability to efficiently 
complete typical behaviors that are tuned for optimal survival. The body must first cope with 
stress, limiting available resources to complete appropriate behaviors resulting in increased 
behavioral variability. It may be difficult to pinpoint consistent behavioral changes in crayfish 
exposed to elevated Mn2+, although increased behavioral variability may be a key component of 
how Mn2+ exposure decreases crayfish survivability.  
After-Shadow Stimulus Motility Discussion 
Distance and Time Moving 
Motility after passing of the shadow stimulus is of high importance in determining how 
elevated Mn2+ exposure impacts behavior when the animal is in the presence of a threat. It was 
expected for crayfish to display reduced After-Shadow motility within the first several weeks of 
experimentation due to the presence of a potential threat. Although distances moved were lower 
than before-shadow recordings, control crayfish still repeatedly moved further distances peaking 
at week 8. Thereafter, control crayfish showed small weekly reductions for the remainder of the 
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experiment, but remained elevated from baseline. 0.0014 ppm Mn2+ treated crayfish displayed 
similar trends, with a smaller increase throughout the eight weeks, and not presenting a reduction 
until weeks 21-24. In comparison, 0.0028 ppm Mn2+ treated crayfish increased very little over 
the first twelve weeks, while displaying the largest reduction of any group thereafter. The highest 
Mn2+ treatment concentration displayed similar trends as 0.0014 ppm Mn2+ treated crayfish 
throughout the experiment, moving comparable distances until weeks 17-20 where a larger spike 
occurred.  
Control crayfish also repeatedly spent more time moving until weeks 5-8, exhibiting a 
slight negative trend thereafter but still moving 59% more than baseline. 0.0014 ppm Mn2+ 
treated crayfish resembled the control group, although showing a weaker initial increase and 
strong reduction weeks 21-24. Although initially increasing for the first four weeks, 0.0028 ppm 
Mn2+ treated crayfish decreased time moving to below their baseline values by weeks 5-8 and 
continued to decrease for the rest of the experiment. 0.014 ppm Mn2+ treated crayfish again 
displayed trends similar to 0.0014 ppm Mn2+ treatments. While 0.014 ppm Mn2+ treated crayfish 
did not consistently spend more time moving than the control group as in the before-shadow 
recordings they continued to display elevated variability primarily during weeks 21-24.  
Place Preference 
Like the observations of before-shadow zone crossing, the control group decreased 
weekly frequency during the After-Shadow recording. 0.0014 ppm Mn2+ treated crayfish 
increased frequency by 56%, peaking at weeks 9-12 and decreasing to baseline levels thereafter; 
this was the only group not to decrease below baseline values. 0.0028 ppm Mn2+ and 0.014 ppm 
Mn2+ treated crayfish exhibited similar trends as the control group until weeks 17-20 where both 
groups increased frequency. While the control group’s distribution was the largest during 
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baseline testing, it continually decreased each week; variability within all Mn2+ treated crayfish 
increased to similar size of the control group by weeks 9-12. 
Control crayfish increased After-Shadow time spent in border until weeks 5-8 although 
changes were minute as they were already spending over 85% of their baseline here. All Mn2+ 
treated crayfish increased during weeks 1-4 by more than 10% within the first four weeks 
whereas the control group only increased by 1%. Throughout the experiment, all Mn2+ treated 
crayfish continued spending elevated time in the border compared with their baseline results. 
Again, 0.0014 ppm Mn2+ treatment distribution increased more so than any other group as weeks 
progressed. 
Within-video Analysis 
Within video-analysis of distance moved and time spent moving during baseline testing, 
week 12, and week 24 contained similar results, as well. When placed into a novel environment, 
crayfish will often momentarily freeze, to analyze potential dangers, and then enter a motility 
phase (Tierney and Andrews 2013). During week 12, however, a reduction in freezing occurred 
upon entering the environment as crayfish immediately initiated the motility phase which was 
postulated to be due to memory of previous weeks. By week 24, control crayfish reduced initial 
time and distance moving, moving less than they did during the first three minutes of baseline 
testing. No other differences were observed between groups for these parameters. 
After-Shadow Behavioral Overview 
Overall, during the 10-minute span After-Shadow stimulus control crayfish increased 
distance moved increasing by 101% at weeks 5-8, contributed mainly to increased time moving 
in the border. After weeks 5-8, the control group gradually moved lesser distances each week 
while also reducing movement time. While still spending elevated time in the border zone 
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compared with baseline during weeks 5-8, they began spending more time within the center 
zone, becoming more prominent during weeks 21-24, suggesting they were freely exploring 
without darting between zones.  
 Meanwhile, 0.0014 ppm Mn2+ treated crayfish increased distance moved until weeks 9-
12 by 85.6%, leveling off and decreasing during weeks 21-24. All Mn2+ treated crayfish 
displayed a larger reduction in distance moved than control crayfish during the last four weeks. 
Like other Mn2+ treatments, they drastically increased border time during weeks 1-4, and 
continued spending more time there until weeks 17-20. After weeks 17-20 they began spending 
more time in the center zone, although still frequenting the border for short bouts of elevated 
activity. 
0.0028 ppm Mn2+ treated crayfish increased distance by 23.2% over the first twelve 
weeks, gradually decreasing thereafter to only 1.8% above baseline during weeks 21-24. During 
the first four weeks, there was a small peak in time moving although a gradual decreasing trend 
was present resulting in a 10% reduction from baseline.  By weeks 21-24 this group was moving 
the least distances of any group and spending the least amount of time moving while occupying 
the center zone. 
0.014 ppm Mn2+ treated crayfish continually increased distances moved, leveling off, and 
then peaking during weeks 17-20 at 111% above baseline; although their rate of increase was not 
as fast as the control group, their peak was still the largest. Until weeks 9-12, they continually 
spent more time traveling further distances within the border. After this point, they spent less 
time moving within the border zone, but continued to travel further distances, indicating they 
began moving at higher velocities when in the border as compared with the center. Until weeks 
21-24, they had remained mostly in the border, although during the last four weeks, they spent
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more time in the center while moving less. All Mn2+ treated crayfish reduced distance traveled 
and increased zone crossing frequency during the last four weeks, with 0.014 ppm Mn2+ treated 
crayfish increasing the most. 
Manganese Neuropathies 
Manganese has essential roles in a multitude of biological pathways. For this reason, 
manganese toxicity may lead to changes in sensory, learning/memory, and/or motor networks 
which are manifested in behavioral change. Different levels of Mn2+ exposure may impact 
behavior in different manners due to each concentration activating and inhibiting various cellular 
pathways. Crayfish chronically treated with 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ 
concentrations often exhibited decreased locomotion while 0.014 ppm Mn2+ treated crayfish 
displayed hyperactivity that lasted throughout experimentation. In comparison, 0.0014 ppm Mn2+ 
and 0.0028 ppm Mn2+ concentrations typically spent increased time in open areas during pre-
shadow trials, while all Mn2+ treated crayfish spent most After-Shadow time concealed in the 
border zone compared with their baseline results.  
I postulate once crayfish were exposed to elevated manganese concentrations, Mn2+ 
entered crayfish circulation via DMT1-like transporters within the gills or via antennule 
chemoreceptors. It is plausible that Mn2+ may exploit these transporters to transverse the cell 
membrane thereby also disturbing divalent ion movement specifically within the gill epithelium. 
Manganese accumulation in dopamine and GABA-rich regions have been extensively studied in 
several vertebrate and invertebrate models due to symptomatic resemblance between Parkinson’s 
disease and manganese toxicity. Although cellular aspects were not studied, I analyzed crayfish 
behavior to determine consistencies with results from previous research in order to determine 
possible neuropathies.  
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I hypothesize observed behavioral changes are due to compounding effects on several 
intercommunicating cellular networks. Dopamine, a crucial basal ganglia chemical, has been 
extensively studied in vertebrate models, although little is known about how it is affected by 
Mn2+ in invertebrates. While all bilaterian animals attain DAT genes, evidence suggests 
invertebrate DAT structurally differs from DAT of vertebrate species, making it plausible that 
differing structures may result in different manganese-dopamine interactions (Pörzgen et al. 
2001). Additionally, it has been suggested that crustacean tyrosine hydroxylase (TH) positive 
cells, important for dopamine production, exhibit greater manganese resistance than mammalian 
cells (Ponzoni 2017).   
In humans, children exposed to elevated manganese levels exhibited significant 
reductions in dopaminergic synaptic function involved in circuits mediating executive function 
(Carvalho et al. 2014). Altered DAT transporters are thought to be a component behind 
dopamine disruption in manganese toxicity, Parkinson’s disease (Huang 2007; Felicio et al. 
2009; Cummings et al. 2011; Roth et al. 2013), and attention-deficit-hyperactive disorder 
(ADHD) (Mergy et al. 2014). A mutated variation of the human DAT gene, found in people with 
the neuropsychiatric disorders leading to excess dopamine within synapses, was inserted into 
mice. While the mice did not become hyperactive, likely due to DAT still removing synaptic 
dopamine but at a lower efficiency, they did display darting behavior (Mergy et al. 2014) similar 
to observations in 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ treatments. Darting behavior was 
mediated after mice were given methylphenidate (Ritalin), often medically prescribed for 
ADHD, suggesting that altered DAT transporters may be a component behind hyperactivity. 
Furthermore, darting behaviors in Mn2+ treated crayfish consistent with the genetically altered 
mice indicates elevated Mn2+ exposure may dysregulate dopamine transporters in invertebrates. 
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While lower Mn2+ treated crayfish were not hyperactive, perhaps these symptoms are the onset 
of hyperactivity observed in the highest Mn2+ treatments. 
Additionally, circadian dysfunction has been observed in several neurological disorders 
including Parkinson’s disease possibly due to dopamine dysregulation. Rats repeatedly exposed 
to MnCl2 for one month displayed circadian dysregulation which is thought to be related to 
dopaminergic degeneration in the brain due to its regulation of the clock gene expression (Li 
2017). Although differences among vertebrate and invertebrate dopamine transporters may 
determine the influence of Mn2+ on each of these systems, strong evidence indicates that in 
crayfish, dopamine is partially responsible for neuromodulating the caudal photoreceptor, which 
is postulated to be essential in the synchronization of locomotor circadian rhythm (Rodriguez-
Sosa et al. 2008). If Mn2+ does similarly impact crayfish dopamine transporters, this may give 
reasoning behind motility in Mn2+ treated crayfish that differed from the control group and may 
further exacerbate neuroinflammation. 
However, GABA dysregulation, resulting in deleterious effects on motor control, has 
been observed as the onset of manganese toxicity prior to other chemical disruption in rats 
exposed to MnCl2 contaminated drinking water (Gwiazda et al. 2002). While several studies 
have discovered conflicting results for how manganese impacts GABA differing by tissue site 
and exposure route (Struve et al. 2007; Erikson et al. 2002), slight changes may still lead to 
biochemical disturbance due to its vast neurobiological interaction as the prominent inhibitory 
chemical. 
When Bonilla (1985) chronically exposed mice to 0.1-5 ppm Mn2+, he discovered an 
increase in total activity during the 1st month, which remained constant for months 2-5, and 
decreased during the eighth month of exposure. Although this experiment focused on vertebrate 
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behavior, the experimental design as well as observed behaviors in Mn2+treated animals were 
comparable to the current study, with specific relation to the elevated motility observed in 0.014 
ppm Mn2+ treatments. Altered striatal GABA levels occurring within 2 months of Mn2+ exposure 
are thought to be responsible for increased motor activity (Bonilla et al. 1978). Due to the 
inhibitory importance of GABA inactivation at the crayfish neuromuscular junction (Horwitz 
and Orkand 1980), dysregulation in crayfish could be responsible for elevated motility observed 
in Mn2+ treatments.  
GABA imbalance is also believed to play a role in anxiety disorders in vertebrates 
(Lydiard 2003) and invertebrates (Fossat et al. 2015) with GAT-1 dysfunction leading to tremors 
and anxiety (Mombereau et al. 2005) which are similar to symptoms of manganese toxicity. 
Stressed rats exhibited reduced GABA receptor density (Biggio et al. 1990), while anxiety 
patients often have a downregulation of GABA transmission within the brain (Tiihonen et al. 
1997; Bremner et al. 2000). In comparison, GABA is essential for suppressing anxiety-like 
behavior of stressed crayfish (Fossat et al. 2015). 
Additionally, GABA dysregulation influences glutamate levels, the main excitatory 
neurotransmitter of the crayfish neuromuscular junction (Kawagoe et al. 1981), due to their 
interconversion process via glutamine synthetase (Erikson et al. 2002; Lee et al. 2009). Without 
glutamate uptake from the synaptic cleft, extracellular concentrations may quickly rise to 
excitotoxic levels thereby jeopardizing cell integrity and further breaking the glutamate-GABA 
balance. Mn2+ may also directly disrupt glutamate transporter function dysregulating excitatory 
synapses as well as inhibiting several steps within ATP synthesis (Erikson et al. 2002; Lee et al. 
2009). NAAG metabolites, important for neuron-glial communication, and interacts with NMDA 
receptors for memory formation, may be another target of Mn2+ toxicity (Guilarte and Chen 
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2007). Glutamate dyshomeostasis and metabolic dysregulation may have compounding impacts 
on motility resulting in excitotoxicity and loss of energy production resulting in fatigue observed 
as reduced time and distance moving in all Mn2+ treated crayfish during weeks 21-24. 
The serotonergic system is an ancient monoamine pathway conserved across taxa 
(Mohammad-Zadeh 2008) which may also have a prominent role in Mn2+ toxicity. In crayfish, it 
is used as a neuromodulator, neurotransmitter, and hormone. Concerning motility, 5-HT 
increases synaptic strength at the crayfish neuromuscular junction (Page and Cooper 2004) and 
regulates tone of motor pathways in snail and leeches, generally augmenting arousal and 
excitation of motor networks (Gillette 2006). Serotonin also has regulatory roles within cricket 
(Saifullah and Tomioka 2002) and rat (Guillete et al. 1993; Prosser 2003) circadian pacemakers, 
as well as crayfish retina photoreceptors and neuroendocrine system which are both postulated as 
circadian pacemakers. Therefore, diurnal variation may influence motor and sensory activity 
(Aréchiga and Rodriquez-Sosa 1997). In addition to motor disruption, elevated manganese 
exposure has shown to dysregulate rat (Li et al. 2017) and human (Bowler et al. 2007) circadian 
rhythms. While 5-HT has neuromodulatory roles within these circuits as does dopamine, it is 
unclear whether the underlying 5-HT network was the main target of manganese toxicity. 
As a physiological response to stress, 5-HT levels within the crayfish brain significantly 
increase which indirectly elevates hemolymph-glucose levels as preparation for fight/flight. 
However, stress-induced hyperactivity of the serotonergic system is believed to be the 
underlying mechanism of anxiety-like behavior in crayfish (Fossat et al. 2015). It was previously 
thought that anxiety was exclusive to humans, although demonstrations in rat (Takeda et al. 
2007) and crayfish (Fossat et al. 2015) revealed primitive stress behavior similar to complex 
anxiety of higher organisms. Additionally, anxiety-like behavior in crayfish was suppressed 
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when injected with human anti-anxiety medication, suggesting similar neurological mechanisms 
(Fossat et al. 2015). Avoidance behavior and hyperactivity, including restlessness, and eventual 
fatigue are often symptoms of anxiety in humans (U.S HHS 2018). Furthermore, excess available 
energy due to hyperactive 5-HT releasing elevated glucose into the hemolymph may in part be 
responsible for the observed hyperactive behavior in 0.014 ppm Mn2+ treatments. 
 Although stress increases serotonergic activity, chronically elevated 5-HT release may 
lead to modulatory downregulation of the serotonergic circuit to prevent excitotoxicity (Page and 
Cooper 2004). Serotonin receptor down-regulation and exhaustion of energy stores, particularly 
if ATP production is inhibited, may be responsible for motility reductions within Mn2+ treated 
crayfish during the last four weeks. Previous research has discovered that crayfish exposed to the 
same Mn2+ concentrations as this study for two weeks resulted in reduction of 5-HT 
immunofluorescence within the ventral nerve cord (Antosen et al. 2018). It is unknown as to 
whether the decrease was a direct result of elevated Mn2+ exposure, but it is postulated to be due 
to the release of elevated levels leading to an exhaustion of serotonin or downregulation of the 
system. For these reasons, I postulate crayfish exposed to elevated Mn2+ experienced 
motivational changes, circadian disruption, and motor disturbance leading to suppressed motor 
activity in lower concentration Mn2+ treatments, with higher Mn2+ concentrations resulting in 
hyperactivity and anxiety-like behavior.  
Studies on starfish tube feet (Sköld et al. 2015) and rat brains (Yousefi Babadi et al. 
2014) suggest that elevated manganese exposure increases acetylcholinesterase (AChE) activity 
responsible for acetylcholine transmission termination. In contrast, P. clarkii exposed to metal 
pollutants lead to strong AChE inhibition which could result in excitotoxic acetylcholine levels 
(Fernandez-Cisnal et al. 2018). In crayfish, ACh is of high abundance within the ventral nerve 
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cord responsible for modulating central pattern generators and coordinating interneurons 
(Tschuluun et al. 2009). Exposure route and concentration of manganese may play a role in how 
ACh is affected which may have contributed to low, or elevated motility observed in Mn2+ 
treatment groups. 
Calcium has numerous biological roles that may affect each of the previously mentioned 
pathways. Ca2+ is tightly regulated at low concentrations, although homeostatic dysregulation 
may lead to Ca2+ elevation to levels considered excitotoxic. Ca2+ dysregulation is often a marker 
of neurological diseases (Bezprozvanny 2009) suggesting it may be a primary target of 
manganese toxicity. Ca2+ ions are important in crustacean physiology with essentiality in 
synaptic plasticity and induction of long-term facilitation (Beaumont et al. 2001). 
Ca2+importance is paralleled in vertebrates, as changes in Ca2+metabolism may alter learning 
ability, immune response (Liu et al. 2015), and may promote apoptosis (Chen et al. 2016).  
Due to calcium’s wide range of physiological roles as a messenger in signal transduction 
pathways (Berg et al. 2015) and neuronal signaling (Berridge 1998), it is plausible that elevated 
Mn2+ has ability to inhibit communication in many areas.  
Ca2+ is directly and indirectly needed for depolarization evoked neurotransmitter release 
observed in glutamatergic synapses (Kupchik et al. 2008) present in the crayfish neuromuscular 
junction, as well as inhibitory GABA release. Manganese may dysregulate neurochemical 
pathways responsible for crayfish locomotion. Mn2+ may competitively inhibit Ca2+ movement 
and binding at the crayfish neuromuscular junction, suppressing glutamate release. Furthermore, 
it may directly inhibit muscle membrane depolarization further reducing neuromuscular 
performance (Mounier and Vassort 1975). This may provide evidence behind the low activity 
levels within the lower exposure groups.  
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Mn2+ may also directly and indirectly deregulate Ca2+ mediated signaling pathways. Mn2+ 
may have impacts on cAMP signaling indirectly disabling Ca2+ channels, disrupting 5-HT 
cascades that modulate neurotransmitter release for escape behavior (Araki et al. 2005) and 
resulting in possible learning/memory deficits (Momohara et al. 2016). Additionally, expression 
of calmodulin, a calcium-binding protein, may be reduced with Mn2+ exposure further bringing 
calcium signaling to a halt (Liu et al. 2015). Slight increase in mitochondrial calcium uptake may 
lead to increased activity of the electron transport chain as it controls the rate of ATP production. 
However, Ca2+ overload may activate ROS production leading to formation of free radicals. 
Furthermore, Ca2+ overload may dysregulate mitochondrial function by triggering pores to open 
within the mitochondrial membrane, resulting in loss of the electrochemical gradient and 
eventual apoptosis. 
The stress response is essential for survival as it physiologically prepares the organism 
for fight or flight. Once the immediate stressor is gone, the body enters a resistance phase where 
it begins to repair itself by demobilizing stress hormones and normalizing the body back to its 
pre-stress state (Selye 1950). However, chronic stress does not allow the body to heal due to 
sustained apprehension leading to eventual exhaustion. Chronic stressors may decrease the 
efficiency of the immune system thereby increasing susceptibility to disease, and in this instance, 
compounding the impacts of elevated Mn2+ exposure. 
General Conclusions 
Both length and concentration of elevated manganese exposure have an impact on 
motility. It is postulated that a dose response curve was not present due to elevated manganese 
having a high range of impacts on cellular physiology primarily including Ca2+  homeostasis 
which may deregulate any of the previously mentioned biochemical pathways. In a natural 
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setting, suppressed motility in open areas and darting behavior observed in the lower Mn2+ 
treated crayfish may greatly increase predation risk in a natural setting due to little movement 
and increased time spent in the open areas. Reduced behavioral output is consistent with 
locomotor defects in manganese treated zebrafish (Bakthavatsalam et al. 2014) and manganism 
patients (Avelino 2014). Additionally, reductions in motility observed in latter weeks may also 
influence ability to forage. 
Elevated motility from 0.014 ppm Mn2+ treatments, open-area avoidance, and 
restlessness (observed as small continuous movements and climbing behavior of crayfish 
attempting to escape the tank) are associated with anxiety-like and hyperactive behaviors, which 
often coexist due to similar, or overlapping pathophysiologies (Biederman and Faraone 2005). 
Studies have found that crayfish exposed to physiological (Fossat et al. 2015) and psychological 
(Bacque-Cazenave et al. 2017) stressors exhibit anxiety-like symptoms similar to observations in 
mice (Mombereau et al. 2005), rats (Molina et al. 2011; Takeda et al. 2007), and humans 
(Bouchard et al. 2007). Elevated movement when chronically exposed to Mn2+ was comparable 
to Attention Deficit Hyperactivity Disorder (ADHD) symptoms seen in children exposed to 
manganese, possibly due to similar impacts on metabolism (Farias et al. 2010; Hong et al. 2014). 
ADHD is a neurodevelopmental disorder characterized by hyperactivity, inattention, delinquent 
behaviors, and social problems (Hong et al. 2014) commonly co-occuring with anxiety disorders 
(Grogan et al, 2018). In children, elevated manganese exposure may increase succeptibility of 
the developing brain potentially increasing prevelance of mood disorders associated with ADHD 
(Hong et al. 2014). Manganese is hypothesized to modulate various chemical networks which are 
relevant to the pathophysiology of ADHD (Hong et al. 2014). This may conribute to the 
noteworthy interaction between manganese exposure and ADHD status. Rats with zinc-
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deficiency, a key marker of manganese toxicity, exhibited motor deficits and anxiety-like 
behavior after just two weeks (Takeda et al. 2007) further suggesting that manganese has ties in 
the pathogenesis of these co-morbid neurobehavioral disorders.  
Elevated manganese exposure has become of increasing interest due to adverse impacts 
that low-level manganese, at concentrations currently considered safe for human consumption, 
has on children. However, much of the previous research has focused exclusively on human 
health, disregarding the impacts of anthropogenic manganese on the environment. Crayfish, 
resilient bio indicators of aquatic contamination, respond to environmental stressors with clear 
behavioral changes that provide useful information on the sub-lethal components of elevated 
manganese exposure so that we can better understand how the health of aquatic organisms is 
influenced. This research concludes that exposure to elevated levels of Mn2+, at concentrations 
below EPA secondary standards, impact crayfish behavior.  
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CHAPTER 4 
 THREAT AVOIDANCE BEHAVIOR 
Animals survive threatening situations by effectively producing prompt escape, freezing, 
or fighting. Threat-avoidance behavior is finely tuned and deviation from this response may 
result in decreased survivability. Analyzing behavioral output gives insight on how 
environmental stressors impact cellular components. This phase of research involved presenting 
a passing shadow stimulus to determine the impacts of elevated Mn2+ exposure on danger 
recognition and response. 
All crayfish remained in the novel environment for 20 minutes before the shadow 
stimulus was manually activated; over 80% of all crayfish met shadow criteria within 25 
minutes. As the shadow passed, crayfish were able to freely move throughout all zones of the 
novel environment while threat-avoidance and subsequent behaviors were recorded. Proper 
threat-avoidance response and the behaviors that follow are important for the survival. Baseline 
(Week 0) testing was completed for pre-treatment comparison. Thereafter, control crayfish and 
Mn2+ treated crayfish were exposed to a passing shadow stimulus each week for 24 weeks. 
Weekly behaviors were analyzed for six months to monitor the exposure time needed for low-
level Mn2+ to cause behavioral change. Data were then binned due to weekly behavioral noise; 
however, binning still allowed for overall behavior trends to be observed.  
Three major categories (escape, stopping, and defensive) were created to characterize 
observed behaviors (Table 1). Within these three major categories, subclassifications were 
created to further describe observed behaviors in more detail; subcategories within stopping 
behavior included startle freezing and freezing, while escape behavior consisted of tail-flipping 
(single and multiple flexions) and fleeing (Table 1). 
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Table 1. Threat Avoidance Behaviors 





Behavior Subcategories Description 
Escape 
Tail-flip (Single-Flexion) 
Rapid abdomen flexion resulting in 
immediate, full-out escape behavior 
Tail-flip (Multiple-
Flexion) 
Repetitive rapid abdomen flexion 
Fleeing 
Increased movement with rapid change 
of direction to actively avoid the shadow 
stimulus 
Stopping 
Freeze All movement was ceased 
Startle Freeze Sudden jerk reaction preceding freezing 
 Defensive 
Elevated thorax while extending 
chelipeds in an aggressive manner (Kelly 
and Chapple, 1990). 
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Major Threat-Avoidance Behaviors 
When characterizing behaviors by the 3 major categories, stopping in response to the 
passing shadow stimulus was the most frequent reaction consisting of over 70% of behavior 
among all treatments. During baseline testing, control crayfish displayed the highest percentage 
of stopping behavior of any group at 87.5% (Fig. 35A). An immediate reduction in stopping 
frequency occurred after one week and decreased until weeks 5-8 by 12%. Control crayfish 
thereafter gradually increased stopping frequency throughout the remaining 6 months where 
levels resumed baseline percentages. 0.0014 ppm Mn2+ treated crayfish did not immediately 
reduce stopping frequency during weeks 1-4, while reducing frequency by 6.3% during weeks 5-
8 (Fig. 35B). Stopping frequency gradually increased afterwards. Although a drop appeared 
during weeks 17-20, stopping frequency still increased 3% above baseline results by weeks 21-
24. 
Animals treated with the second highest Mn2+ concentration displayed the most 
consistent trends in stopping behavior over the 6 months. Figure 35C shows slight frequency 
reductions from baseline every other weekly bin, with frequency remaining near 75% for the first 
sixteen weeks. The largest increase occurred during the last four weeks where 84.4% of crayfish 
selected stopping behavior. While a prominent increase didn’t occur until twelve weeks after the 
control group, they displayed the largest increase from baseline (+9.6%). 0.014 ppm Mn2+ 
treated crayfish were the only group to initially increase stopping frequency during the first four 
weeks (Fig. 35D). Trends similar to 0.0014 ppm Mn2+ treated crayfish occurred afterwards 
although change was more drastic. 
In opposition to stopping behavior, control crayfish continually increased escape 
frequency until weeks 5-8, choosing this behavior 18.5% more than baseline testing (Fig. 35A). 
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Escape frequency slightly decreased during weeks 9-12 but remained elevated compared with 
baseline testing until weeks 13-16. As stopping became the prominent behavior of choice after 
weeks 13-16, frequency of escape behavior decreased in a proportionate manner. Stopping and 
escape behavior were often directly proportional due to a very small percentage of animals 
displaying defensive behavior. While animals treated with the lowest Mn2+ concentration did not 
display any escape during baseline, they immediately increased escape frequency during weeks 
1-4, continuing to gradually increase throughout weeks 5-8 (Fig. 35B). They began reducing
frequency during weeks 13-16, several weeks earlier than the control group, although the 
reduction was only temporary with frequency remaining elevated in later weeks compared with 
the control group. 
0.0028 ppm Mn2+ treatment increase was less immediate than the control group, 
remaining at baseline levels until weeks 5-8. By weeks 9-12, escape frequency increased by 25% 
displaying similar trends as 0.0014 ppm Mn2+ treated crayfish after weeks 9-12 while remaining 
elevated from baseline (Fig. 35C). 0.014 ppm Mn2+ treated crayfish also did not attempt to 
escape during baseline testing, although frequency gradually increased for the first twelve weeks 
(Fig. 35D). After weeks 9-12, 0.014 ppm Mn2+ treated crayfish displayed similar trends in escape 
frequencies as the other Mn2+ treatments. Out of all treatments, the control animals were the only 
ones to reduce escape frequency below baseline levels by the end of the experiment. All Mn2+ 
treated crayfish exhibited a positive trend in escape behavior, increasing frequency in early 
weeks and remaining elevated above baseline levels for the entire experiment.  
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Figure 35. Major Threat Avoidance Behaviors in Response to Shadow Stimulus 
No significant differences between groups were detected (Kruskal-Wallis test: Week 0 p = 0.85, 
Week 12 p = 0.98, Week 24 p = 0.52) although there were differing trends between the control 
group and Mn2+ treatments. Three categories were created to classify major observed behaviors 
with each behavior being represented as a color on the stacked bar graphs. Line trends overlay 
the stacked bars for visualization of change over time. (A) The control group initially reduced 
stopping while replacing it with escape behavior; however, as weeks progressed, stopping 
frequency rose once again (Control group Friedman p = 0.55). (B) Stopping did not decrease for 
several weeks after the control group, with lesser change occurring; escape remained elevated in 
later weeks (0.0014 ppm Mn2+ treatment Friedman p = 0.48) (C) 0.0028 ppm Mn2+ treated 
crayfish followed similar trends as 0.0014 ppm Mn2+ treated crayfish with delayed escape and 
larger fluctuations in later weeks (0.0028 ppm Mn2+ treatment Friedman p = 0.43) (D) 0.014 ppm 
Mn2+ treated crayfish were the only group to increase stopping behavior during weeks 1-4, 
followed by similar changes as other Mn2+ treated crayfish with larger changes the last eight 








Threat- Avoidance Subcategories 
While each Mn2+ treatment displayed trends in escape and stopping behavior that differed 
from the control group, subcategories constituting the three major behaviors showed more 
detailed results further suggesting elevated Mn2+ exposure may negatively affect the efficiency 
of highly essential behaviors. Stopping behaviors were split into startle freezing and freezing; 
although there were subtle differences between these subcategories, slight changes in the 
contextual response may increase predation risk. Startle freezing was the most frequent response 
for all crayfish during baseline, consisting of 100% of the control group’s baseline stopping 
behavior (Fig. 36A). Control crayfish immediately reduced frequency by 13.6% during weeks 1-
4 and continued decreasing frequency of this behavior until weeks 13-16 (-56.5% from baseline). 
This was the first instance where freezing became the primary stopping behavior. A moderate 
increase emerged thereafter with a peak during weeks 17-20, although levels remained 53.5% 
below baseline. 
0.0014 ppm Mn2+ treated crayfish temporarily decreased startle freeze frequency by 4.2% 
during weeks 1-4, where it then became the sole stopping behavior used by this treatment until 
weeks 9-12 (Fig. 36B). The delayed transition between startle freeze to freezing, as seen in the 
control group, gave rise to significantly different frequencies between the control group and 
0.0014 ppm Mn2+ treated crayfish during weeks 13-16 (Dunn’s test: p= 0.05). A reduction 
occurred until weeks 17-20, where frequency became constant while presenting elevated startle 
freeze frequency compared with the control group for the remaining weeks. Figure 36C depicts 
that 83% of 0.0028 ppm Mn2+ treatment baseline stopping behaviors were startle freezing, 
remaining constant for the next eight weeks. After weeks 5-8, a 15.1% decline from baseline was 
observed, continually declining through weeks 21-24 (-42.7%). Although this was the lowest 
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startle freeze frequency observed from any group, this was still lesser reduction from the control 
group. Startle freeze occurrence within 0.014 ppm Mn2+ treated crayfish steadily decreased 
throughout the experiment, becoming more gradual during the last four weeks (Fig. 36D). 
Throughout the experiment, no Mn2+ treated crayfish reduced weekly startle freeze frequency as 
much as the control group. For this reason, control animals showed the largest increase in 
freezing frequency over time. In opposition to other Mn2+ treatments, 0.0028 ppm Mn2+ treated 
crayfish were the only other group where startle freeze frequency surpassed that of freezing. 
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Figure 36. Startle Freeze and Freeze Behavior Subcategories in Response to Shadow  
The x-axis represents treatment weeks while the y-axis represents the percent of stopping 
behavior with crayfish either freezing or startle freezing. Stopping behavior subcategories are 
represented by specific color within the stacked bar graph. (A) Immediately after baseline 
testing, control crayfish began increasing frequency of freezing while gradually reducing startle 
response frequency. (B) Other than a small change during weeks 1-4, startle freezing dominated 
stopping behavior of 0.0014 ppm Mn2+ treated crayfish until weeks 13-16. (C) 0.0028 ppm Mn2+ 
treatment trend resembled the control group, although freezing did not become the primary 
behavior until weeks 21-24. (D) Although gradually increasing over time, freezing frequency 
also remained low in 0.014 ppm Mn2+ treated crayfish compared with the control group. 
A-Control B-0.0014 ppm
D- 0.014 ppmC-0.0028 ppm
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The third most frequent threat-avoidance behavior observed across all groups was tail-
flipping. Therefore, escape behavior presented in figures 35A-D accurately represent changes in 
overall tail-flip frequency over time. Tail-flip behavior was further categorized by number of 
flexions; a single tail-flip involved one abdominal flexion, while multiple tail-flip behavior 
consisted of additional repetitive flexions that resembled swimming behavior. Overall, the 
control group displayed the most tail-flip behavior (single and multiple flexions) of any group 
prominently within the first eight weeks and decreasing thereafter. Focusing on tail-flip 
subcategories, it was determined that the control group only presented multiple-flexion baseline 
tail-flip behavior; rapid reduction in multiple-flexion tail-flips occurred weeks 1-4 (-66.7%) with 
frequency continuing to decline until weeks 5-8 as they were replaced by single tail-flips (Fig. 
37A). Single-flexion tail-flips occurred at a higher frequency than multiple-flexion immediately 
after baseline testing and continued to be the constant tail-flip of choice for over 60% of the time 
during the second half of the experiment, slightly increasing during weeks 21-24.   
Overall, all Mn2+ treated crayfish exhibited lower frequencies of tail-flip behaviors 
compared with the control group. While no tail-flips were present in 0.0014 ppm Mn2+
treatment’s baseline testing, frequency increased during weeks 1-4, with single-flexions being 
the dominant choice (83.3%) (Fig. 37B). A small reduction in single-flexions occurred over the 
next four weeks, remaining constant at approximately 75% of tail-flip behavior until throughout 
weeks 13-16. Beginning weeks 17-20, 0.0014 ppm Mn2+ treated crayfish exclusively used single-
flexion tail-flips. 
0.0028 ppm Mn2+ treated crayfish displayed very little multiple-flexion behavior, 
consisting of 33.3% of weeks’ 1-4 tail-flip behavior, and recurring at lesser frequencies between 
weeks 9-16 (Fig. 37C). While 0.014 ppm Mn2+ treated crayfish did utilize tail-flip behavior as an 
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escape tactic, multiple-flexions were never observed by them. Furthermore, overall tail-flip 
frequency decreased by Mn2+ treatment concentration, with 0.014 ppm Mn2+ treated crayfish 
displaying the least tail-flip behavior. 
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Figure 37. Single vs Multiple-Flexion Tail-flip Behavior in Response to Shadow 
Throughout the experiment, the control group displayed the highest frequency of multiple-
flexion tail flips, while this behavior decreased in frequency by concentration. All groups 
except 0.014 ppm Mn2+ treated crayfish are represented because the highest concentration 
treatment did not display any multiple-flexion tail-flips rendering the graph unfeasible. (A) The 
control group immediately reduced the frequency of multiple-flexion tail-flips, remaining near 
35% for much of the experiment. (B) 0.014 ppm Mn2+ did not use multiple-flexion tail-flips 
during baseline testing, and it never consisted of more than 25% of weekly tail-flip behavior. 
(C) 0.0028 ppm Mn2+ displayed even lesser use of multiple-flexion tail-flips with the most 





A small percentage of the total control crayfish behavioral repertoire consisted of 
defensive behavior (1%) and fleeing (3.5%) (see Appendix C: Fig. 1-4 for stacked bar graphs 
displaying all threat-avoidance behaviors for each treatment, as well as statistics for individual 
behaviors). The control group did not display any defensive or fleeing behavior during baseline 
testing. Defensive behavior increased weeks 1-4, plateauing throughout weeks 5-8 and never 
appearing again for the rest of the experiment. Baseline fleeing behavior did not exist in any 
group. Fleeing behavior within the control group was not present until week 5, marginally 
fluctuating but remaining elevated from baseline throughout the experiment.  
Defensive behavior was a higher occurrence in 0.0014 ppm Mn2+ treated crayfish during 
baseline testing, consisting of 25% of behavior. A 22% reduction occurred during weeks 1-4, 
remaining constant and eventually disappearing during the last eight weeks. In opposition, 
fleeing behavior became increasingly prevalent, increasing until weeks 17-20 where it made up 
12.5% of behavior during those weeks. A reduction occurred during weeks 21-24, although 
frequency still remained elevated compared with the control group. Twelve percent of 0.0028 
ppm Mn2+ treatment baseline behavior was defensive, remaining the same throughout weeks 1-4, 
with a small increase during weeks 5-8. Similar to the control group, defensive behavior 
diminished throughout the remainder of the experiment with little use during weeks 13-16. 
Fleeing became present during weeks 1-4 but was not a consistent behavior of choice until after 
weeks 5-8. Fleeing was used the most during weeks 17-20 where it was 15.6% of behavior. 
0.014 ppm Mn2+ treated crayfish decreased baseline defensive behavior by 25% during 
weeks 1-4, increasing by 9.4% during weeks 5-8 with a steady decline again until weeks 13-16. 
A small increase in frequency was present thereafter making this treatment the only group to 
display any defensive behavior during the last eight weeks. Fleeing increased after baseline, 
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fluctuating for the first twelve weeks with a peak during weeks 5-8. During weeks 17-20, fleeing 
consisted of 21.9% of this group’s behavior which was the highest percentage of fleeing 
observed in any group. 
Tail-flip Latencies  
Escape behavior must proceed in a timely manner to avoid eminent threats and increase 
chances of survival. Therefore, escape latencies were analyzed to determine if elevated Mn2+ 
exposure decreased tail-flip efficiency. Figure 38A illustrates that only two crayfish tail-flipped 
during pre-treatment baseline testing with one being from the control group and the other a 
0.0028 ppm Mn2+ treatment. Baseline tail-flip latency comparisons revealed that the control 
crayfish displayed a slower reaction than the Mn2+ treated crayfish with the 0.0028 ppm Mn2+ 
treatment crayfish initiating escape before the shadow stimulus reached their location. 
During weeks 1-4, all groups contained crayfish that tail-flipped with the n of each group 
decreasing by treatment concentration (Fig. 38B). All groups displayed a median latency near 
zero, meaning that they initiated escape at the time the shadow reached their location. The 
Control group (n=8) displayed the largest variability in latency with data being skewed towards 
the fastest latency of any group at -0.2 seconds. They also contained a single outlier on the upper 
limit with a latency of 0.367 seconds. All Mn2+ treatment distributions were smaller, although all 
contained a lesser number of crayfish that tail-flipped, possibly influencing distribution. 
Regardless, all Mn2+ treatment showed a higher level of agreement containing latencies which 
were closer to zero seconds. By weeks 9-12, variability of all groups’ latencies increased, while 
latencies of the control group remained the most spread out (Fig. 38C). The central tendency of 
all groups slowed with no crayfish initiating escape prior to the shadow reaching their location. 
However, the control group contained the longest median latency, while 0.014 ppm Mn2+ treated 
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crayfish had the shortest. While 0.0028 ppm Mn2+ and 0.014 ppm Mn2+ treated crayfish 
contained lower outliers with fast reactions, the control group contained the largest, and crayfish 
within the lower quartile of their data continued to display the shortest latencies of any group.   
While the control group contained the largest sample of crayfish that tail-flipped 
throughout the first several weeks, by weeks 21-24, the control group contained a smaller sample 
of crayfish that tail-flipped than two of the Mn2+ treated crayfish (Fig. 38D). With this decrease 
in sample size also came a reduction in distribution of the data. The control group decreased 
range drastically with the upper 50% of crayfish displaying shorter latencies than previous 
weeks. While the central tendencies in escape latency remained similar to weeks 9-12, the lower 
quartile of 0.014 ppm Mn2+ treated crayfish displayed the shortest latency with a reaction of      
-0.034 seconds. 0.014 ppm Mn2+ treated crayfish also were the only group to display negative
latencies during the last bin. Also, while all groups increased median latency over weeks, 0.014 
ppm Mn2+ treatment median latency remained the same from weeks 1-4.  
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Figure 38. Weekly Tail-flip Latency in Response to Shadow Stimulus  
Crayfish are displayed on the x-axis while tail flip latency for each treatment measured in 
seconds is on the y-axis. Zero on the y-axis represents when the shadow reached the location of 
the crayfish. Behavior represented on the negative y-axis were executed prior to the shadow 
reaching their position. (A) Only two crayfish tail-flipped during baseline testing with latencies 
hovering around zero seconds (Baseline Kruskal-Wallis: p = 0.32). (B) Tail-flip latency 
comparison during weeks 1-4 where the control group had the largest range in latency while 
displaying the highest frequency of tail flip behavior (Kruskal-Wallis: p = 0.44). (C) During 
weeks 5-8, median latencies were similar, but the control group still exhibited the largest range, 
as well (Kruskal-Wallis: p = 0.52). (D) During weeks 21-24, all Mn2+ treated crayfish exhibited 
larger spreads than the control group and displayed shorter median latencies (Kruskal-Wallis: p = 
0.75). 
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Change in Length 
Carapace (calcified, protective region covering the cephalothorax) change-in-length 
percentage was measured over the 6-month experiment. Control crayfish carapace grew a 
median 13.9%, with a maximum growth of 37.4% (Fig. 39A). While all groups exhibited similar 
median growths, 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ treated crayfish displayed smaller 
ranges in growth; the control group contained more crayfish with larger carapace growth. In 
opposition, 0.014 ppm Mn2+ treatment data were negatively skewed, indicating an increased 
prevalence of lesser growth. 
Percentage change in total-length (measured rostrum to telson) over 6 months revealed 
that control crayfish total-length increased a median 16.9% which was the largest increase of any 
group, while 0.028 ppm Mn2+ treated crayfish were similar (Fig. 39B). The control group 
exhibited a negative skew with the lower 50% of the data being widely distributed. Lesser 
median growth was observed in a concentration dependent manner, with 0.014 ppm Mn2+ treated 
crayfish growing a median 13.4%. 
Total length/carapace length ratios were calculated to determine whether carapace or 
total-length growth rate was larger. A value less than 1 specifies that carapace length increased 
more so in proportion to the abdomen muscle. In opposition, a value larger than 1 states the total-
length increased to a greater degree, thus resulting in more abdomen growth. All groups’ central 
ratios were greater than 1, indicating that abdomen muscle increased more than the carapace 
with the control group containing the largest median ratio (Fig. 39C). The control group 
displayed a median ratio of 1.045 while 0.014 ppm Mn2+ treated crayfish exhibited the smallest 
at 1.002. Data distribution also decreased by treatment concentration with 0.014 ppm Mn2+ 
treatment data clustered closest to 1. 
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Figure 39. Change in Crayfish Length 
(A) The control group displayed the largest carapace growth, although medians were similar 
(Kruskal-Wallis: p = 0.69). (B) Growth percentage over 6 months measuring change in total 
crayfish length (rostrum to telson) with the control group containing the largest median (One-
way ANOVA: p = 0.76). (C) Ratio of total-length percentage increase to carapace growth with 














































Figure 40 shows differences in mortality rate among each group with 20% death of 
control subjects, 27.3% 0.0014 ppm Mn2+ treatments, 26.7% 0.0028 ppm Mn2+ treatments, and 
20% 0.014 ppm Mn2+ treatments. Additionally, 9.1% 0.0014 ppm Mn2+ treatments, 33.3% 
0.0028 ppm Mn2+ treatments, and 10% 0.014 ppm Mn2+ treated crayfish did not meet shadow 
activation criteria, i.e., crayfish were not oriented in the proper direction to activate shadow 
stimulus within the time constraint (Fig. 41). To maintain complete data sets, additional crayfish 
were added to a treatment group for mortalities, and for crayfish that did not meet shadow 
criteria; these additional crayfish were analyzed for an entire 6-month period, as well. (control 
group n=10, 0.0014 ppm Mn2+ treated crayfish n=11, 0.0028 ppm Mn2+ treated crayfish n=15, 
0.014 ppm Mn2+ treated crayfish n=10). Crayfish that did not meet shadow activation criteria 
were still analyzed for the remaining weeks of the experiment to observe these behavioral 





















Figure 40. Mortality Percentage 
Percentage of mortality across treated crayfish where 0.0014 Mn2+ and 0.0028 Mn2+ treated 
crayfish slightly deviated from the control group but did not significantly differ (Kruskal-Wallis: 







































Figure 41. Crayfish Mortality and Unmet Shadow Criteria  
Daily temperatures during each experimental trial (white points) overlaid with crayfish mortality 
(colored circles) and crayfish that did not meet (DNM) shadow activation criteria (colored 
squares). Statistical analysis revealed that temperature and crayfish mortality had a weak 
negative correlation (Kendall test: p = 0.049) which provides possible reasoning behind crayfish 












Threat Avoidance Discussion  
Analysis of Behavioral Repertoire 
 Approaching stimuli representing potential danger evoke specific fight, flight, or other 
threat avoidance behaviors seen across taxa from crustaceans (Liden and Herberholz 2008; Liden 
et al. 2010; Schadegg and Herberholz 2017; Tomsic et al. 2017), fish (Law and Blake 1996), and 
mice (De Franceschi et al. 2016). Freezing is often the behavior of choice to distant, less 
immediate threats while escape is predominantly used for imminent predators; however, 
behavioral flexibility, due to neural modulation, leads to production of numerous outputs (Liden 
and Herberholz 2008) evidenced by pre-treatment baseline differences. Slight behavioral 
differences are often an important survival aspect. Nevertheless, as time progressed, Mn2+ treated 
crayfish behavior deviated from that of the control group. 
When comparing stopping and escape behavior, it is apparent that control crayfish felt 
threatened by the passing shadow stimulus during weeks 1-4 and retained some sense of learned 
experience from baseline testing evident by the immediate elevation in escape behavior. During 
the first several weeks, control crayfish also exhibited an increase in defensive behavior, 
although it seemingly proved ineffective as they ceased its use early on. After the first several 
weeks, frequency of stopping behavior increased and became the behavior of choice for the 
remainder of the experiment. This change in behavior indicates that crayfish retained learning 
and memory ability for up to several weeks while no longer associating the passing shadow as 
being an eminent threat.  
0.0028 ppm Mn2+ treated crayfish differed in that stopping behavior remained constant 
throughout weeks 5-8. Although a slight fluctuation occurred thereafter, a large increase was not 
present until weeks 21-24. In comparison, escape did not increase during weeks 1-4, but instead 
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defensive behavior continued to be utilized more often. 0.0028 ppm Mn2+ treated crayfish did not 
show large increases in escape frequency until weeks 9-12. When they finally did increase 
escape frequency, it remained elevated compared with the control group for the remaining 
weeks. 0.0028 ppm Mn2+ treated crayfish displayed elevated defensive frequency early on, while 
attempting to fight the passing shadow for several weeks after the control group reduced this 
behavior. It was not until weeks 9-12, that 0.0028 ppm Mn2+ treated crayfish largely reduced the 
use of this behavior. 0.0014 ppm Mn2+ treated crayfish displayed similar trends in behavior as 
0.0028 ppm Mn2+ treatments, but with less fluctuations. 
Crayfish are capable of defending themselves with their chelipeds, although juveniles 
typically rely on predator avoidance due to chelipeds being of small proportion to their body 
mass (Barki et al. 2003; Edwards and Herberholz 2005). As crayfish mature, the abdomen 
becomes a smaller ratio of total body mass resulting in shorter distance per tail-flip. Likewise, 
chelipeds become a larger fraction giving better opportunity for defense (Edwards and 
Herberholz 2005). This is likely the reason control crayfish exhibited low frequency of defensive 
behavior. It was expected for Mn2+ treated crayfish to display elevated defensive behavior 
compared with the control group due to elevated baseline frequency.  
0.014 ppm Mn2+ treated crayfish were the only group to initially increase stopping 
behavior during the first four weeks indicating that Mn2+ exposure at this concentration impacted 
behavior within the first month of exposure. They also shared many similarities with 0.0028 ppm 
Mn2+ treatments, as they showed lesser increases in escape frequency early on and utilized 
defensive behavior throughout the experiment. Furthermore, all Mn2+ treated crayfish displayed 
similar trends in stopping and escape behavior after weeks 9-12 with 0.014 ppm Mn2+ treated 
crayfish containing the largest fluctuation in trends between weeks 13-24. Similar changes 
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among Mn2+ treated crayfish indicate that all Mn2+ concentrations used may similarly impact 
threat-avoidance pathways with increasing severity over time and concentration. 
Threat avoidance observed across taxa is often preceded by a startle reflex- an 
involuntary reaction to a sudden, intense stimulus which prepares the body to fight/flight. Its 
interruptive properties function to clear ongoing motor, cognitive, and autonomic activity to 
reorient maximal neural processing towards the stimulus (Blumenthal 2015). As a startling 
stimulus is repeatedly presented, the startle response may habituate (De la Casa et al. 2014; 
Blumenthal 2015) which is perhaps the reasoning behind the reduction in startle freeze frequency 
from the control group as weeks progressed. Immediate reductions in startle frequency, 
continuing throughout the experiment, suggest control crayfish were no longer surprised by the 
passing shadow stimulus. Shifting between the startle reflex to pure freezing when repeatedly 
exposed to the shadow stimulus further indicates learning capacity. It is hypothesized that 
crayfish were capable of recalling experiences from prior weeks due to their ability to remember 
spatial features of a novel environment for up to one week (Tierney and Andrews 2013). These 
data indicate crayfish may remember shadow stimulus interaction, as well as recollection of their 
location when the stimulus passed from the previous week. Frequency reduction in control 
animals’ startle response as experimentation progressed suggests untreated crayfish responded to 
the repeated shadow as if it was no longer a surprising stimulus, while elevated Mn2+ exposure 
likely was a source of neuronal disruption leading to behavioral deviation from the control 
group. In Mn2+ treated crayfish, freezing behavior showed little signs of increase from baseline 
until weeks 9-12, when startle freezing began to consistently become a lesser occurrence. While 
Mn2+ treated crayfish also decreased startle freezing over time, they consistently displayed 
elevated frequency compared with control subjects.  
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Although startle intensity was not measured in the current experiment, induction of 
negative affect increased startle intensity, anxiety, and fear in human (De la Casa et al. 2014) and 
non-human subjects (Bradley et al. 1999). In addition to a human’s psychological state, affect 
may also describe primitive responses an organism experiences during stimulus interaction such 
as aggression, fear, or surprise (Panksepp 2010). Rats given benzodiazepines (common anxiety 
medication for humans), displayed a reduced startle response to a discrete, conditioned stimulus 
indicating that organisms other than humans display anxiety-like behavior, and the notion that 
this behavior may manifest within startle behavior (Davis et al. 1993). Although crayfish are not 
capable of complex emotions as humans, stressors including elevated metal exposure may 
similarly influence conserved neurological pathways underlying basic survival behavior; these 
similarities may be partially responsible for the sustained apprehension and elevated startle 
frequency observed in Mn2+ treated crayfish.  
In rat brains, elevated Mn2+ exposure leads to alterations in amino acid composition, 
specifically glycine (Santos et al. 2012A). In comparison, it has recently been discovered that 
altered glycine levels are the cause behind hyperactive acoustic startle responses within humans 
(Gimenez et al. 2012). While it is unclear if glycine plays the same roles in the neurological 
mechanisms responsible for crayfish startle behavior, direct changes in amino acid levels may be 
another pathophysiology of elevated Mn2+ exposure. Environmental stressors may modulate 
reflex function and behavior which may sensitize or reduce response; both hypoactive and 
hyperactive reflexes indicate neurological pathway disturbance. As with humans, a change in 
reflexes indicates neurological impacts which may be detrimental to overall health and survival. 
When inconspicuous behaviors fail and the threat becomes imminent, a strong, fast 
escape is often the next strategy. Escape should be resistant to false negatives since failure to 
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detect a predator means death, and resistant to false positives since executing unnecessary escape 
wastes energy and, for a tail-flipping crayfish, may thrust them into the open water-column 
(Yager 2010). Control crayfish tail-flipped the most of any group which consisted of 21% of 
their overall behavioral repertoire. As weeks progressed, the reduction in escape response was 
primarily due to a decrease in tail-flip occurrence. Properties of circuits may change due to 
learning and communication with other neural circuits. Giant-fiber, and likely non-giant 
mediated, escape habituate under repeated stimulation of sensory neurons that act on these 
pathways (Krasne and Edwards 2002). The presence of reduced tail-flip frequency over time 
suggests a learned false positive resistance, possibly due to synaptic habituation within tail-flip 
circuitry, to the repeated passing shadow stimulus. In opposition, tail-flipping was a lesser 
occurrence in Mn2+ treated crayfish suggesting neurological deficit of the physiological stressor 
that either blocked signaling or reduced excitability of the neurological pathways. While tail-
flipping lesser frequencies than the control group, all Mn2+ treated crayfish displayed elevated 
tail-flip behavior in later weeks after the control group reduced this behavior. This suggests that 
Mn2+ treated crayfish were not capable of learned false positive resistance. ACh signaling 
disruption within sensory neurons would inhibit proper communication to efficiently tail-flip, 
possibly being a source of reduced tail-flip frequency. Furthermore, Mn2+ has ability to impact 
GABA-ergic input that directly inhibits giant-fibers which could alter this circuit’s excitability; 
an elevation in the tail-flip escape threshold would certainly contribute to a lesser occurrence of 
this behavior. Another component of this circuitry that Mn2+ may influence is Ca2+ as proper 
influx into post-synaptic neurons is needed to induce synaptic plasticity of giant fiber pathways 
(Krasne and Edwards, 2002). 
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Extensive studies on crayfish escape have revealed that, although medial giant fibers play 
a role in rostrally located stimuli, visually evoked tail flips are typically mediated by non-giant 
mechanisms (Liden and Herberholz 2008). Additional repetitive tail-flips, observed mostly 
among control crayfish, are believed to be non-giant mediated due to giant fiber inhibition during 
similar non-giant swimming patterns (Liden and Herberholz 2008). Therefore, it was expected 
for control subjects to utilize non-giant tail flips to approaching shadow stimuli, especially if the 
shadow was no longer a surprising threat. While electrophysiological data were not obtained, 
35.7% of the control group’s overall tail flips, 16.7% 0.0014 ppm Mn2+, 9.7% 0.0028 ppm Mn2+, 
and 0% 0.014 ppm Mn2+ contained multiple flexions. While single-flexions were the primary 
tail-flip of choice, this may provide reasoning as to why the control group displayed a higher 
frequency of multiple-flexion tail-flips compared with the Mn2+ treatments.  
Although there are subtle differences between several observed threat avoidance 
behaviors, slight changes in the contextual response may increase predation risk. For example, 
utilizing non-giant tail flip circuitry for an imminent threat is a less successful avoidance 
mechanism than giant-mediated tail flips due to weaker and less prompt behavioral output (Liden 
and Herberholz 2008). However, giant fiber utilization does not give opportunity to predetermine 
escape direction and angle while being more energetically costly. In comparison, non-giant 
circuits lead to less prompt, variable behavioral output which may be neuroeconomically 
beneficial in lesser threatening scenarios. 
Serotonin, one of the most prominent neurochemicals present across taxa, regulates 
learned avoidance behavior in aplysia (Marinesco et al. 2004), modulates gastropod motor 
coordination and escape (Gillette and Jing 2001; Jing and Gillette 2003), may suppress giant 
fiber escape mechanisms (Krasne and Edwards 2002), and facilitates vertebrate spinal reflexes 
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(Shay et al. 2005). Therefore, 5-HT dysregulation may partially underlie elevated startle 
response frequency and suppressed tail-flip frequency observed among Mn2+ treated crayfish 
compared with the control group. Unnecessary use of the startle reflex delays proper escape 
behavior giving opportunity for the predator to attack. While the dynamics of 5-HT within the 
crayfish system are context dependent and therefore complex, 5-HT plays a modulatory role in 
crayfish aggression. In general, however, high 5-HT levels are associated with increased 
aggression in crayfish. If elevated Mn2+ exposure influences the serotonergic system as it is 
believed to, then prolonged elevated 5-HT levels may be responsible for the higher frequency of 
defensive behaviors observed in Mn2+ treated crayfish throughout the experiment compared with 
the control group. While defensive behaviors were still a small percentage of the overall 
behavioral repertoire, increased frequency may still provide insight to the pathophysiology of 
Mn2+. Furthermore, while elevated 5-HT has the capability of suppressing giant-fiber escape 
mechanisms, chronically elevated 5-HT may cause eventual downregulation of 5-HT receptors 
resulting in the elevated tail-flip frequency of Mn2+ treated crayfish in weeks after the control 
group had reduced this behavior.  
Due to calcium’s roles within many physiological processes, dysregulation via elevated 
Mn2+ may lead to further changes in threat-avoidance circuitry. Inhibition of crustacean muscle 
depolarization, as well as, dysregulation of Ca2+ induced neurochemical release may lead to 
reduced tail-flip efficiency, or capability. Perhaps this gives reasoning to the elevated fleeing 
behavior seen in Mn2+ treated crayfish as compared with the control. If Mn2+ treated crayfish 
found it increasingly difficult to tail-flip to escape immediate danger, the most similar observed 
option would be to flee. If crayfish exhibit similar learning and memory formation mechanisms 
as vertebrate (Agranoff et al. 1999) and other invertebrate models (Perisse et al. 2009), 
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displacement of Ca2+ would not allow proper cellular communication needed to initiate long-
term potentiation and memory consolidation becoming an underlying cause of delayed 
behavioral trends. In addition to motor impairments, manganese may also reduce efficiency of 
sensory pathways prior to muscle activation. Medial Giant, and non-giant mediated tail-flips are 
fed by cholinergic inputs via visual and rostrally located tactile sensory neurons (Glantz and 
Viancour 1983). Due to manganese’s ability to dysregulate acetylcholine transmission, improper 
neuronal signaling may have not been sufficient to activate tail-flip pathways leading to a 
reduction in tail-flip frequency. It is hypothesized Mn2+ exposure at the current concentrations 
specifically dysregulates non-giant mediated circuitry due to the frequency reduction by  Mn2+ 
concentration. 
Regardless of underlying circuitry, escape behavior must proceed rapidly while being 
optimally timed to disrupt the predatory attack and increase survival chances (Yager 2010). For 
this reason, it was expected for crayfish to display short latency responses early in the 
experiment. During week 1-4, median latencies of all groups were similar, although the control 
group displayed a larger percentage of crayfish that initiated escape faster. Early differences 
specifically among Mn2+ treated crayfish were expected due to possible Ca2+ and neurochemical 
disturbances within tail-flip escape circuitry which may result in a delayed response. During 
weeks 9-12, variability of tail-flip latency within the control group continued to increase. While 
they still consistently displayed short frequencies compared with Mn2+ treatments, their central 
tendency increased from previous weeks; similarly, the median of the two lower Mn2+ treated 
crayfish increased. 
By weeks 21-24, medians of the control group and lower Mn2+ treated crayfish were 
similar to weeks 9-12, although the distribution of control group data greatly decreased. The 
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control group also showed a decline in the number of crayfish performing tail-flips indicating 
that sample size may have influenced distribution. Nonetheless, although the control group 
continually contained crayfish with short latencies, their central tendency slowed as time 
progressed. In comparison, 0.014 ppm Mn2+ treatment median did not change throughout the 
entire experiment; whether this was due to Mn2+ impacts or due to the recurring small sample 
size is unknown. 
Further explanation of tail flip latencies came when categorized by arena zone. Control 
crayfish displayed more than double tail flip frequency within the border zone closest to where 
the shadow originated from than any other treatment. Control crayfish had the longest latencies 
within this zone of any tail-flip behavior likely because this border region created “inescapable” 
scenarios that made timely tail-flip execution physiologically difficult. All other zones gave 
crayfish more time to analyze the approaching stimulus and initiate escape. 
In addition, I hypothesize control crayfish displayed longer latencies as weeks progressed 
due to memory of previous interaction with the shadow stimulus. Many studies have reported 
crayfish memory lasting up to 24 hours (Basil and Sandeman 2000; Kawai et al. 2004; 
Shuranova et al. 2005; Ramalho and Anastacio 2011; Tierney and Lee 2011); however, evidence 
indicates invertebrate memory may last much longer with desert ants retaining spatial memory 
for 20 days (Ziegler and Wehner 1997), nautiluses remembering escape location for up to 21 
days, and spatial memory in crayfish lasting up to one week (Tierney and Andrews 2013). 
Learning ability is essential for survival and prey are required to maintain a high degree of 
plasticity to choose the best context-specific threat avoidance behavior (Hazlett 2000). Recalling 
that previous interactions with the shadow stimulus were non-threatening may have been also 
responsible for slower latencies as weeks progressed. Additionally, non-giant mediated tail-flips, 
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suspected to be used mostly by control crayfish, utilize sensory guidance to adjust escape angle 
and direction which would contribute longer latencies and high variability. Shorter latencies and 
increased speeds do not always result in successful escape. Tail-flipping must occur in a timely 
manner and may be influenced by context and past experiences. As previously mentioned, past 
studies within the Antonsen lab revealed that short-term manganese exposure impacts tail flip 
trajectory, as well (Lefevre et al. 2015). Results suggest that manganese may influence several 
neurological pathways that effect different aspects of tail flip mechanics. I postulate that Mn2+ 
exposure may impact crayfish decision-making ability for proper escape, although studies on the 
mechanisms of Mn2+ exposure on crayfish learning/memory have yet to be conducted. 
Change in Length 
While 0.0028 ppm Mn2+ and 0.014 ppm Mn2+ treated crayfish displayed a larger median 
carapace growth than the control group, the control group contained a larger distribution of 
crayfish whose carapaces grew a larger percentage. While slight elevations in Mn2+ 
concentrations may be beneficial for some pathways due to its essentiality, it was not expected 
for median carapace growth to be high in 0.014 ppm Mn2+ treated crayfish due to the ability of 
Mn2+ to displace calcium. This is perhaps the reasoning behind the strong negative skew. Data 
comparing carapace growth to overall growth indicate the control crayfish abdomen muscles 
grew the most of any group throughout the 6-month trial. Analyzing change in length of the 
carapace and abdomen tissue provides evidence of whether Mn2+ stimulated muscle growth or 
led to muscle degeneration, either of which may also change typical locomotion and escape. 
Mortality 
Mortality is an obvious marker of toxicological impacts; however, the purpose of this 
study was not to investigate lethal Mn2+ concentrations. 0.0014 ppm Mn2+ and 0.0028 ppm Mn2+ 
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treatment mortality were slightly elevated compared with the control group, so low 0.014 ppm 
Mn2+ treatment mortality was surprising because past research has shown exposure to the same 
Mn2+ concentrations for a shorter period of time increased mortality with increasing treatment 
concentrations (Antonsen et al. 2018). I postulate these differences are due to crayfish within the 
current study being larger. Larger crayfish may be capable of maintaining and excreting Mn2+ 
concentrations at these levels. Additionally, 10% of control deaths and 6.7% of 0.0028 ppm 
Mn2+ deaths within the current study showed signs of exoskeleton molting which may have been 
a mortality factor. Crayfish within younger stages of development experience more frequent 
molting. This stressful experience increases vulnerability to disease while proper calcium 
reuptake and formation of the exoskeleton may become displaced by Mn2+. Additionally, 
statistical analysis revealed that temperature and crayfish mortality had a weak negative 
correlation indicating that large temperature drops as being partially responsible for mortality. 
Additionally, various crayfish molted between treatments. I hypothesize larger sample sizes than 
what was used for this study would provide more accurate mortality results.   
Closing Remarks 
While a single mechanism of toxicity is uncertain, the effects of elevated Mn2+ exposure 
are complicated and likely compounded due to its essentiality in a multitude of biological 
processes. A dose-response curve was not present due to elevated manganese having a high 
range of impacts on cellular physiology primarily thought to influence Ca2+  and neurochemical 
homeostasis, as well as metabolism, energy production, neuromodulator and neurotransmitter 
regulation, immune function, sensory function, and circadian rhythm where different optimal 
concentrations are required.  
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Both length and concentration of elevated manganese exposure have an impact on 
motility and selection of threat-avoidance behavior. In a natural setting, suppressed motility 
observed in crayfish exposed to lower Mn2+ concentrations, increased motility observed in the 
highest Mn2+ treatment concentration, and incorrect contextual threat-avoidance behavior may 
result in higher vulnerability to predation and decreased survivability. As with humans, global 
anthropogenic effects of elevated manganese exposure are of increasing concern to the 
environment, specifically on aquatic ecosystems. Exposure to elevated levels of Mn2+, at 
concentrations below EPA secondary standards, impacts crayfish behavior which may be 
reverberated throughout the ecosystem. Detrimental impacts to the survivability of keystone 
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APPENDIX B: MOTILITY 
 
Table 1B. Distance Moved Before Shadow Raw Data 
    Week Treatment n     mean       sd        min        Q1   median       Q3       max 
1      0    0.0014 8 22.23053 13.09718  2.5628271 13.835030 24.90710 27.57492  43.39789 
2      1    0.0014 8 24.14541 17.51193  6.4912277 14.148626 21.87865 28.14048  62.01316 
3      2    0.0014 8 34.21196 23.08507  5.0728002 23.939076 32.52553 42.54204  69.49878 
4      3    0.0014 8 30.97466 17.11107  9.9767639 21.551292 25.82799 37.79346  59.63052 
5      4    0.0014 8 32.47427 24.80185  3.3162482 16.054863 27.62976 42.12964  72.26724 
6      5    0.0014 8 40.83410 22.85937 18.2608356 28.532053 32.98318 46.61519  78.00583 
7      6    0.0014 8 32.01022 22.40416  4.3696982 17.703070 28.30433 42.61390  75.67666 
8      7    0.0014 8 42.96512 21.71268 17.1801857 28.166381 40.79588 53.30845  78.93816 
9      8    0.0014 8 37.31712 20.89504 17.4597169 25.264319 32.20835 43.34265  82.60644 
10     9    0.0014 8 50.68281 19.30577 19.7976162 39.641995 54.61722 61.30424  75.43975 
11    10    0.0014 8 36.42302 18.62476 12.8803123 27.837712 34.27010 38.17331  76.09033 
12    11    0.0014 8 33.05447 21.38257  7.3022909 18.958679 29.42623 38.34292  72.35839 
13    12    0.0014 8 44.58248 27.00839 21.6261759 24.836893 33.27386 57.75531  98.82790 
14    13    0.0014 8 50.18451 17.48289 26.6627981 37.407616 48.91642 61.89304  78.31253 
15    14    0.0014 8 39.24023 14.97900 19.3996970 32.629809 39.50595 44.64537  67.53883 
16    15    0.0014 8 31.36164 22.70847  2.9869382 14.942298 30.02411 42.68375  71.34159 
17    16    0.0014 8 36.95248 17.35127 12.5997046 29.749634 35.76726 40.16925  71.66063 
18    17    0.0014 8 48.13002 34.40141  1.3627326 27.478654 47.58573 68.99027 106.60214 
19    18    0.0014 8 41.13820 14.14429 20.8546132 32.423176 36.93153 52.64189  61.06668 
20    19    0.0014 8 35.14140 25.12057 10.1155758 12.780209 32.41693 50.53153  75.42503 
21    20    0.0014 8 42.68826 32.93323  4.6441204 13.447382 49.52397 55.27422 103.41237 
22    21    0.0014 8 46.35220 31.20273 17.8099798 28.096658 36.08617 51.68395 104.47905 
23    22    0.0014 8 36.81288 25.52947 10.9933952 15.576095 31.78528 52.06937  76.01322 
24    23    0.0014 8 26.84772 18.30586  2.6321661 17.979987 21.75356 33.49435  63.56061 
25    24    0.0014 8 37.21631 22.09997 11.8571313 23.465973 32.61879 48.11538  70.81822 
    week treatment n     mean        sd        min       Q1   median        Q3       max 
26     0    0.0028 8 27.17684 12.32585 11.9930828 14.588620 29.57224 35.83218  44.16072 
27     1    0.0028 8 24.37179 20.93104  6.4299728 11.536412 19.89717 26.87738  72.52717 
28     2    0.0028 8 32.16951 12.72604 17.8554286 21.899708 32.26240 38.41239  55.55485 
29     3    0.0028 8 31.52563 17.74585 10.0182561 13.550016 35.02950 45.42862  55.95307 
30     4    0.0028 8 37.05920 15.82998 15.4459216 23.523226 39.81617 45.33185  60.47383 
31     5    0.0028 8 29.20557 18.56505  1.8041199 16.365880 28.05176 41.50280  60.28061 
32     6    0.0028 8 23.95887 19.15983  3.7739298  8.269374 19.37015 37.06899  59.07937 
33     7    0.0028 8 32.21975 17.16520  7.0476524 22.864699 33.50980 40.04754  56.47026 
34     8    0.0028 8 30.34164 19.05400  6.8258163 15.585318 28.68790 46.71911  55.62082 
35     9    0.0028 8 29.43517 12.50356  9.9443203 24.054806 31.49551 34.79304  46.30379 
36    10    0.0028 8 27.50292 16.22335  4.4334154 18.997847 26.75024 38.50416  52.34185 
37    11    0.0028 8 36.05324 20.54061  3.5034151 29.066650 34.81942 37.91835  77.43673 
38    12    0.0028 8 41.75046 30.05742  3.9648683 27.011339 37.10410 52.40854  98.95758 
39    13    0.0028 8 37.65340 19.09883 13.0380200 28.548764 33.51267 42.96605  77.38825 
40    14    0.0028 8 35.48049 13.43429 14.5641837 28.093169 34.29139 44.12259  54.40093 
41    15    0.0028 8 25.15161 13.59033  5.3116253 15.174100 24.70655 34.57383  47.19152 
42    16    0.0028 8 31.40312 17.99230  2.8011626 17.185184 35.58877 42.09498  58.09109 
43    17    0.0028 8 38.46401 14.86078 11.0152589 32.748831 42.36742 48.89960  52.94472 
44    18    0.0028 8 26.89047 21.56524  2.5133878 12.308253 22.69111 37.97526  61.39397 
174 
  
45    19    0.0028 8 29.79113 18.90370  5.9038571 19.894970 28.97701 36.29689  67.02453 
46    20    0.0028 8 27.24689 19.44666  0.6553242 13.448787 25.89408 37.33998  55.72132 
47    21    0.0028 8 29.45711 15.61255  8.3296821 20.530667 31.19906 37.71888  49.32090 
48    22    0.0028 8 22.37846 12.81908  7.6320436 13.503444 18.92992 31.16561  42.98661 
49    23    0.0028 8 30.01991 25.44794  1.4067702  9.037518 31.38287 36.90747  80.60738 
50    24    0.0028 8 29.10700 15.98237  2.7313896 16.305039 34.03278 42.11279  45.33647 
    week treatment n     mean        sd        min       Q1   median        Q3       max 
51     0     0.014 8 24.55710 18.93484  4.1988707 12.535232 18.30173 35.84542  52.61063 
52     1     0.014 8 20.58248 18.10565  0.8333455  4.124496 19.77448 29.28793  46.55460 
53     2     0.014 8 35.73825 19.29233 15.9548452 22.660952 29.40694 46.14725  68.85609 
54     3     0.014 8 37.73806 10.36484 27.2234456 31.144514 34.47928 40.77856  54.15126 
55     4     0.014 8 41.62442 20.41746 12.8906582 32.251403 38.40117 45.11015  81.98933 
56     5     0.014 8 41.10998 30.59106  5.9497601 22.432534 35.17383 50.55093 104.63996 
57     6     0.014 8 42.43298 24.92232 17.5126047 20.770036 41.90016 53.31660  90.07858 
58     7     0.014 8 52.09987 33.60594 19.0213431 26.506763 37.80269 80.37973  99.32573 
59     8     0.014 8 36.38674 26.17550  5.9791524 16.662857 31.52081 52.89909  83.35649 
60     9     0.014 8 43.14486 23.55947 19.9965735 29.873607 34.29458 48.74095  91.89205 
61    10     0.014 8 45.13004 24.07072  6.6496753 30.246745 46.47378 62.62909  77.47712 
62    11     0.014 8 45.45028 14.33145 22.9489630 39.409533 44.60164 56.85564  64.87218 
63    12     0.014 8 46.52714 29.32586  4.9467087 25.221303 50.51395 61.37706  89.69895 
64    13     0.014 8 52.18180 29.67484  9.9800180 31.394427 47.44413 80.09096  90.58703 
65    14     0.014 8 45.29368 21.44092 12.8623986 34.133708 42.20166 57.65556  79.29361 
66    15     0.014 8 42.83420 22.88171  2.6714157 35.058943 45.27187 56.24243  71.95397 
67    16     0.014 8 37.31534 27.55209  1.2140992 16.142519 37.92265 57.11200  78.13003 
68    17     0.014 8 49.50447 33.57586  1.7185915 34.192353 48.15680 64.14436 105.70622 
69    18     0.014 8 56.41512 35.92192 17.7441875 23.143304 54.82661 79.45787 105.36297 
70    19     0.014 8 44.64979 26.38842  8.6299910 30.984848 40.16240 53.51517  95.84840 
71    20     0.014 8 57.92951 36.62982  4.3474662 33.807331 53.06557 94.89475 101.23554 
72    21     0.014 8 40.02085 30.55883  4.8950045 13.097594 39.44655 59.23599  91.49618 
73    22     0.014 8 41.26416 30.67496  1.3361587 20.800320 31.02427 65.02083  86.32945 
74    23     0.014 8 53.00790 38.06775  5.9867989 22.393289 52.67473 80.79031 108.33947 
75    24     0.014 8 39.33485 26.78163  3.8540000 22.001130 31.06792 59.70633  84.88821 
    week treatment n     mean        sd        min       Q1   median        Q3       max 
76     0   Control 8 22.44255 14.47033  6.5631806 11.315736 19.00074 32.05912  49.41036 
77     1   Control 8 26.33736 15.97470  3.5533456 18.706120 27.35504 38.71751  45.97966 
78     2   Control 8 25.53501 14.65908  7.8589996 16.996059 22.48446 32.02499  47.26320 
79     3   Control 8 28.77392 15.50961 11.7613498 13.400875 28.51712 42.17913  48.30198 
80     4   Control 8 36.73243 14.74273 15.5125616 28.331221 36.79427 42.60322  63.04324 
81     5   Control 8 40.85108 18.98955  4.9746100 33.720487 42.77569 51.28146  64.05261 
82     6   Control 8 49.15314 23.38845 15.1937397 34.528514 51.88684 67.27816  76.76305 
83     7   Control 8 42.30967 25.18947 12.5120074 26.013509 37.52976 60.36652  79.10561 
84     8   Control 8 48.06808 19.90219 27.9183087 30.148665 45.69241 57.63217  80.99630 
85     9   Control 8 38.30866 19.71589 19.9416102 24.758315 27.58900 51.75522  72.30142 
86    10   Control 8 46.51715 19.26304 24.3737333 29.560900 47.65028 58.03972  77.33699 
87    11   Control 8 38.15585 21.98074  0.1506425 25.434028 40.74768 53.93962  62.33347 
88    12   Control 8 46.18114 28.48467 11.8851060 26.712691 43.92065 55.79257 101.82383 
89    13   Control 8 48.70185 24.09309 12.7825958 30.672957 52.71499 62.07963  80.30271 
90    14   Control 8 29.93026 18.29630 10.5376906 16.023138 21.72334 50.22395  53.40582 
91    15   Control 8 40.96128 20.34527 13.3877990 26.146194 40.82432 51.62225  73.82941 
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92    16   Control 8 36.87211 24.00617 12.8995895 17.159375 32.16139 52.82725  76.39418 
93    17   Control 8 37.19735 21.78971 13.7983785 21.592474 31.66663 47.26961  78.16481 
94    18   Control 8 39.11283 23.40639 14.6907635 20.098900 36.25755 51.10533  83.81526 
95    19   Control 8 42.34690 27.35123  1.3258025 26.469392 38.17348 57.21303  91.91331 
96    20   Control 8 42.01159 25.06063  8.4868058 26.502694 37.03324 57.48616  83.73783 
97    21   Control 8 39.24913 24.28963 11.9643362 27.293776 33.09039 41.71400  91.75010 
98    22   Control 8 43.62245 25.48432 16.0188704 25.176008 39.64016 49.70537  95.49223 
99    23   Control 8 39.48536 25.47665 10.7490677 24.121527 33.90470 48.51409  91.67059 
100   24   Control 8 34.03348 17.40820 14.4552493 17.251801 35.13212 43.05961  61.88402  
Table 2B. Border Distance Moved Before Shadow Raw Data 
   week treatment n     mean        sd        min       Q1   median        Q3       max 
1     0   control 8 44.75939 15.395912 20.3881334 38.32211 42.94484  52.05328  70.60454 
2     1   control 8 52.48564  8.522901 37.9575720 48.12036 53.13574  57.94385  63.28330 
3     2   control 8 60.71629 12.983762 37.7897245 55.23717 61.67892  67.11807  80.82423 
4     3   control 8 57.70546 18.229854 40.0075367 44.17978 51.43454  66.67757  93.29952 
5     4   control 8 56.88790 17.056226 40.9575720 42.50309 52.81985  66.42883  90.01768 
6     5   control 8 60.93836 19.165976 27.1098606 53.83244 68.00947  75.56683  77.01451 
7     6   control 8 68.28320 25.034152 35.4220425 54.09183 74.95221  76.26767 112.36600 
8     7   control 8 80.04355 20.806855 48.7037290 63.99134 84.08190  95.54940 104.40355 
9     8   control 8 65.16630 28.028764 23.4663454 54.93545 68.51528  73.87796 112.98451 
10    9   control 8 63.10998 23.329626 16.7276456 53.58350 71.10493  79.38395  84.58700 
11   10   control 8 67.11387 26.610306 23.9806848 48.49057 70.16812  81.75513 106.42084 
12   11   control 8 66.94868 28.537942 24.2085968 56.96782 75.36687  78.92746 108.48193 
13   12   control 8 81.70100 24.023861 52.5880214 69.62722 76.84634  91.19676 129.01177 
14   13   control 8 68.58953 17.128968 44.7948830 56.87115 68.24716  78.45338  96.40365 
15   14   control 8 58.63944 32.026226 -0.6640327 43.31736 62.66405  76.63520  99.58089 
16   15   control 8 71.95394 17.963270 41.0495132 64.98729 73.30371  81.66791  98.34524 
17   16   control 8 70.16297 32.277495  7.2675865 59.49525 73.00834  86.58079 114.42714 
18   17   control 8 81.83867 30.736966 38.7133830 67.53411 79.29542  86.27129 146.35042 
19   18   control 8 84.81316 29.308533 49.9435260 68.09341 78.74480 100.36548 138.83807 
20   19   control 8 69.05970 40.325187  4.2861634 41.25297 72.30765  93.01189 132.96429 
21   20   control 8 78.57540 23.240043 34.1570541 69.62816 78.29635  93.27930 108.92088 
22   21   control 8 73.95166 24.111706 47.1574477 52.21418 74.21112  83.71683 118.38338 
23   22   control 8 79.73725 39.984033 32.2878385 55.70554 77.70169  92.48141 157.49645 
24   23   control 8 62.60487 43.228443 -2.4038105 29.71875 79.87105  88.58759 116.93279 
25   24   control 8 72.27707 29.716195 31.5499545 57.69361 69.72137  91.23857 116.63113 
   week treatment n     mean       sd      min       Q1   median       Q3       max 
1     0    0.0014 8 65.82415 21.22763 28.61937 55.60899 63.50179 80.39568  98.08703 
2     1    0.0014 8 58.95268 23.69744 32.80170 43.12379 53.41088 68.13200  98.49969 
3     2    0.0014 8 60.04950 16.72464 41.96091 43.51853 61.30757 69.84861  89.15000 
4     3    0.0014 8 57.69938 19.39456 33.43331 38.14520 61.23123 71.26223  84.36900 
5     4    0.0014 8 62.23717 18.27452 33.56128 45.37596 69.45478 75.02574  82.77063 
6     5    0.0014 8 63.53862 23.43185 34.69904 41.14701 67.69242 74.32564 100.59037 
7     6    0.0014 8 63.65258 22.15805 36.54636 47.15030 60.31755 79.55660  99.38301 
8     7    0.0014 8 67.95422 23.44080 33.58503 51.89885 70.15120 87.30673  98.96170 
9     8    0.0014 8 63.79356 23.50116 29.24191 51.28871 59.69747 73.64064 101.61725 
10    9    0.0014 8 58.88455 32.07635 16.58660 35.95826 61.39479 83.47811 101.08719 
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11   10    0.0014 8 68.52583 29.87345 32.43045 43.99337 65.93203 88.15720 115.51947 
12   11    0.0014 8 61.45182 17.94793 38.86669 49.88797 54.99565 75.17566  89.20528 
13   12    0.0014 8 65.28732 19.73496 43.02138 49.94656 59.25660 81.20153  92.85869 
14   13    0.0014 8 69.89999 20.57269 43.85042 57.49008 63.84978 82.95639 103.01713 
15   14    0.0014 8 69.28917 20.53032 35.46406 56.44679 73.78508 81.33872  98.63678 
16   15    0.0014 8 58.19998 19.30073 29.69234 44.94602 60.14863 69.33014  87.74644 
17   16    0.0014 8 63.29684 14.90972 48.23689 54.42645 60.51897 64.75003  95.88899 
18   17    0.0014 8 62.97322 23.66616 23.70567 49.29515 62.97021 77.49098  99.88076 
19   18    0.0014 8 73.43129 26.94706 40.90622 53.01324 71.39856 91.20188 114.76126 
20   19    0.0014 8 62.97777 19.76260 43.66291 48.23849 55.77302 74.93380  92.69719 
21   20    0.0014 8 66.28485 19.49020 43.65014 51.86025 63.33997 80.04475  94.22438 
22   21    0.0014 8 64.27790 27.42855 25.06803 44.55730 61.44464 88.22969 103.58812 
23   22    0.0014 8 58.32759 22.66247 32.87386 40.45563 50.46999 83.34713  85.48269 
24   23    0.0014 8 68.19708 28.33004 42.04196 49.50836 55.19938 84.03073 120.70868 
25   24    0.0014 8 56.25792 25.88499 18.57672 41.68067 56.23081 69.13117 101.60036 
   week treatment n     mean       sd        min       Q1   median       Q3       max 
1     0    0.0028 8 51.96696 19.95887 17.6588509 44.12202 50.86108 63.45326  80.37287 
2     1    0.0028 8 43.43436 19.41154 -0.2412487 40.49502 47.96358 55.98999  59.74072 
3     2    0.0028 8 51.75855 13.45892 22.8428231 48.72473 55.52354 60.89544  64.17569 
4     3    0.0028 8 54.06191 21.31454 27.0650727 38.38897 52.35709 66.30424  89.61416 
5     4    0.0028 8 33.59752 19.44710  3.7328302 19.47884 39.55507 44.97392  61.73587 
6     5    0.0028 8 59.07272 18.09548 30.6216114 49.32241 60.32985 69.48728  88.53733 
7     6    0.0028 8 53.10856 17.85594 20.4138344 42.60481 58.51807 62.17283  78.42877 
8     7    0.0028 8 51.82557 18.31310 21.7757103 43.99594 57.79366 62.25040  73.82520 
9     8    0.0028 8 50.61365 19.62312 14.4945867 38.63530 53.76087 64.07413  72.49703 
10    9    0.0028 8 63.13186 15.28868 39.8522418 53.96785 59.46574 77.66824  83.53742 
11   10    0.0028 8 50.99604 20.74530  7.4682336 45.40117 54.57302 67.93200  69.03420 
12   11    0.0028 8 60.81916 20.72033 32.7523183 45.79188 61.58685 68.03321 101.06912 
13   12    0.0028 8 57.90743 19.98541 19.2587284 51.91872 59.44762 65.61740  90.07965 
14   13    0.0028 8 55.02552 23.97230 20.6716985 39.29526 55.71499 73.59441  84.60118 
15   14    0.0028 8 53.28854 13.06758 31.2278292 46.23959 53.41615 63.23161  68.70239 
16   15    0.0028 8 50.29820 23.11640 19.4226340 26.92365 60.13874 63.95982  80.48604 
17   16    0.0028 8 60.21056 16.99084 29.2009446 56.29381 66.64665 70.16238  77.83974 
18   17    0.0028 8 51.77712 15.00046 34.8309900 42.67208 50.84520 57.90412  81.50547 
19   18    0.0028 8 53.28214 16.22449 26.1920618 45.22636 55.84470 61.43293  78.10651 
20   19    0.0028 8 43.98439 21.28115  3.9213079 33.22745 50.81629 54.20775  73.43604 
21   20    0.0028 8 68.15460 20.84538 41.7300145 57.05188 64.08061 80.94449  98.90852 
22   21    0.0028 8 52.12480 18.01982 19.6562580 43.89432 52.52054 68.61359  71.65341 
23   22    0.0028 8 56.23429 26.44765 21.2056876 35.52069 59.93103 70.29118  99.65584 
24   23    0.0028 8 63.15166 19.44183 20.6864360 59.23685 71.24588 76.24810  76.96389 
25   24    0.0028 8 45.56094 18.98199 15.7826373 28.06167 54.43514 61.06137  62.21242 
   week treatment n     mean       sd       min       Q1    median        Q3       max 
1     0     0.014 8 48.75538 26.49189 17.240820 30.10230  48.92500  58.17085  93.55512 
2     1     0.014 8 49.72199 25.56546 19.438831 27.79841  50.05816  64.78955  90.55948 
3     2     0.014 8 55.83226 23.19194 38.681647 41.32085  48.01459  58.03218 107.89000 
4     3     0.014 8 64.75594 21.09305 37.384600 47.58768  64.53255  83.76611  92.54463 
5     4     0.014 8 66.27353 22.26487 38.633880 52.50462  63.19629  76.37607 109.02920 
6     5     0.014 8 75.77468 27.57188 53.714140 58.51510  64.41012  79.71215 132.45308 
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7     6     0.014 8 72.75445 20.90379 50.231852 55.51735  71.18803  83.02062 106.58485 
8     7     0.014 8 76.25906 32.37085 46.813877 54.31477  65.54882  82.68222 140.33264 
9     8     0.014 8 72.13597 35.62655 20.473947 53.36480  66.97772  87.62816 132.61461 
10    9     0.014 8 78.92168 34.98479 34.979800 60.03018  70.99317  86.25180 149.28502 
11   10     0.014 8 88.33502 33.94224 39.850619 60.80994  85.40942 122.12881 128.27794 
12   11     0.014 8 88.41956 36.75131 46.366836 58.58969  80.56184 124.20642 134.88536 
13   12     0.014 8 78.79211 51.99201 -8.552979 46.17774  83.92163 105.17700 159.18942 
14   13     0.014 8 91.98692 32.87588 34.696721 82.50638  96.62219 113.68845 132.03072 
15   14     0.014 8 77.76684 27.89171 41.639785 52.09359  82.06651  94.58070 123.81807 
16   15     0.014 8 86.40827 34.19827 42.257760 68.99175  82.20089  96.22335 153.46082 
17   16     0.014 8 94.08887 42.98930 33.772951 60.03797 106.79201 121.08033 146.31949 
18   17     0.014 8 85.96628 28.93360 45.911929 62.55968  95.58921 100.88568 129.25175 
19   18     0.014 8 90.72643 41.72413 50.225100 58.72279  79.07516 113.77285 163.05027 
20   19     0.014 8 85.23931 38.53114 34.278637 50.50105  92.94371 104.03815 152.65584 
21   20     0.014 8 85.67902 36.03750 45.536174 57.74057  79.06557 114.01579 144.94994 
22   21     0.014 8 88.79945 44.78807 25.790891 64.78140  77.76525 114.51831 164.06715 
23   22     0.014 8 78.49155 34.62125 39.596175 41.37802  86.57190  97.43984 130.04099 
24   23     0.014 8 99.16892 43.67258 37.303307 56.75022 108.14972 135.65526 149.53439 
25   24     0.014 8 86.37834 39.15826 31.008338 57.30680  83.86570 116.00877 148.24994  
Table 3B. Week 0 Distance Moved within 10-Minute Video Before Shadow Raw Data 
   Minute Treatment n      mean       sd       min        Q1    median        Q3       max 
1       1    0.0014 8 12.483796 3.951928 6.4046377 10.773055 11.928585 14.094307 18.584190 
2       2    0.0014 8 10.747968 2.004189 8.1077942  9.435906 10.730504 12.020234 13.948534 
3       3    0.0014 8  9.384299 3.079976 6.1732011  7.560054  8.240375 11.104402 15.099159 
4       4    0.0014 8  8.269666 2.799353 4.2971935  7.249362  8.012537  9.226881 12.837915 
5       5    0.0014 8  8.093206 2.031253 6.1312513  6.697802  7.225993  9.285802 11.929217 
6       6    0.0014 8  7.578691 1.427567 6.0049293  6.501950  7.145362  8.543109 10.103652 
7       7    0.0014 8  6.745246 2.067352 2.9667163  5.801556  6.613639  8.521148  9.055691 
8       8    0.0014 8  4.889974 2.171153 1.8796051  3.639132  4.418173  5.940320  9.064631 
9       9    0.0014 8  5.276876 3.042995 0.3371716  3.548625  4.793489  7.991398  9.005864 
10     10    0.0014 8  3.287758 2.072947 0.0604345  1.651729  4.064714  4.994386  5.206014 
   Minute Treatment n      mean       sd       min        Q1    median        Q3       max 
11      1    0.0028 8  5.955932 3.418624 1.6978935  3.788211  4.809962  7.932983 11.993061 
12      2    0.0028 8  6.900239 2.762048 2.7966490  5.525595  6.423165  7.978909 12.112534 
13      3    0.0028 8  6.157783 3.402700 0.0728420  4.210389  6.253723  9.031102 10.160436 
14      4    0.0028 8  5.516330 2.574620 0.0836622  5.165956  5.623745  7.229622  8.371517 
15      5    0.0028 8  4.965789 2.503898 0.0490670  4.032537  5.547855  6.630538  7.476892 
16      6    0.0028 8  5.390921 2.763716 0.0857051  3.983500  5.706272  7.135877  8.684694 
17      7    0.0028 8  5.348073 2.507857 1.5224314  3.562849  6.002885  6.972480  8.294623 
18      8    0.0028 8  4.172858 1.261884 2.0981653  3.206713  4.664077  5.075334  5.636397 
19      9    0.0028 8  4.728780 2.063864 0.1535998  4.428103  5.204788  5.931032  6.760966 
20     10    0.0028 8  2.707067 1.601553 0.0564849  1.725783  3.165082  3.680480  4.912381 
   Minute Treatment n      mean       sd       min        Q1    median        Q3       max 
21      1     0.014 8  6.717633 4.990488 2.0263806  2.357998  5.786208  9.157147 15.872712 
22      2     0.014 8  6.657189 4.332816 3.0558937  3.527510  5.004144  8.588096 15.842984 
23      3     0.014 8  5.440444 3.286437 0.1876484  4.063828  5.020659  6.832436 11.310859 
24      4     0.014 8  5.313792 1.780963 3.2904883  3.688597  4.998240  6.981239  7.677742 
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25      5     0.014 8  5.325978 2.804903 0.7799314  3.421586  5.159453  7.992864  8.580146 
26      6     0.014 8  5.134808 2.992853 0.4129888  2.648500  5.873050  7.326397  8.480941 
27      7     0.014 8  5.493142 2.600486 2.3403124  4.154024  4.832312  6.694819  9.917984 
28      8     0.014 8  3.698664 2.354129 0.1273334  2.200244  3.832447  5.150981  6.887741 
29      9     0.014 8  4.377359 2.807151 0.3824220  2.601664  3.969630  5.855271  8.369874 
30     10     0.014 8  3.062870 1.460436 0.4599274  2.587215  3.015175  4.185080  4.925194 
   Minute Treatment n      mean       sd       min        Q1    median        Q3       max 
31      1   Control 8  8.526895 3.321236 3.8613217  6.816583  7.999040 10.067162 14.977726 
32      2   Control 8  7.517953 3.918199 1.6074566  4.180945  8.236931  9.771126 13.223637 
33      3   Control 8  5.754892 2.456584 1.1487865  4.525544  6.101242  7.520795  8.672436 
34      4   Control 8  5.951535 1.907583 3.4123466  4.692336  5.951751  7.624485  8.164187 
35      5   Control 8  6.437271 2.324698 1.0941537  6.320754  7.050592  7.478438  8.862850 
36      6   Control 8  5.375288 2.706656 0.1229455  4.745426  5.858329  6.387313  9.165479 
37      7   Control 8  6.250877 2.483808 2.3105656  4.247023  6.786521  8.012108  9.515055 
38      8   Control 8  5.804633 2.360410 0.6735053  5.306555  6.373553  7.166499  7.970795 
39      9   Control 8  4.447956 2.635537 0.1042295  3.074732  4.348814  6.245978  8.094872 
40     10   Control 8  2.998659 2.113663 0.0804327  1.401390  3.426282  4.254174  6.054317 
 
Table 4B. Week 12 Distance Moved within 10-Minute Video Before Shadow Raw Data 
   Minute Treatment n      mean        sd       min       Q1    median        Q3       max 
1       1    0.0014 8 13.048539 4.8466921 7.5947668 9.243929 12.252341 16.318050 19.999069 
2       2    0.0014 8 11.544023 3.8684652 6.0514904 8.672167 11.607462 13.215053 17.390128 
3       3    0.0014 8  8.856582 3.3444911 3.7646754 6.260915  9.554707 11.578493 12.812134 
4       4    0.0014 8  8.331194 3.5649580 2.2816295 6.569499  8.904957 10.694919 12.378059 
5       5    0.0014 8  9.433343 3.3178722 3.9936696 7.624459  9.262080 12.236786 13.695921 
6       6    0.0014 8  7.625136 3.1754328 2.4090781 6.097993  7.478214  9.536264 12.142417 
7       7    0.0014 8  6.848344 3.6234629 3.1634356 4.404271  5.150285  9.061972 13.375582 
8       8    0.0014 8  5.998599 3.2824792 2.1079574 3.581330  5.139460  8.371759 11.513932 
9       9    0.0014 8  5.970959 3.9812234 0.0652275 4.268832  6.084803  7.220674 13.320656 
10     10    0.0014 8  2.973167 2.0697004 0.0373201 1.770181  2.478901  4.056518  6.601732 
   Minute Treatment n      mean        sd       min       Q1    median        Q3       max 
11      1    0.0028 8  8.816906 3.1615485 5.4471753 6.657186  7.711342 11.166611 14.163542 
12      2    0.0028 8  8.470031 4.1053867 3.3807959 4.505442  8.812514 11.124778 14.703443 
13      3    0.0028 8  6.853265 3.1183965 0.1149290 5.806116  7.878935  8.474275 10.375135 
14      4    0.0028 8  6.652414 2.9618970 1.5670481 5.500200  6.420446  9.210024 10.322522 
15      5    0.0028 8  6.229154 2.8655377 1.4785014 4.705747  5.957924  8.208687 10.242563 
16      6    0.0028 8  6.634150 1.7990436 4.3282094 5.138657  6.580373  7.858531  9.487993 
17      7    0.0028 8  6.199564 1.4006377 3.2936603 5.861528  6.287971  7.037875  8.052032 
18      8    0.0028 8  6.289132 2.8987587 0.0956065 6.139832  6.755227  7.523001 10.010545 
19      9    0.0028 8  5.567159 1.9505828 1.1817584 5.305503  6.174897  6.677889  7.312533 
20     10    0.0028 8  3.529950 2.2463462 0.0341448 2.350429  3.561819  4.031635  7.854847 
   Minute Treatment n      mean        sd       min       Q1    median        Q3       max 
21      1     0.014 8 12.152970 5.8930714 6.4921912 9.225150 10.733363 12.384526 25.904577 
22      2     0.014 8 11.625224 6.5743579 4.9767178 8.106222  8.839929 13.374463 24.355570 
23      3     0.014 8 10.481670 5.3046346 5.2640422 6.348562  9.252811 12.521232 20.300518 
24      4     0.014 8  9.326829 4.6424161 4.4557195 5.691114  8.197034 12.170348 17.107060 
25      5     0.014 8  8.507779 4.3012485 4.4861931 5.203295  6.501878 11.890078 15.605440 
26      6     0.014 8  8.125228 3.8253742 5.0886521 5.226858  7.106591  9.206326 16.487824 
179 
  
27      7     0.014 8  6.771629 3.8371450 2.8382687 3.375758  6.559656  8.395114 14.100626 
28      8     0.014 8  8.253897 2.9538957 4.4056006 6.008134  8.448961 10.931741 11.352615 
29      9     0.014 8  9.381821 4.3410756 3.9782696 6.017347  9.385669 12.640584 14.733031 
30     10     0.014 8  5.392326 2.5875566 2.8170063 3.442204  5.075229  6.042347 10.254854 
   Minute Treatment n      mean        sd       min       Q1    median        Q3       max 
31      1   Control 8  9.464548 4.1937359 4.2822171 6.524335  9.385728 11.516997 15.518510 
32      2   Control 8  8.694750 4.8434552 0.0326258 7.131209  8.022642 10.767847 17.057745 
33      3   Control 8  7.700632 4.8121607 0.0395241 4.409649  8.135440 11.933730 13.163002 
34      4   Control 8  7.107386 4.4086294 0.0476682 5.586633  7.391025  8.994872 12.722898 
35      5   Control 8  7.565449 3.5442600 0.0508542 6.628863  8.900299  9.355549 11.131566 
36      6   Control 8  7.120048 3.0854033 0.0409454 6.935158  7.726527  8.919707 10.069131 
37      7   Control 8  6.128692 2.7137740 1.2956630 5.859507  5.991644  6.255062 11.351654 
38      8   Control 8  6.816460 2.8695491 1.3175863 5.405344  7.190584  9.188995  9.848645 
39      9   Control 8  6.846726 3.3039241 2.1594352 4.178051  8.378867  8.895409 10.914428 
40     10   Control 8  2.873014 0.8977834 1.7498010 2.146710  2.975860  3.610119  4.007234 
 
Table 5B. Week 24 Distance Moved within 10-Minute Video Before Shadow Raw Data 
   Minute Treatment n      mean        sd       min        Q1    median        Q3       max 
1       1    0.0014 8 11.111000 4.3490880 3.7155354  8.291151 11.315854 14.720919 16.500149 
2       2    0.0014 8  9.547070 4.5031179 3.5554541  5.231686 10.439559 12.650942 16.101751 
3       3    0.0014 8  8.372184 4.3349874 1.2985992  6.519212  6.875774 12.485674 14.217973 
4       4    0.0014 8  7.682815 3.8618386 1.5692912  5.415592  7.031810 11.258508 12.462357 
5       5    0.0014 8  8.122358 3.4626272 3.1193176  6.270140  7.754830  9.800868 13.341024 
6       6    0.0014 8  6.615517 4.0299342 0.8419966  4.496887  5.948723  9.691448 12.563259 
7       7    0.0014 8  7.825572 3.3585933 1.7292432  6.268789  8.208829  9.008212 13.085692 
8       8    0.0014 8  7.501586 2.6544409 3.4854637  5.718588  7.566387  9.987490 10.377412 
9       9    0.0014 8  6.525479 3.6961254 0.7865954  4.264906  7.085903  8.810416 11.636189 
10     10    0.0014 8  4.517642 2.1484420 0.0390843  4.087216  5.045808  5.566632  6.946049 
   Minute Treatment n      mean        sd       min        Q1    median        Q3       max 
11      1    0.0028 8  7.821399 0.9510378 6.6677622  7.063000  7.707504  8.292860  9.330388 
12      2    0.0028 8  7.311493 2.3120092 4.5043260  6.021606  6.724458  8.315364 10.791240 
13      3    0.0028 8  5.703041 3.3422915 0.4509523  3.715301  6.286773  7.965064  9.658005 
14      4    0.0028 8  5.528632 2.5508335 1.1011700  4.852810  5.845521  6.592697  8.992066 
15      5    0.0028 8  5.539293 2.6472161 2.1587278  3.541398  5.185525  7.140645  9.722865 
16      6    0.0028 8  5.687450 1.9120519 3.7138965  4.433345  5.019351  6.336659  9.319522 
17      7    0.0028 8  5.643281 1.9543715 2.1300999  4.510736  6.111917  7.089295  7.675197 
18      8    0.0028 8  5.917675 2.3749194 4.1902997  4.378142  4.856151  6.505789 11.029881 
19      9    0.0028 8  6.360627 2.4490284 3.5368392  3.845268  6.575531  7.996479  9.860276 
20     10    0.0028 8  2.920250 1.8843606 0.0326626  1.988173  3.259726  3.825742  5.283398 
   Minute Treatment n      mean        sd       min        Q1    median        Q3       max 
21      1     0.014 8 12.320509 3.9343970 5.7322849 10.006907 13.302199 14.418346 17.580467 
22      2     0.014 8  9.260972 3.9775541 4.2612216  5.739165  8.961395 13.209916 13.981506 
23      3     0.014 8  8.496680 5.4280855 1.3046124  3.963229  8.598681 11.509083 15.886912 
24      4     0.014 8  9.070768 6.3139875 2.2486914  4.741451  6.749628 13.847870 18.381820 
25      5     0.014 8  8.239221 5.0016005 2.4367620  3.984068  7.738468 11.232148 16.310296 
26      6     0.014 8  8.187006 4.7580026 2.5486711  4.789260  6.447689 12.004717 15.527397 
27      7     0.014 8  7.989941 4.3591533 3.5364481  4.202314  7.021402 10.987946 15.025691 
180 
28 8     0.014 8  6.896664 3.7621056 3.0616555  3.736301  6.307039  9.356357 12.931085 
29 9     0.014 8  7.250784 5.0692169 0.6710334  3.973473  6.342187 11.099216 15.468445 
30     10     0.014 8  3.899026 2.4427981 1.0154769  2.134063  3.096689  5.714925  8.023083 
   Minute Treatment n      mean  sd       min   Q1    median        Q3  max 
31 1   Control 8  9.093840 4.8728622 1.8098419  5.475312 10.590916 12.224608 15.076478 
32 2   Control 8  8.698643 1.4710222 7.2471518  7.359850  8.388303  9.610043 10.896552 
33 3   Control 8  7.948732 2.4670258 5.2073130  6.855660  7.265279  8.337173 13.486269 
34 4   Control 8  8.366469 3.0533585 2.7544689  7.125438  8.938385  9.722874 13.007453 
35 5   Control 8  7.569204 3.8344348 3.8733730  5.160569  6.398314  8.375071 14.656935 
36 6   Control 8  8.404543 2.8295424 4.4571784  6.569481  8.441893  9.574272 13.755142 
37 7   Control 8  7.822077 1.5247060 6.0185842  6.692241  7.641227  8.653741 10.505315 
38 8   Control 8  7.698184 2.1683522 3.2654264  7.342687  8.144078  8.912543  9.882875 
39 9   Control 8  7.755944 2.7894664 3.2730889  6.564507  7.404563  8.852908 12.702730 
40     10   Control 8  4.304006 2.4118376 1.1884923  3.022751  4.564833  4.939889  8.876046 
 
Table 6B. Border Time Before Shadow Raw Data 
    week treatment n     mean        sd      min Q1   median       Q3  max 
1 0    0.0014 8 91.40069  4.925058 83.01330 89.32272 92.41550 94.53564  97.33669 
2 1    0.0014 8 92.03568  6.532916 78.07310 90.46769 92.96711 95.06995  99.88878 
3 2    0.0014 8 95.51842  4.637727 85.42500 94.13184 97.14938 98.68737  99.50831 
4 3    0.0014 8 95.26823  3.910695 88.97210 94.07634 97.15523 97.48303  98.72981 
5 4    0.0014 8 91.72763  7.038693 80.71290 88.57994 92.41688 96.23331 100.00000 
6 5    0.0014 8 94.82996  5.679656 82.62700 93.49245 97.14060 98.23666  99.33856 
7 6    0.0014 8 91.06174  8.834329 75.21660 85.65470 94.98050 97.76096  98.71217 
8 7    0.0014 8 95.94064  3.003733 88.77310 96.14844 96.58159 97.38791  98.21470 
9 8    0.0014 8 94.27577  4.817587 84.34120 92.15044 95.64200 96.69510  99.86537 
10     9    0.0014 8 94.73630  5.910980 81.14020 94.73777 95.41384 98.63469  99.88293 
11    10    0.0014 8 93.53781  6.046619 79.83490 93.30221 94.10267 96.95915  99.77172 
12    11    0.0014 8 92.46297  6.239503 78.81640 90.74572 94.50656 95.55578  98.65371 
13    12    0.0014 8 95.56378  5.347420 83.39380 95.67724 96.84481 98.66396  99.74830 
14    13    0.0014 8 92.64140  4.083921 85.69920 91.52278 92.63931 94.55339  98.81761 
15    14    0.0014 8 92.55736  9.080132 71.30060 92.80614 96.08113 97.36449  98.71810 
16    15    0.0014 8 94.91626  3.992862 88.69120 91.40863 96.18344 98.11078  99.53173 
17    16    0.0014 8 94.52043  3.805525 87.87170 92.49430 95.62180 97.67765  98.03910 
18    17    0.0014 8 93.05121  7.918904 78.38910 87.51462 96.41173 99.45270  99.83024 
19    18    0.0014 8 91.68447  9.401263 73.84690 85.58007 95.97577 98.41079 100.00000 
20    19    0.0014 8 92.70145  6.854289 79.32570 90.11466 95.20897 97.16840  99.37954 
21    20    0.0014 8 92.84353  7.148924 77.78040 91.01954 93.96219 98.36396  99.38539 
22    21    0.0014 8 93.10881  7.147973 80.07490 90.69310 95.56018 98.32885  99.43807 
23    22    0.0014 8 90.73872 13.785046 57.84700 91.62814 95.18555 97.51489  99.84781 
24    23    0.0014 8 94.19255  5.675519 85.31370 91.09819 96.50843 98.43421  99.52002 
25    24    0.0014 8 90.12673 11.619748 70.20020 88.51117 95.89090 97.21670  97.86935 
    week treatment n     mean        sd      min       Q1   median       Q3       max 
181 
26     0    0.0028 8 88.26366  6.289282 79.37250 83.98940 88.91910 90.66760  98.85273 
27     1    0.0028 8 91.79789  5.143106 83.38800 88.84045 92.61004 95.68749  97.76399 
28     2    0.0028 8 91.48403  7.716834 73.21470 91.45692 94.16135 95.60553  96.83329 
29     3    0.0028 8 92.15787  4.768211 83.28850 90.25696 91.77885 95.40799  98.93468 
30     4    0.0028 8 90.38209  6.484914 80.92370 85.42060 89.88526 96.49233  98.67712 
31     5    0.0028 8 90.24600  9.461440 71.10750 86.06740 92.99344 97.13913  99.26832 
32     6    0.0028 8 89.82432  7.869516 74.32690 85.52548 92.77394 94.32217  99.16296 
33     7    0.0028 8 90.46683  5.531859 81.09820 86.21370 92.16518 93.81439  97.55912 
34     8    0.0028 8 83.18602 19.377348 48.13860 70.26750 93.66074 96.55379  99.84196 
35     9    0.0028 8 84.89010 18.335215 43.65490 81.02903 91.79935 96.04162  99.87122 
36    10    0.0028 8 85.41820 15.255384 51.99600 83.13558 88.61191 94.25779  99.91220 
37    11    0.0028 8 93.20709  5.062322 83.20650 91.58570 93.50269 96.32698  98.96394 
38    12    0.0028 8 94.34563  4.185887 85.55960 93.34319 94.98084 96.10600  99.89463 
39    13    0.0028 8 92.24479  7.041815 80.54210 88.49654 93.48221 98.03178 100.00000 
40    14    0.0028 8 92.74295  5.400271 82.98250 90.30672 91.85179 97.27376 100.00000 
41    15    0.0028 8 92.02688  5.841288 81.21630 89.92185 93.09295 95.86163  98.26153 
42    16    0.0028 8 91.49350  7.211923 74.28000 91.82130 93.92707 95.24408  96.51136 
43    17    0.0028 8 89.49367  7.236591 77.60480 84.83025 91.91029 94.17730  98.05666 
44    18    0.0028 8 90.29270  8.052629 79.41350 82.93800 92.81199 96.23478 100.00000 
45    19    0.0028 8 82.00498 19.008587 36.61320 83.04093 86.58980 91.48765  96.06064 
46    20    0.0028 8 90.91987  6.641139 82.90210 83.75385 92.16812 97.21523  98.23226 
47    21    0.0028 8 88.34948 13.831201 63.66780 82.55970 94.02950 98.94346  99.63707 
48    22    0.0028 8 88.43063 12.365358 64.87360 85.85662 91.29570 97.82399  99.35027 
49    23    0.0028 8 93.82097  6.018369 81.72560 90.80133 95.40798 98.61859  99.07516 
50    24    0.0028 8 88.42740  9.622234 73.04500 84.63978 88.82290 94.56245 100.00000 
    week treatment n     mean        sd      min Q1   median       Q3  max 
51     0     0.014 8 89.73955 15.599648 53.00320 88.91858 96.38551 97.93216 100.00000 
52     1     0.014 8 88.92749 10.331038 68.39150 83.74067 91.76717 95.81606 100.00000 
53     2     0.014 8 92.22196  6.611943 81.43880 87.99020 93.59635 96.98491 100.00000 
54     3     0.014 8 92.65161  6.025100 82.77820 88.00923 94.04121 97.13765  99.79513 
55     4     0.014 8 90.88398 11.964247 71.13670 86.38931 96.85950 98.92004  99.90635 
56     5     0.014 8 93.55526  5.964749 84.24160 91.34278 94.94264 97.69960  99.77757 
57     6     0.014 8 93.45660  7.983273 79.29060 86.78002 98.51030 99.24052  99.37368 
58     7     0.014 8 87.48081 13.385636 60.36060 82.12140 89.79142 98.42543  99.83025 
59     8     0.014 8 91.23058 11.684618 72.40530 88.56799 97.27815 98.27763  99.26242 
60     9     0.014 8 92.79809  9.610424 73.42540 89.02776 97.60302 99.45856 100.00000 
61    10     0.014 8 88.17753 25.961315 24.78930 95.23676 98.23812 99.36783 100.00000 
62    11     0.014 8 92.88296 10.352978 71.80400 89.72871 98.48689 99.63122 100.00000 
63    12     0.014 8 91.51806 10.186983 71.59750 84.83355 97.05865 98.49567  99.51417 
64    13     0.014 8 94.18462  7.228623 80.37930 91.13351 97.32791 99.66635  99.85952 
65    14     0.014 8 93.41994  6.617593 83.56940 89.61309 94.07022 99.55660  99.92391 
66    15     0.014 8 96.06283  4.392111 86.92340 94.14803 97.76399 99.05467 100.00000 
67    16     0.014 8 91.89886  8.542847 81.43180 82.26703 95.40798 99.25748  99.80684 
68    17     0.014 8 96.32551  4.487081 89.29990 92.21054 99.32686 99.61221  99.66050 
69    18     0.014 8 95.85058  3.889349 89.76180 94.51095 96.48794 98.87761  99.96488 
70    19     0.014 8 93.67244  8.908102 74.66050 89.63213 98.22934 99.75119  99.87708 
71    20     0.014 8 94.72801  6.358349 86.34980 87.83220 98.55713 99.69560 100.00000 
72    21     0.014 8 91.65594 12.322068 67.85880 91.12328 97.45668 99.00931  99.70148 
73    22     0.014 8 90.83488 12.358960 65.03750 90.22157 95.91406 98.04055 100.00000 
182 
74    23     0.014 8 93.97169  8.312612 81.62020 87.51610 99.56684 99.76733  99.97073 
75    24     0.014 8 91.93470 11.031938 69.84310 88.91799 96.85671 99.75855  99.98244 
    week treatment n     mean        sd      min       Q1   median       Q3       max 
76     0   Control 8 88.82170  9.397738 73.29080 83.23330 90.72175 96.16880  99.24491 
77     1   Control 8 85.84038  8.788576 72.51230 80.76528 85.80250 91.31937  98.83517 
78     2   Control 8 88.13167 10.020170 68.78550 84.28940 92.10080 93.37831 100.00000 
79     3   Control 8 88.97359  7.429093 76.69160 86.55465 90.61402 94.71142  96.00211 
80     4   Control 8 88.63263 12.541458 62.25120 87.81754 93.81585 95.36847  99.25076 
81     5   Control 8 92.70002  5.785214 82.98990 90.08137 94.01779 97.49327  98.36094 
82     6   Control 8 92.99052  3.506543 87.74880 89.90868 94.88411 95.36555  96.69867 
83     7   Control 8 92.69273  4.105264 85.20840 91.11303 93.06369 94.17145  99.61367 
84     8   Control 8 91.34618  6.223922 82.45620 87.25217 91.83737 96.54204  99.19808 
85     9   Control 8 91.86593  7.142086 79.64180 88.50386 93.93878 97.76107  97.98642 
86    10   Control 8 90.73971  8.121149 77.35760 85.56838 92.04226 98.05081  99.06930 
87    11   Control 8 92.68436  7.228025 80.65440 90.36487 95.32018 97.87521  98.63615 
88    12   Control 8 94.79698  5.433498 81.93630 94.77563 96.34453 97.58828  99.18052 
89    13   Control 8 95.10573  4.136018 90.11941 90.65605 96.10455 98.43567 100.00000 
90    14   Control 8 92.36548  6.344242 81.22800 89.44565 95.33189 96.84793  97.63521 
91    15   Control 8 95.19137  2.476492 91.94568 93.63294 95.02736 96.30941  99.70733 
92    16   Control 8 95.51170  3.104519 91.03735 93.34465 96.58745 97.72280  98.87019 
93    17   Control 8 92.68012  8.225535 76.88930 92.25446 96.13380 97.42449  98.81761 
94    18   Control 8 93.34337  7.771068 76.39310 92.58417 95.29367 98.23079  99.98829 
95    19   Control 8 90.92274  9.665613 73.74150 84.82937 94.42731 98.99463  99.48490 
96    20   Control 8 96.13454  4.026016 89.70970 93.63147 97.34839 99.58880 100.00000 
97    21   Control 8 92.86247  7.203298 79.99880 88.63412 96.03723 98.37567  99.23320 
98    22   Control 8 92.93197 13.635778 59.56440 95.68748 97.57082 99.15125  99.95903 
99    23   Control 8 92.98318  7.192539 81.32750 87.44142 95.62456 98.93029  99.68391 
100   24   Control 8 91.52129  8.732083 75.96000 87.34342 93.78659 98.08436 100.00000 
Table 7B. Zone Crossing Before Shadow Raw Data 
    Week Treatment n   mean        sd min    Q1 median    Q3 max percZero 
1 0    0.0014 8 16.375  8.943274   5 10.75   16.0 19.75  30      0.0 
2 1    0.0014 8 10.875  5.743008   1  8.75    9.5 15.00  20      0.0 
3 2    0.0014 8  9.125  5.566160   1  5.25   10.0 13.50  15      0.0 
4 3    0.0014 8  8.125  4.356850   4  6.00    6.5  8.50  18      0.0 
5 4    0.0014 8 14.500 10.212038   0  7.75   16.0 23.25  26     12.5 
6 5    0.0014 8 10.500  5.682052   3  7.00   10.5 13.25  19      0.0 
7 6    0.0014 8 13.875  9.991961   3  8.50   10.5 18.50  31      0.0 
8 7    0.0014 8 12.125  6.334430   5  5.75   12.5 18.25  19      0.0 
9 8    0.0014 8 10.375  7.366672   2  5.75    9.5 13.50  21      0.0 
10     9    0.0014 8 10.000  5.631544   1  6.75   10.0 12.50  18      0.0 
11    10    0.0014 8 14.625  6.864765   4 10.75   14.0 18.50  24      0.0 
12    11    0.0014 8 13.750  9.051440   4  7.25   13.0 16.75  32      0.0 
13    12    0.0014 8  9.125  6.197638   2  3.75    8.5 13.00  19      0.0 
14    13    0.0014 8 14.750  6.519202   8 11.00   13.0 17.25  25      0.0 
15    14    0.0014 8 11.625  4.657942   6  7.00   11.5 16.25  17      0.0 
16    15    0.0014 8  9.375  4.897157   1  7.75    9.0 10.75  18      0.0 
183 
17    16    0.0014 8 11.250  5.574175   3  9.00   12.0 16.00  17      0.0 
18    17    0.0014 8 13.500 15.574705   1  2.00   11.5 15.25  49      0.0 
19    18    0.0014 8 14.375  9.410291   0  8.25   15.0 23.00  24     12.5 
20    19    0.0014 8 14.125  6.621124   4  7.75   17.5 19.25  20      0.0 
21    20    0.0014 8 15.375 11.249603   2  9.50   14.5 18.25  39      0.0 
22    21    0.0014 8 12.875  6.174544   2 10.00   13.5 17.25  21  0.0 
23    22    0.0014 8 11.000  7.071068   1  7.25   10.5 17.50  19      0.0 
24    23    0.0014 8 13.875  8.078852   3  7.00   16.0 18.50  24    0.0 
25    24    0.0014 8 15.750 11.360961   5  6.00   11.0 27.00  33      0.0 
    Week Treatment n   mean        sd min    Q1 median    Q3 max percZero 
26     0    0.0028 8 13.750  8.276473   3  9.25   13.0 18.25  25      0.0 
27     1    0.0028 8 11.750  6.627863   3  7.75   10.0 15.50  24      0.0 
28     2    0.0028 8 12.375  6.116430   5  9.25   11.0 14.25  24      0.0 
29     3    0.0028 8 14.125  6.220645   5 11.00   13.0 16.00  26      0.0 
30     4    0.0028 8 14.875  9.920217   2  6.75   14.5 23.00  27      0.0 
31     5    0.0028 8 11.625  6.523310   3  7.75   10.5 18.00  20      0.0 
32     6    0.0028 8 16.000  8.815571   2 12.75   18.5 22.25  25      0.0 
33     7    0.0028 8 18.375  6.631903   7 16.00   18.5 21.00  29      0.0 
34     8    0.0028 8 13.375  7.707835   1 10.00   14.5 17.75  24      0.0 
35     9    0.0028 8 14.125  7.567553   2  9.75   13.5 18.50  25      0.0 
36    10    0.0028 8 17.750  9.192388   2 14.25   21.0 23.00  29      0.0 
37    11    0.0028 8 10.375  3.925648   5  8.25   10.5 12.25  17      0.0 
38    12    0.0028 8 11.625  4.627171   2 10.00   12.5 14.25  17      0.0 
39    13    0.0028 8 11.250  7.086204   0  8.50   11.0 13.25  25     12.5 
40    14    0.0028 8 12.125  9.125122   0  5.75   12.5 14.75  30     12.5 
41    15    0.0028 8 12.250  5.063878   5  8.75   11.5 16.25  20      0.0 
42    16    0.0028 8 16.875 11.063938   7 11.75   14.0 17.00  43      0.0 
43    17    0.0028 8 14.125  6.010408   7  9.25   14.0 18.00  23      0.0 
44    18    0.0028 8 16.125 11.089731   0  9.00   15.5 22.25  35     12.5 
45    19    0.0028 8 20.750 17.926437   2 13.50   15.5 21.25  62      0.0 
46    20    0.0028 8 18.250 11.913378   3 11.25   18.5 22.00  41      0.0 
47    21    0.0028 8 13.125  8.559665   2  3.75   17.0 20.25  21      0.0 
48    22    0.0028 8 17.000 17.614929   2  5.50   10.0 21.50  48      0.0 
49    23    0.0028 8 12.625 12.512137   1  5.50    8.5 14.75  40      0.0 
50    24    0.0028 8 20.375 15.909903   0 10.50   21.5 25.00  50     12.5 
    Week Treatment n   mean        sd min    Q1 median    Q3 max percZero 
51     0     0.014 8  9.625  7.170127   0  3.75    9.0 16.25  19     12.5 
52     1     0.014 8 10.500  7.425824   0  7.00   10.5 13.00  25     12.5 
53     2     0.014 8 10.125  5.743008   0  7.50   10.5 13.50  18     12.5 
54     3     0.014 8 12.000  8.194074   1  9.00   12.5 13.50  28      0.0 
55     4     0.014 8  9.000  9.396048   1  2.50    6.5 11.25  29      0.0 
56     5     0.014 8  9.875  5.938675   4  5.00    9.0 12.50  21  0.0 
57     6     0.014 8 12.625 11.224177   3  4.50    7.5 19.25  30      0.0 
58     7     0.014 8 13.125  8.967202   1  6.00   15.5 16.75  28      0.0 
59     8     0.014 8 10.875  8.526220   2  4.75    8.5 14.25  26      0.0 
60     9     0.014 8 12.375 12.591806   0  1.75    8.5 21.25  34     12.5 
61    10     0.014 8  7.000  6.436503   0  1.50    6.5 10.75  18     25.0 
62    11     0.014 8 11.125 12.540648   0  2.75    5.5 16.75  36     12.5 
63    12     0.014 8 14.000 13.721724   1  5.50   11.0 15.25  44      0.0 
184 
64    13     0.014 8  7.625  6.674846   1  1.75    6.5 13.00  18      0.0 
65    14     0.014 8  8.125  5.767830   1  3.25    8.5 13.00  16      0.0 
66    15     0.014 8  8.000  7.270292   0  2.75    6.0 11.75  20     12.5 
67    16     0.014 8 14.500 10.941402   1  6.75   13.5 22.00  33  0.0 
68    17     0.014 8  7.000  5.398413   3  3.00    3.5 12.00  16      0.0 
69    18     0.014 8  8.875  5.841661   1  6.75    7.0 10.50  21      0.0 
70    19     0.014 8 10.750 11.285262   1  2.00    7.0 15.00  29      0.0 
71    20     0.014 8  9.000  7.634508   0  3.25    7.5 15.25  21     12.5 
72    21     0.014 8 10.625  7.689278   2  3.75   10.0 15.25  23      0.0 
73    22     0.014 8 11.375  8.617880   0  5.75    9.0 17.75  23     12.5 
74    23     0.014 8  9.750 10.593125   1  2.50    3.0 20.25  26      0.0 
75    24     0.014 8  8.625  7.463004   1  1.75    8.0 13.25  20      0.0 
    Week Treatment n   mean        sd min    Q1 median    Q3 max percZero 
76     0   Control 8 17.625 13.752273   2  8.75   16.0 21.00  44      0.0 
77     1   Control 8 15.625  7.981004   5 10.00   15.0 22.50  26      0.0 
78     2   Control 8 18.125 11.205069   0 13.25   15.5 25.25  34     12.5 
79     3   Control 8 15.875  8.322731   5 11.25   14.5 18.75  29      0.0 
80     4   Control 8 15.125  7.809106   5  9.75   12.5 23.00  26      0.0 
81     5   Control 8 15.750  9.558093   5  6.00   15.5 24.00  28      0.0 
82     6   Control 8 15.500  7.764388   2 12.75   17.0 21.50  23      0.0 
83     7   Control 8 15.375  8.175530   2 10.50   15.0 22.50  25      0.0 
84     8   Control 8 15.750  7.206148   6  9.25   18.0 22.00  23      0.0 
85     9   Control 8 16.500 11.637378   5  8.00   13.0 20.25  38      0.0 
86    10   Control 8 13.875  8.322731   4  7.25   13.0 19.25  27      0.0 
87    11   Control 8 12.875  7.510707   6  7.00   10.0 17.50  27      0.0 
88    12   Control 8  9.125  4.823677   4  5.00    7.5 13.50  16      0.0 
89    13   Control 8 10.250  8.293715   0  4.75    8.0 14.75  24     12.5 
90    14   Control 8 15.000 11.326328   4 11.75   12.0 13.25  42      0.0 
91    15   Control 8 11.375  4.983903   2  8.75   12.0 15.25  17      0.0 
92    16   Control 8 10.375  5.604526   3  6.75   11.0 15.00  17      0.0 
93    17   Control 8 11.000  9.335034   4  6.00    6.0 12.25  27      0.0 
94    18   Control 8  9.500  6.047432   1  5.75    9.5 11.50  21  0.0 
95    19   Control 8 13.375 12.727220   1  3.75   10.5 17.50  38      0.0 
96    20   Control 8 10.875  9.598177   0  3.75    7.5 18.50  27     12.5 
97    21   Control 8 17.250 19.919481   2  8.50   11.0 15.25  65      0.0 
98    22   Control 8  9.625  9.738546   1  3.25    8.0 11.00  31      0.0 
99    23   Control 8 12.000 10.042766   1  5.00    9.5 18.50  30      0.0 
100   24   Control 8 12.625  8.262436   0  9.25   11.0 17.00  28     12.5 
Table 8B. Time Moving Before Shadow Raw Data 
    Week Treatment n     mean        sd      min Q1   median       Q3     max 
1 0    0.0014 8 85.33331  7.728425 74.76590 77.55133 88.47670 90.46318 94.6906 
2 1    0.0014 8 70.16215 29.609158  0.42730 71.38407 75.44780 88.15117 92.4491 
3 2    0.0014 8 80.81149 14.793242 53.85740 73.37663 83.87090 93.96807 94.5329 
4 3    0.0014 8 74.16660 16.515290 39.55160 70.93332 76.63895 79.86710 97.8986 
5 4    0.0014 8 76.58994 16.001294 41.34860 74.11030 81.80170 86.31320 91.3369 
6 5    0.0014 8 84.19574  8.711826 68.99440 80.80370 83.28845 90.60670 95.1182 
7 6    0.0014 8 81.05723  6.993538 72.34840 75.55505 80.96170 87.57685 89.3058 
185 
8 7    0.0014 8 83.73990 10.719666 61.54880 81.54705 86.55760 90.21157 94.8139 
9 8    0.0014 8 84.91079  7.736101 74.25660 78.43063 85.71390 89.82670 95.9130 
10     9    0.0014 8 87.04197  8.831903 71.34750 81.72558 90.52915 91.93400 98.5659 
11    10    0.0014 8 87.11586  6.542318 78.54720 82.36215 87.11955 92.07882 95.3699 
12    11    0.0014 8 74.17248 16.514505 49.91220 60.35620 78.37155 89.26630 90.1077 
13    12    0.0014 8 81.88686 11.270345 61.48220 76.91407 81.12500 91.03110 95.3348 
14    13    0.0014 8 81.27030  9.058351 67.56610 74.57455 81.34220 89.13455 92.7359 
15    14    0.0014 8 83.32870  8.606205 67.62470 79.19985 83.35575 88.29608 95.3231 
16    15    0.0014 8 73.91076 17.652707 47.16380 64.82672 79.05350 86.13547 91.6589 
17    16    0.0014 8 78.76944  9.534138 64.97690 73.14155 79.00670 86.20507 90.0667 
18    17    0.0014 8 79.87406 14.797999 50.57360 74.74495 82.33965 88.41312 97.9395 
19    18    0.0014 8 81.64715  8.644324 68.91240 75.30728 82.03580 87.18625 95.1531 
20    19    0.0014 8 81.77309 10.165384 69.09970 71.63868 83.77725 90.39583 93.4617 
21    20    0.0014 8 84.22230 14.138234 57.82020 80.17782 85.78495 94.55048 99.9941 
22    21    0.0014 8 84.45411  6.989600 71.89260 80.50805 84.95085 89.77700 92.2676 
23    22    0.0014 8 82.34834 12.227912 61.60740 72.58430 88.15560 90.25465 95.3463 
24    23    0.0014 8 77.02773 18.389007 33.70020 78.52667 81.61440 83.64402 94.0236 
25    24    0.0014 8 73.02959 17.680126 46.57570 61.46688 76.38140 86.00010 93.2861 
    Week Treatment n     mean        sd      min Q1   median       Q3     max 
26     0    0.0028 8 77.04331 19.987299 31.36850 76.81018 79.64995 91.14510 92.8174 
27     1    0.0028 8 81.55145  7.610447 71.67530 74.92095 83.43770 86.15225 91.5769 
28     2    0.0028 8 87.52860  5.989540 76.84380 84.82205 88.54805 92.07300 94.1641 
29     3    0.0028 8 82.08705  9.114230 68.57290 76.18825 83.11580 87.40490 96.4821 
30     4    0.0028 8 69.86362 28.258451  7.88457 59.94497 80.80660 85.60790 95.8207 
31     5    0.0028 8 82.38338 11.446452 59.35960 78.49452 87.43855 89.10385 92.1564 
32     6    0.0028 8 77.55976 13.269466 49.56100 73.99830 78.52085 86.55470 90.5818 
33     7    0.0028 8 82.72354  5.146157 75.14050 78.34235 83.75090 87.46637 88.3627 
34     8    0.0028 8 67.46664 15.510334 47.50640 52.68525 71.29770 77.32385 86.8181 
35     9    0.0028 8 74.07151 21.219980 37.08150 61.04688 84.72550 88.09560 94.2227 
36    10    0.0028 8 77.60446 13.711123 47.66450 73.47402 82.45725 84.86820 90.5818 
37    11    0.0028 8 82.56409 10.440734 59.59380 80.90170 85.11765 88.29313 92.9817 
38    12    0.0028 8 81.64073 14.942037 48.19130 79.71200 85.54790 89.52537 94.9950 
39    13    0.0028 8 80.96894 10.730798 58.55770 77.27115 83.22995 86.57892 94.4568 
40    14    0.0028 8 82.46495  8.655302 64.66280 79.79802 84.40350 88.58350 91.3077 
41    15    0.0028 8 81.18196 12.511741 52.08970 80.92657 84.88935 87.70635 91.5594 
42    16    0.0028 8 81.21560  9.950067 67.19740 76.57018 81.09050 85.47907 95.7738 
43    17    0.0028 8 83.08410  8.923881 70.89090 76.69795 81.67585 90.42195 97.1494 
44    18    0.0028 8 80.11351  5.500348 72.85760 75.90250 80.44370 84.09477 87.0288 
45    19    0.0028 8 74.74518 26.449060 11.62490 73.75135 84.10500 89.75355 91.0443 
46    20    0.0028 8 92.24423  6.002705 80.94710 88.10295 95.20605 96.20697 97.6645 
47    21    0.0028 8 76.11407 13.049821 56.55580 64.95650 77.35890 85.97662 92.3027 
48    22    0.0028 8 73.27969 17.345720 45.11820 57.85677 81.39435 85.37082 92.0042 
49    23    0.0028 8 70.53381 31.275704  3.68181 69.07922 81.36850 91.75543 92.4783 
50    24    0.0028 8 79.98194 12.182076 56.08760 75.57403 79.85120 88.75350 94.6266 
    Week Treatment n     mean        sd      min Q1   median       Q3     max 
51     0     0.014 8 74.53500 17.998125 41.55350 64.89298 75.44080 88.73305 97.3014 
52     1     0.014 8 78.10813 15.830098 56.28660 64.76675 79.35785 93.51870 93.6959 
53     2     0.014 8 82.86872  9.730207 68.54950 77.45848 80.00470 90.59210 98.0820 
54     3     0.014 8 85.71594  7.332766 74.42640 82.15360 86.28495 89.95703 96.1777 
186 
55     4     0.014 8 86.16086  8.622903 72.86350 78.80585 88.99850 92.60860 95.3816 
56     5     0.014 8 84.94324 11.143300 66.07150 80.07635 85.66785 94.66895 97.2313 
57     6     0.014 8 86.27518  6.583106 78.10230 82.05335 86.01030 89.21215 97.7933 
58     7     0.014 8 81.69392 15.382609 58.03680 72.56645 85.00870 94.13017 98.1035 
59     8     0.014 8 82.36396 13.291934 64.82090 68.82330 86.67705 93.36368 95.8204 
60     9     0.014 8 79.43106 16.531801 46.49380 74.48493 82.08560 89.67748 97.7523 
61    10     0.014 8 85.40153 22.284404 32.71480 87.27460 93.69875 97.49180 98.8059 
62    11     0.014 8 85.61296 11.350149 66.74080 77.14383 88.31655 94.88400 98.7591 
63    12     0.014 8 85.32439  8.216336 74.66050 79.54920 85.53855 92.77978 94.0646 
64    13     0.014 8 81.28148 14.470988 55.45540 73.38442 85.08840 92.49155 96.9387 
65    14     0.014 8 82.50764 12.648405 62.95950 71.55815 85.49185 92.87637 98.0332 
66    15     0.014 8 86.29712  9.879618 70.45190 81.28075 83.64845 95.36260 98.9464 
67    16     0.014 8 83.93077 13.627087 64.41110 75.08490 84.20680 95.42697 99.6318 
68    17     0.014 8 83.44723 11.197049 62.86580 77.75405 85.95180 92.80610 92.9232 
69    18     0.014 8 85.06108 11.238297 64.52030 81.06127 86.00445 93.09735 97.3367 
70    19     0.014 8 83.78115 12.833979 58.44060 79.08152 84.49425 92.39640 98.8820 
71    20     0.014 8 84.39105 13.855899 57.39290 76.33315 89.29990 92.26443 99.6078 
72    21     0.014 8 79.17278 16.893586 47.17280 71.08407 80.98515 93.67538 95.9553 
73    22     0.014 8 84.96156 11.939529 65.81010 77.34870 87.11585 93.20530 99.1805 
74    23     0.014 8 88.29750 10.135799 70.51630 80.52565 93.33290 96.01233 97.4128 
75    24     0.014 8 80.98366 15.074152 55.54320 70.13435 83.51085 92.22810 97.8986 
76     0   Control 8 76.11989 10.275704 56.26900 73.84120 75.88905 78.81812 92.5369 
    Week Treatment n     mean        sd      min Q1   median       Q3     max 
77     1   Control 8 79.81286  6.040149 69.39240 77.10722 79.45450 82.84575 88.8024 
78     2   Control 8 80.26969  8.308553 64.72720 77.32820 79.59840 84.34358 92.4198 
79     3   Control 8 78.34084 10.589738 60.95760 71.73230 80.17440 85.39865 90.7691 
80     4   Control 8 82.06436  8.530444 69.40410 78.31595 80.18615 88.74093 93.0930 
81     5   Control 8 79.81354  7.630522 66.94570 76.66345 77.84480 86.12300 90.2716 
82     6   Control 8 80.03175 12.089505 51.76770 80.48610 84.27475 86.49470 88.5624 
83     7   Control 8 82.88825 11.342006 56.84270 81.29393 86.67760 90.39453 90.6521 
84     8   Control 8 76.48049 11.447131 56.14020 73.13860 78.95860 84.05210 89.4287 
85     9   Control 8 81.34878 10.262664 62.40930 75.79460 85.32835 88.47310 91.4072 
86    10   Control 8 80.64550  9.289482 68.96510 72.79323 79.58860 89.69795 92.2266 
87    11   Control 8 83.38523  7.828665 71.80400 75.75952 87.56805 88.34875 92.1564 
88    12   Control 8 76.61911 22.150065 23.45470 80.13665 82.31625 86.12735 92.6481 
89    13   Control 8 82.37162 11.266360 60.22590 76.60380 85.39570 88.78777 96.1950 
90    14   Control 8 83.34228  6.173833 76.10040 78.51757 82.30450 87.89947 92.5076 
91    15   Control 8 82.70658  8.564462 68.12220 76.77615 86.08640 89.38478 91.2023 
92    16   Control 8 74.15105 25.004586 13.50390 79.13107 82.18590 84.83227 90.5025 
93    17   Control 8 85.01286  5.381060 77.89620 81.29387 84.68160 88.93845 93.5788 
94    18   Control 8 84.51545  9.404174 70.51760 77.79115 86.70100 92.92900 93.5378 
95    19   Control 8 82.97295 11.302155 64.73890 76.11175 83.69200 92.95628 95.5338 
96    20   Control 8 88.40875  7.630415 73.03910 84.70352 90.57890 93.84510 96.5114 
97    21   Control 8 85.12132  7.239814 71.15430 82.93875 85.71765 88.56533 95.6099 
98    22   Control 8 82.42931 10.608492 68.61390 75.54260 80.20370 92.04520 96.3650 
99    23   Control 8 85.18597  9.679170 68.61390 81.63250 89.44625 92.32762 92.7535 
100   24   Control 8 84.67561  9.566471 71.17190 76.00535 85.43915 93.65485 96.3065 
187 
Table 9B. Border Time Moving Before Shadow Raw Data 
    Week Treatment n     mean        sd      min Q1   median       Q3  max 
1 0    0.0014 8 86.73419  6.597289 76.72633 81.16872 88.35784 91.97592  94.83040 
2 1    0.0014 8 74.11312 22.940090 20.90513 73.04367 78.91521 86.47274  93.45252 
3 2    0.0014 8 82.44347 14.502929 53.09510 77.14652 87.20449 93.53128  94.21915 
4 3    0.0014 8 79.78682  8.370650 69.12358 76.84124 77.93890 80.49401  98.28602 
5 4    0.0014 8 81.68990  7.456611 68.13540 78.76352 81.74129 87.18057  91.37257 
6 5    0.0014 8 84.84313  7.952851 69.81535 81.94337 83.57956 90.75081  95.07858 
7 6    0.0014 8 83.78607  7.864903 67.10823 81.78617 84.48465 90.04886  91.21290 
8 7    0.0014 8 83.50793  9.790520 63.95712 82.02851 86.15921 88.88790  93.85620 
9 8    0.0014 8 86.59137  6.607467 78.20977 81.40629 86.62881 89.76688  97.68410 
10     9    0.0014 8 87.13445  6.888116 74.20758 85.95429 88.96081 91.64492  94.14600 
11    10    0.0014 8 88.31383  6.583039 78.63015 84.23947 89.34682 91.09701  98.33792 
12    11    0.0014 8 77.54887 13.305907 54.61855 70.72363 80.17956 88.73456  89.94537 
13    12    0.0014 8 82.56546 10.224675 69.37450 72.59357 83.74667 91.32157  94.84475 
14    13    0.0014 8 82.04679  5.862181 74.27997 77.18388 81.64600 86.82053  90.17522 
15    14    0.0014 8 85.15560  5.790414 75.07660 82.64148 85.13506 87.94304  95.02067 
16    15    0.0014 8 75.99588 16.416231 48.33835 69.05137 79.70966 90.01068  90.93880 
17    16    0.0014 8 82.15540  7.643935 71.56195 76.91784 81.08439 89.89957  91.12540 
18    17    0.0014 8 78.46983 10.846190 60.36920 71.67264 79.26436 86.99794  92.11118 
19    18    0.0014 8 81.70905  9.564221 63.90928 78.33925 80.41569 87.29074  95.73873 
20    19    0.0014 8 84.36200  7.827452 74.04138 78.24112 83.65493 91.33504  94.47540 
21    20    0.0014 8 88.04079  9.724859 71.62377 84.43971 88.46469 95.34916 100.00000 
22    21    0.0014 8 85.56267  6.045255 73.57507 83.17200 86.44537 88.49934  93.05112 
23    22    0.0014 8 85.40642 10.469160 66.11583 83.16105 88.84465 90.65506  96.60635 
24    23    0.0014 8 78.72505 18.937601 33.51772 81.66031 84.68282 86.43966  93.30848 
25    24    0.0014 8 78.09793 12.869001 55.84730 71.20203 78.57512 85.43145  95.05442 
    Week Treatment n     mean       sd      min Q1   median       Q3  max 
26     0    0.0028 8 79.84181 14.730150 47.90293 77.78843 79.66329 90.94995  94.38480 
27     1    0.0028 8 82.91859  6.640982 74.76332 78.47093 82.56141 86.59851  93.37690 
28     2    0.0028 8 88.71229  4.213788 83.52823 84.49210 89.89386 91.96170  93.64800 
29     3    0.0028 8 83.04338  7.393303 74.81573 77.36843 82.61356 87.49644  95.20305 
30     4    0.0028 8 73.70154 21.376373 27.13437 67.27145 80.65724 83.83455  96.57230 
31     5    0.0028 8 83.96016  8.820874 70.60332 77.33407 87.59124 89.37407  94.08035 
32     6    0.0028 8 74.92878 22.807576 20.36042 76.48436 79.95132 86.19372  91.06283 
33     7    0.0028 8 82.57867  5.528769 73.57535 78.38016 83.03581 87.37810  88.73953 
34     8    0.0028 8 73.87536 11.094835 55.67083 69.63698 74.77792 79.03098  89.64875 
35     9    0.0028 8 77.20743 19.862745 33.34038 71.21909 84.89423 89.85574  94.23125 
36    10    0.0028 8 83.55169  6.275463 71.73557 79.82113 85.47266 88.07489  90.18955 
37    11    0.0028 8 84.76104  8.535297 67.08973 82.82043 87.51640 90.68649  91.78038 
38    12    0.0028 8 84.03718 11.839988 56.89450 84.51318 86.48671 89.04625  95.44397 
39    13    0.0028 8 81.60084 10.633255 62.05100 75.72291 84.42416 89.26557  93.49475 
40    14    0.0028 8 83.61939  9.767510 63.39025 80.38591 86.55675 89.54194  93.75215 
41    15    0.0028 8 81.31125 12.857151 51.39872 80.55051 85.50850 88.47968  91.45222 
42    16    0.0028 8 82.73469  8.776419 69.30195 77.96698 81.37574 86.54757  95.75345 
43    17    0.0028 8 86.92775  7.457101 73.81862 82.53104 89.43550 91.06444  97.17880 
188 
44    18    0.0028 8 80.82085  5.379348 70.82030 78.63881 80.40435 84.61452  87.08957 
45    19    0.0028 8 81.64285 12.619254 53.47478 80.52723 85.42974 89.62302  91.43950 
46    20    0.0028 8 92.37581  5.707909 83.40358 88.76544 95.31091 96.15926  97.79520 
47    21    0.0028 8 80.87382  8.941765 66.35762 75.09838 81.30327 85.92691  92.93730 
48    22    0.0028 8 75.83603 14.545110 48.07415 66.57246 81.66735 85.79058  90.30317 
49    23    0.0028 8 73.55058 24.535650 24.83538 69.87146 82.19664 90.93328  92.51413 
50    24    0.0028 8 81.86500 10.701326 65.13815 75.51886 79.54425 91.78584  95.67288 
    Week Treatment n     mean     sd      min Q1   median       Q3  max 
51     0     0.014 8 71.91329 13.961880 48.89350 66.01492 73.81735 80.72967  88.58237 
52     1     0.014 8 81.98105 13.197299 63.81442 73.95031 83.32788 92.63359  98.10712 
53     2     0.014 8 84.65362  8.149201 75.10613 79.40883 83.06855 90.80305  97.86602 
54     3     0.014 8 87.02374  5.703453 77.47035 84.51859 87.08230 91.40099  93.79470 
55     4     0.014 8 84.41704  8.299061 72.70135 77.62004 84.67859 89.93032  95.52568 
56     5     0.014 8 85.70129  8.652216 72.88638 80.28742 86.45101 94.06258  94.58522 
57     6     0.014 8 85.89749  5.293847 79.88657 80.66402 85.83960 90.60661  92.54483 
58     7     0.014 8 86.01404  9.464603 71.27442 78.83091 87.13431 93.24466  98.21653 
59     8     0.014 8 84.47595 10.458873 67.39338 77.40527 86.72355 92.45640  95.98833 
60     9     0.014 8 78.27525 16.896177 42.63347 75.04816 82.68063 87.62099  97.03163 
61    10     0.014 8 85.89857 11.360285 69.12642 77.05031 87.19293 96.87494  98.14615 
62    11     0.014 8 86.25243 10.146571 68.61765 80.65467 88.11431 92.92301  99.17618 
63    12     0.014 8 85.50366  6.763725 77.19570 78.73386 86.49913 90.85606  94.92427 
64    13     0.014 8 82.69075 11.825964 63.89957 73.07625 86.28111 91.34687  97.32890 
65    14     0.014 8 80.92612 11.738890 68.45300 71.32107 78.62847 89.22804  98.22333 
66    15     0.014 8 83.01931  9.264877 70.62980 76.76016 83.73557 86.61103  99.38380 
67    16     0.014 8 84.61372 11.759040 67.68515 76.47806 83.61359 94.37318  99.73448 
68    17     0.014 8 85.18882  7.661912 75.25383 78.72420 84.50702 92.52937  94.07480 
69    18     0.014 8 84.76938 11.570700 63.14875 81.27048 86.72990 91.95271  97.05152 
70    19     0.014 8 84.10020 10.145246 64.66638 80.14080 85.75495 88.82984  98.85190 
71    20     0.014 8 79.88600 11.180234 62.06262 73.78113 78.70103 87.53359  97.03800 
72    21     0.014 8 77.81251 13.603993 56.10583 69.04727 77.90391 86.72147  95.98135 
73    22     0.014 8 82.65176 11.516784 66.98727 72.56182 83.87206 91.72947  99.14363 
74    23     0.014 8 82.33995 17.679996 47.63643 75.89543 86.94189 95.77916  98.46815 
75    24     0.014 8 80.02381 15.836042 55.13728 69.74220 79.58768 92.44836  98.27868 
    Week Treatment n     mean        sd      min Q1   median       Q3  max 
76     0   Control 8 81.30310 13.135404 52.34430 79.68219 83.02605 90.48034  93.45680 
77     1   Control 8 79.39546  7.827563 66.80387 73.99437 82.10035 84.64266  88.68595 
78     2   Control 8 80.91212 11.009351 59.87005 78.74123 86.34504 87.54863  89.23342 
79     3   Control 8 82.85110  4.284752 76.55825 80.47632 81.59405 86.65944  89.20987 
80     4   Control 8 80.98076  4.243803 75.24375 79.14524 80.06633 81.98480  89.76292 
81     5   Control 8 85.60584  3.886132 79.56180 83.47094 85.37791 87.21874  91.43667 
82     6   Control 8 80.87093  5.517826 73.18497 75.83128 81.71308 84.87026  87.95607 
83     7   Control 8 84.42820  7.867537 70.49580 82.44649 86.34812 89.98651  92.35610 
84     8   Control 8 80.93309 11.866416 62.39648 76.39644 83.67364 86.92727  96.54623 
85     9   Control 8 80.61833  8.398650 64.71545 76.76369 83.28105 86.60727  89.43507 
86    10   Control 8 85.04364  4.192622 77.69810 83.50151 84.58124 86.96554  92.33485 
87    11   Control 8 83.82782  5.106516 76.02927 80.22574 83.55240 87.80458  91.11200 
88    12   Control 8 83.22779  5.785775 74.80598 79.76249 82.30626 86.51828  91.32648 
89    13   Control 8 79.32566  9.368176 62.36962 74.99689 78.52541 86.47334  91.60135 
90    14   Control 8 83.14492  5.902987 74.55605 79.97558 84.42984 86.63008  89.99140 
189 
91    15   Control 8 84.06943  4.805873 76.55137 82.07488 84.31236 87.00084  90.91955 
92    16   Control 8 78.62677 17.254619 37.84255 77.30383 86.15228 87.61162  89.74728 
93    17   Control 8 82.76733  7.517264 66.47673 82.33657 84.68409 86.37371  91.12405 
94    18   Control 8 86.51273  6.348748 74.40923 83.15792 87.50379 91.06006  93.16118 
95    19   Control 8 78.15076 15.488685 46.62232 72.46869 80.41881 89.13971  94.36800 
96    20   Control 8 88.71678  5.232768 80.25253 85.84502 88.29259 92.11194  97.23098 
97    21   Control 8 87.50971  5.329859 79.71627 82.67244 89.18501 91.76734  93.72537 
98    22   Control 8 84.49961  8.436723 67.78418 81.70943 86.54278 89.90494  93.94960 
99    23   Control 8 84.23074 10.121645 61.75727 82.63816 87.28004 89.94531  92.92585 
100   24   Control 8 85.87372  8.588109 74.53692 77.09637 88.04518 92.83327  96.36057 
Table 10B. Week 0 Time Moving within 10-Minute Video Before Shadow Raw Data 
   Minute Treatment n     mean        sd      min       Q1   median       Q3      max percZero 
1 1    0.0014 8 95.65275  4.621801 85.18250 94.69615 97.59180 98.37037  98.9616      0.0 
2 2    0.0014 8 94.55020  4.241494 85.70820 93.74385 94.77265 96.73288 100.0000      0.0 
3 3    0.0014 8 92.46189  7.896232 74.10170 92.38542 94.96730 97.17780  98.2761      0.0 
4 4    0.0014 8 83.65396 12.679329 58.39050 82.78472 89.26725 90.43505  94.2722      0.0 
5 5    0.0014 8 86.61155  9.821089 71.63620 78.96552 88.87800 93.24335  98.3873      0.0 
6 6    0.0014 8 88.51654  6.293875 75.03110 88.05773 89.68435 91.57507  94.8283      0.0 
7 7    0.0014 8 85.88898 13.617620 57.79200 85.12432 89.51755 93.25728  99.3883      0.0 
8 8    0.0014 8 75.52670 24.560716 27.54020 64.45538 86.90385 92.92500  96.1684      0.0 
9       9    0.0014 8 72.36575 31.364690  6.61759 60.90480 79.36595 97.42800  99.4995      0.0 
10     10    0.0014 8 77.14641 32.517734  0.00000 77.28872 86.88165 96.77393  98.3092     12.5 
   Minute Treatment n     mean  sd      min Q1   median     Q3      max percZero 
11 1    0.0028 8 86.52281 12.582668 69.83770 75.09498 90.21155 96.34443  99.9319      0.0 
12 2    0.0028 8 88.89878  8.611345 73.69650 86.18088 89.82310 92.63168  99.6663      0.0 
13 3    0.0028 8 78.34385 32.388338  1.19698 77.51965 90.01800 96.10707  98.8481      0.0 
14 4    0.0028 8 76.13263 31.349255  0.00000 80.74505 85.75590 88.59937  97.1083     12.5 
15 5    0.0028 8 75.79835 31.045425  0.00000 78.89598 88.40005 90.47668  90.9251     12.5 
16 6    0.0028 8 72.10660 31.663011  0.00000 67.50385 76.88740 95.42018  96.9969     12.5 
17 7    0.0028 8 76.38622 24.615957 36.48020 57.78402 89.66590 93.31260  99.8013      0.0 
18 8    0.0028 8 71.05164 18.802237 44.20450 54.63555 72.19500 84.97548  94.6055      0.0 
19 9    0.0028 8 73.44384 31.503517  0.66732 71.05360 84.79065 92.86790  94.7727      0.0 
20     10    0.0028 8 69.43325 33.917233  0.00000 66.77235 84.84100 88.84273  94.5363     12.5 
   Minute Treatment n     mean  sd      min Q1   median       Q3      max percZero 
21 1     0.014 8 74.56575 28.965160 29.93370 59.27833 84.69295 97.87032  99.7176      0.0 
22 2     0.014 8 80.01515 19.629328 41.97230 74.41540 83.40705 94.03583  99.7219      0.0 
23 3     0.014 8 78.37301 30.514544  5.67222 78.82650 89.96240 92.58997  99.8888     0.0 
24 4     0.014 8 79.74241 13.589446 58.49900 74.04608 81.84335 85.59703  99.8888      0.0 
25 5     0.014 8 78.84740 20.044442 34.42530 76.86898 82.61140 90.05970  99.8888      0.0 
26 6     0.014 8 68.79646 30.331686 11.01080 52.56128 82.55965 87.12890  99.7219      0.0 
27 7     0.014 8 78.61926 18.624225 50.78520 66.13357 81.21570 93.63653  99.6663      0.0 
28 8     0.014 8 63.08229 34.105085  1.16235 46.38352 68.16870 92.21460  99.4439      0.0 
29 9     0.014 8 66.33140 29.135875  5.12388 53.14255 78.03130 84.73373  92.3814      0.0 
30     10     0.014 8 78.62748 29.043844  8.52145 80.35452 88.70305 91.78217  98.2483      0.0 
   Minute Treatment n     mean  sd      min Q1   median       Q3      max percZero 
31 1   Control 8 97.42926  3.316555 92.19080 95.46165 99.19800 99.92765  99.9333      0.0 
190 
32 2   Control 8 85.38882 21.675634 33.54610 86.35505 90.78335 97.24733  99.6663      0.0 
33 3   Control 8 78.87185 23.187091 28.54110 76.51538 86.92505 90.61583 100.0000      0.0 
34 4   Control 8 81.83934 18.084133 52.28660 73.08267 90.90780 93.25728  97.4975      0.0 
35 5   Control 8 74.90900 22.704155 25.69460 68.41952 82.76090 88.48610  97.3307      0.0 
36 6   Control 8 67.81373 32.404758  0.00000 65.23987 81.03700 86.56678  94.4390     12.5 
37 7   Control 8 80.65831 14.027815 52.56470 74.13345 85.24740 90.76885  94.4946      0.0 
38 8   Control 8 76.78647 25.169419 22.42950 69.77265 81.58375 94.20265  98.7210      0.0 
39 9   Control 8 56.80662 29.739464  0.00000 41.65735 58.65005 81.07460  91.8253     12.5 
40     10   Control 8 60.16107 37.546264  0.00000 43.60151 70.68415 88.81390  95.5232     12.5  
Table 10B. Week 12 Time Moving within 10-Minute Video Before Shadow Raw Data 
   Minute Treatment n     mean  sd      min Q1   median       Q3      max percZero 
1 1    0.0014 8 36.36104 32.586257  4.20434 11.86373 29.00345 46.86162  99.8263      0.0 
2 2    0.0014 8 57.65826 42.340183  0.00000 21.47932 71.09600 93.52140 100.0000     25.0 
3 3    0.0014 8 74.34790 31.759539  0.00000 78.43585 85.93070 88.29412  99.4439     12.5 
4 4    0.0014 8 70.83855 28.581296 18.81210 49.99530 81.03840 93.00708 100.0000      0.0 
5 5    0.0014 8 67.58962 27.618989 15.35880 49.96025 75.16350 88.41925  95.7180      0.0 
6 6    0.0014 8 51.58225 39.700223  0.00000 16.27195 59.57150 87.65460  89.4660    12.5 
7 7    0.0014 8 57.99855 41.000426  0.00000 27.26272 70.84190 92.13502  98.9990     25.0 
8 8    0.0014 8 71.58460 32.126944  0.00000 67.00468 82.05920 93.64652  95.7736     12.5 
9 9    0.0014 8 62.28615 37.355396  0.00000 37.83472 77.39450 91.76968  97.6088     12.5 
10     10    0.0014 8 75.75408 34.881846  0.00000 70.88845 89.12290 99.76435 100.0000     12.5 
   Minute Treatment n     mean  sd      min Q1   median       Q3      max percZero 
11 1    0.0028 8 44.76292 36.442590  6.19182 14.27043 40.54075 66.18555  96.5295      0.0 
12 2    0.0028 8 46.75270 38.393373  1.66830 13.67280 43.98615 78.06982  96.3371      0.0 
13 3    0.0028 8 55.73644 38.636863  0.00000 25.92225 73.87650 86.65360  89.2673     25.0 
14 4    0.0028 8 58.87145 38.892014  0.00000 34.79603 79.55535 86.58410  91.2136     25.0 
15 5    0.0028 8 70.18939 35.175645  0.00000 66.71412 87.12490 90.65750  96.3854     12.5 
16 6    0.0028 8 75.30585 30.912843  3.78148 75.66672 78.65100 96.39925 100.0000      0.0 
17 7    0.0028 8 66.30867 36.431556  0.00000 44.35298 84.00555 91.43620 100.0000     12.5 
18 8    0.0028 8 62.05974 43.215286  0.00000 26.98065 87.01780 94.87920  96.0517 25. 0
19 9    0.0028 8 69.99276 43.398874  0.00000 64.73587 90.92895 96.34365  98.3873  25.0
20     10    0.0028 8 77.98990 25.379168 19.94000 75.17713 83.01180 94.64822  99.8332      0.0 
   Minute Treatment n     mean  sd      min Q1   median       Q3      max percZero 
21 1     0.014 8 97.43866  5.230462 84.77160 97.64033 99.87520 99.94000 100.0000      0.0 
22 2     0.014 8 92.16629  6.280918 81.62230 90.06770 92.54825 96.31583  99.8888      0.0 
23 3     0.014 8 83.02671  9.852445 65.25970 79.41633 84.15115 87.96707  98.1093      0.0 
24      4     0.014 8 82.65465 13.525912 58.18130 77.61695 84.33785 94.36947  95.8293      0.0 
25 5     0.014 8 81.04264 10.663163 67.56890 70.87427 83.17800 88.22460  94.0497      0.0 
26 6     0.014 8 86.01939  8.719093 73.91890 79.46478 85.54140 94.46680  96.1073      0.0 
27 7     0.014 8 79.45975 13.121043 59.96080 67.77993 81.26880 91.61690  93.6605      0.0 
28 8     0.014 8 82.47191 12.942531 55.51200 75.87915 88.99195 91.28302  92.1959      0.0 
29 9     0.014 8 82.46632 18.292735 50.77740 76.87300 87.26530 94.85605 100.0000      0.0 
30     10     0.014 8 89.69795  9.666684 76.33570 81.05330 93.76670 96.56087 100.0000      0.0 
   Minute Treatment n     mean        sd      min       Q1   median       Q3      max 
31 1   Control 8 86.40374 23.734165 28.89530 90.75920 95.25200 96.44983  99.8829      0.0 
32 2   Control 8 81.87314 34.019856  0.00000 87.58508 95.25995 98.47073 100.0000     12.5 
191 
33      3   Control 8 74.77755 31.762576  0.00000 75.23233 80.37765 92.21457  99.2771   12.5 
34 4   Control 8 67.83988 30.979036  0.00000 63.80783 74.97550 87.12630  98.2761     12.5 
35 5   Control 8 75.65506 31.751577  0.00000 77.00522 87.26535 90.07358  98.9990     12.5 
36 6   Control 8 78.12379 31.834084  0.00000 85.76387 89.58905 91.81940  93.9941     12.5 
37 7   Control 8 73.56171 15.548822 40.85470 71.52768 74.31345 82.26037  92.8819      0.0 
38 8   Control 8 80.05030 12.794797 58.74280 71.54565 82.09630 89.58843  96.5335      0.0 
39 9   Control 8 72.62825 23.145494 33.42710 54.21360 86.45620 88.88590  91.9365      0.0 
40     10   Control 8 76.62538 19.451466 43.14080 65.00368 77.40105 90.13420 100.0000     0.0  
Table 11B. Week 24 Time Moving within 10-Minute Video Before Shadow Raw Data 
   Minute Treatment n     mean        sd     min       Q1   median        Q3      max 
1 1    0.0014 8 96.98732  3.744646 90.2344 95.24200 98.57070  99.94033  99.9425      0.0 
2 2    0.0014 8 84.37064 16.527695 58.2501 70.85773 92.72970  97.39363  98.7210      0.0 
3 3    0.0014 8 74.58060 26.574368 27.8447 64.82337 86.83365  90.46953 100.0000      0.0 
4 4    0.0014 8 73.55612 21.070682 33.8268 63.55757 76.61735  87.20970  97.9980      0.0 
5 5    0.0014 8 80.28859 15.561508 60.6254 66.18127 83.36210  91.67240  99.8860      0.0 
6 6    0.0014 8 65.47912 27.781573 21.7330 52.93285 69.86465  84.66165  96.6739      0.0 
7 7    0.0014 8 80.72680 16.373617 43.9132 77.75277 84.55225  89.10435  96.6078      0.0 
8 8    0.0014 8 83.86354 11.701250 59.2247 80.01233 86.98725  89.57258  98.3317      0.0 
9 9    0.0014 8 66.37783 27.559648 15.9655 45.14915 81.06095  85.56005  91.2692      0.0 
10     10    0.0014 8 76.00983 31.872236  0.0000 77.91263 85.18355  92.16957  97.7225     12.5 
   Minute Treatment n     mean  sd     min Q1   median        Q3      max 
11 1    0.0028 8 93.25538 11.011827 68.0372 92.86185 97.88830  99.85790 100.0000      0.0 
12 2    0.0028 8 91.04018 11.132751 70.9716 85.89033 95.35655 100.00000 100.0000      0.0 
13 3    0.0028 8 79.15485 29.401871 10.2614 79.06875 87.41755  96.80242 100.0000      0.0 
14 4    0.0028 8 75.61370 24.889277 29.3593 68.95640 79.20325  94.89775 100.0000      0.0 
15 5    0.0028 8 80.43156 20.170699 37.9949 77.26670 85.45800  93.91070 100.0000      0.0 
16 6    0.0028 8 78.15623 14.382855 50.3959 74.26647 79.89700  84.78475 100.0000      0.0 
17 7    0.0028 8 85.49110 15.744385 52.9170 80.77287 88.16695  97.94245 100.0000      0.0 
18 8    0.0028 8 80.99989 16.284481 52.7315 74.60010 82.16765  92.42312 100.0000      0.0 
19 9    0.0028 8 86.21308 12.163415 69.0175 77.29122 89.10045  94.92562 100.0000      0.0 
20     10    0.0028 8 70.91152 30.969391  0.0000 70.12020 82.82840  89.18887  92.7017     12.5 
   Minute Treatment n     mean  sd     min Q1   median        Q3      max 
21 1     0.014 8 93.22950 15.652712 54.7754 97.59645 99.14065  99.94175  99.9425      0.0 
22 2     0.014 8 89.78695 10.447761 72.2082 84.89593 93.07655  97.51145  99.8888      0.0 
23      3     0.014 8 77.50409 24.626205 30.9483 67.60715 83.27460  97.97020  98.7210      0.0 
24 4     0.014 8 77.75470 21.159337 45.1129 67.27025 82.90130  92.64560  99.4995      0.0 
25 5     0.014 8 80.79303 20.311906 41.2202 70.90000 86.79130  96.74685 100.0000      0.0 
26 6     0.014 8 83.00123 10.338871 69.7482 76.22285 80.20285  91.31090  99.4995      0.0 
27 7     0.014 8 86.07734 13.006472 67.1213 78.05265 86.79260  98.16490 100.0000      0.0 
28      8     0.014 8 71.42775 23.049758 43.2090 49.04405 74.61675  89.47583 100.0000      0.0 
29 9     0.014 8 73.68552 29.677545 13.5766 70.04488 84.15115  90.19465 100.0000      0.0 
30     10     0.014 8 74.97679 22.363089 35.7685 61.05072 78.97520  90.21922 100.0000      0.0 
   Minute Treatment n     mean  sd     min Q1   median        Q3      max 
31 1   Control 8 84.91050 21.710925 39.2220 78.32188 95.24235  99.84888  99.9415      0.0 
32 2   Control 8 92.86471  8.500435 73.6144 93.00702 95.24535  97.49757 100.0000      0.0 
33 3   Control 8 85.19418 13.137497 66.2871 74.91988 86.04985  96.99707 100.0000      0.0 
192 
34 4   Control 8 82.77149 16.349397 49.8794 76.28108 85.43020  95.37042  99.4439      0.0 
35 5   Control 8 80.10221 13.489883 60.0059 66.99013 85.79165  89.68433  95.1063      0.0 
36 6   Control 8 85.52020 10.754748 68.9008 76.17370 89.01705  92.53432 100.0000      0.0 
37 7   Control 8 84.83073  7.869814 67.8018 83.89557 86.15310  88.83630  93.8273     0.0 
38 8   Control 8 82.75925 16.193992 48.0657 78.58550 85.06875  95.09243  97.3307      0.0 
39 9   Control 8 85.94891 16.401097 52.4457 81.04488 91.57510  96.99707 100.0000      0.0 
40     10   Control 8 76.49781 27.409971 22.0865 68.24957 85.92920  96.66943 100.0000      0.0  
Table 12B. Distance Moved After-Shadow Raw Data 
    Week Treatment n     mean       sd        min Q1   median Q3       max 
1 0    0.0014 8 22.23053 13.09718  2.5628271 13.835030 24.90710 27.57492  43.39789 
2 1    0.0014 8 24.14541 17.51193  6.4912277 14.148626 21.87865 28.14048  62.01316 
3 2    0.0014 8 34.21196 23.08507  5.0728002 23.939076 32.52553 42.54204  69.49878 
4 3    0.0014 8 30.97466 17.11107  9.9767639 21.551292 25.82799 37.79346  59.63052 
5 4    0.0014 8 32.47427 24.80185  3.3162482 16.054863 27.62976 42.12964  72.26724 
6 5    0.0014 8 40.83410 22.85937 18.2608356 28.532053 32.98318 46.61519  78.00583 
7 6    0.0014 8 32.01022 22.40416  4.3696982 17.703070 28.30433 42.61390  75.67666 
8 7    0.0014 8 42.96512 21.71268 17.1801857 28.166381 40.79588 53.30845  78.93816 
9 8    0.0014 8 37.31712 20.89504 17.4597169 25.264319 32.20835 43.34265  82.60644 
10     9    0.0014 8 50.68281 19.30577 19.7976162 39.641995 54.61722 61.30424  75.43975 
11    10    0.0014 8 36.42302 18.62476 12.8803123 27.837712 34.27010 38.17331  76.09033 
12    11    0.0014 8 33.05447 21.38257  7.3022909 18.958679 29.42623 38.34292  72.35839 
13    12    0.0014 8 44.58248 27.00839 21.6261759 24.836893 33.27386 57.75531  98.82790 
14    13    0.0014 8 50.18451 17.48289 26.6627981 37.407616 48.91642 61.89304  78.31253 
15    14    0.0014 8 39.24023 14.97900 19.3996970 32.629809 39.50595 44.64537  67.53883 
16    15    0.0014 8 31.36164 22.70847  2.9869382 14.942298 30.02411 42.68375  71.34159 
17    16    0.0014 8 36.95248 17.35127 12.5997046 29.749634 35.76726 40.16925  71.66063 
18    17    0.0014 8 48.13002 34.40141  1.3627326 27.478654 47.58573 68.99027 106.60214 
19    18    0.0014 8 41.13820 14.14429 20.8546132 32.423176 36.93153 52.64189  61.06668 
20    19    0.0014 8 35.14140 25.12057 10.1155758 12.780209 32.41693 50.53153  75.42503 
21    20    0.0014 8 42.68826 32.93323  4.6441204 13.447382 49.52397 55.27422 103.41237 
22    21    0.0014 8 46.35220 31.20273 17.8099798 28.096658 36.08617 51.68395 104.47905 
23    22    0.0014 8 36.81288 25.52947 10.9933952 15.576095 31.78528 52.06937  76.01322 
24    23    0.0014 8 26.84772 18.30586  2.6321661 17.979987 21.75356 33.49435  63.56061 
25    24    0.0014 8 37.21631 22.09997 11.8571313 23.465973 32.61879 48.11538  70.81822 
Week Treatment n     mean sd        min        Q1   median       Q3       max 
26     0    0.0028 8 27.17684 12.32585 11.9930828 14.588620 29.57224 35.83218  44.16072 
27     1    0.0028 8 24.37179 20.93104  6.4299728 11.536412 19.89717 26.87738  72.52717 
28     2    0.0028 8 32.16951 12.72604 17.8554286 21.899708 32.26240 38.41239  55.55485 
29     3    0.0028 8 31.52563 17.74585 10.0182561 13.550016 35.02950 45.42862  55.95307 
30     4    0.0028 8 37.05920 15.82998 15.4459216 23.523226 39.81617 45.33185  60.47383 
31     5    0.0028 8 29.20557 18.56505  1.8041199 16.365880 28.05176 41.50280  60.28061 
32     6    0.0028 8 23.95887 19.15983  3.7739298  8.269374 19.37015 37.06899  59.07937 
33     7    0.0028 8 32.21975 17.16520  7.0476524 22.864699 33.50980 40.04754  56.47026 
34     8    0.0028 8 30.34164 19.05400  6.8258163 15.585318 28.68790 46.71911  55.62082 
35     9    0.0028 8 29.43517 12.50356  9.9443203 24.054806 31.49551 34.79304  46.30379 
36    10    0.0028 8 27.50292 16.22335  4.4334154 18.997847 26.75024 38.50416  52.34185 
193 
37    11    0.0028 8 36.05324 20.54061  3.5034151 29.066650 34.81942 37.91835  77.43673 
38    12    0.0028 8 41.75046 30.05742  3.9648683 27.011339 37.10410 52.40854  98.95758 
39    13    0.0028 8 37.65340 19.09883 13.0380200 28.548764 33.51267 42.96605  77.38825 
40    14    0.0028 8 35.48049 13.43429 14.5641837 28.093169 34.29139 44.12259  54.40093 
41    15    0.0028 8 25.15161 13.59033  5.3116253 15.174100 24.70655 34.57383  47.19152 
42    16    0.0028 8 31.40312 17.99230  2.8011626 17.185184 35.58877 42.09498  58.09109 
43    17    0.0028 8 38.46401 14.86078 11.0152589 32.748831 42.36742 48.89960  52.94472 
44    18    0.0028 8 26.89047 21.56524  2.5133878 12.308253 22.69111 37.97526  61.39397 
45    19    0.0028 8 29.79113 18.90370  5.9038571 19.894970 28.97701 36.29689  67.02453 
46    20    0.0028 8 27.24689 19.44666  0.6553242 13.448787 25.89408 37.33998  55.72132 
47    21    0.0028 8 29.45711 15.61255  8.3296821 20.530667 31.19906 37.71888  49.32090 
48    22    0.0028 8 22.37846 12.81908  7.6320436 13.503444 18.92992 31.16561  42.98661 
49    23    0.0028 8 30.01991 25.44794  1.4067702  9.037518 31.38287 36.90747  80.60738 
50    24    0.0028 8 29.10700 15.98237  2.7313896 16.305039 34.03278 42.11279  45.33647 
Week Treatment n     mean sd        min        Q1   median       Q3       max 
51     0     0.014 8 24.55710 18.93484  4.1988707 12.535232 18.30173 35.84542  52.61063 
52     1     0.014 8 20.58248 18.10565  0.8333455  4.124496 19.77448 29.28793  46.55460 
53     2     0.014 8 35.73825 19.29233 15.9548452 22.660952 29.40694 46.14725  68.85609 
54     3     0.014 8 37.73806 10.36484 27.2234456 31.144514 34.47928 40.77856  54.15126 
55     4     0.014 8 41.62442 20.41746 12.8906582 32.251403 38.40117 45.11015  81.98933 
56     5     0.014 8 41.10998 30.59106  5.9497601 22.432534 35.17383 50.55093 104.63996 
57     6     0.014 8 42.43298 24.92232 17.5126047 20.770036 41.90016 53.31660  90.07858 
58     7     0.014 8 52.09987 33.60594 19.0213431 26.506763 37.80269 80.37973  99.32573 
59     8     0.014 8 36.38674 26.17550  5.9791524 16.662857 31.52081 52.89909  83.35649 
60     9     0.014 8 43.14486 23.55947 19.9965735 29.873607 34.29458 48.74095  91.89205 
61    10     0.014 8 45.13004 24.07072  6.6496753 30.246745 46.47378 62.62909  77.47712 
62    11     0.014 8 45.45028 14.33145 22.9489630 39.409533 44.60164 56.85564  64.87218 
63    12     0.014 8 46.52714 29.32586  4.9467087 25.221303 50.51395 61.37706  89.69895 
64    13     0.014 8 52.18180 29.67484  9.9800180 31.394427 47.44413 80.09096  90.58703 
65    14     0.014 8 45.29368 21.44092 12.8623986 34.133708 42.20166 57.65556  79.29361 
66    15     0.014 8 42.83420 22.88171  2.6714157 35.058943 45.27187 56.24243  71.95397 
67    16     0.014 8 37.31534 27.55209  1.2140992 16.142519 37.92265 57.11200  78.13003 
68    17     0.014 8 49.50447 33.57586  1.7185915 34.192353 48.15680 64.14436 105.70622 
69    18     0.014 8 56.41512 35.92192 17.7441875 23.143304 54.82661 79.45787 105.36297 
70    19     0.014 8 44.64979 26.38842  8.6299910 30.984848 40.16240 53.51517  95.84840 
71    20     0.014 8 57.92951 36.62982  4.3474662 33.807331 53.06557 94.89475 101.23554 
72    21     0.014 8 40.02085 30.55883  4.8950045 13.097594 39.44655 59.23599  91.49618 
73    22     0.014 8 41.26416 30.67496  1.3361587 20.800320 31.02427 65.02083  86.32945 
74    23     0.014 8 53.00790 38.06775  5.9867989 22.393289 52.67473 80.79031 108.33947 
75    24     0.014 8 39.33485 26.78163  3.8540000 22.001130 31.06792 59.70633  84.88821 
Week Treatment n     mean sd        min        Q1   median       Q3       max 
76     0   Control 8 22.44255 14.47033  6.5631806 11.315736 19.00074 32.05912  49.41036 
77     1   Control 8 26.33736 15.97470  3.5533456 18.706120 27.35504 38.71751  45.97966 
78     2   Control 8 25.53501 14.65908  7.8589996 16.996059 22.48446 32.02499  47.26320 
79     3   Control 8 28.77392 15.50961 11.7613498 13.400875 28.51712 42.17913  48.30198 
80     4   Control 8 36.73243 14.74273 15.5125616 28.331221 36.79427 42.60322  63.04324 
81     5   Control 8 40.85108 18.98955  4.9746100 33.720487 42.77569 51.28146  64.05261 
82     6   Control 8 49.15314 23.38845 15.1937397 34.528514 51.88684 67.27816  76.76305 
83     7   Control 8 42.30967 25.18947 12.5120074 26.013509 37.52976 60.36652  79.10561 
194 
84     8   Control 8 48.06808 19.90219 27.9183087 30.148665 45.69241 57.63217  80.99630 
85     9   Control 8 38.30866 19.71589 19.9416102 24.758315 27.58900 51.75522  72.30142 
86    10   Control 8 46.51715 19.26304 24.3737333 29.560900 47.65028 58.03972  77.33699 
87    11   Control 8 38.15585 21.98074  0.1506425 25.434028 40.74768 53.93962  62.33347 
88    12   Control 8 46.18114 28.48467 11.8851060 26.712691 43.92065 55.79257 101.82383 
89    13   Control 8 48.70185 24.09309 12.7825958 30.672957 52.71499 62.07963  80.30271 
90    14   Control 8 29.93026 18.29630 10.5376906 16.023138 21.72334 50.22395  53.40582 
91    15   Control 8 40.96128 20.34527 13.3877990 26.146194 40.82432 51.62225  73.82941 
92    16   Control 8 36.87211 24.00617 12.8995895 17.159375 32.16139 52.82725  76.39418 
93    17   Control 8 37.19735 21.78971 13.7983785 21.592474 31.66663 47.26961  78.16481 
94    18   Control 8 39.11283 23.40639 14.6907635 20.098900 36.25755 51.10533  83.81526 
95    19   Control 8 42.34690 27.35123  1.3258025 26.469392 38.17348 57.21303  91.91331 
96    20   Control 8 42.01159 25.06063  8.4868058 26.502694 37.03324 57.48616  83.73783 
97    21   Control 8 39.24913 24.28963 11.9643362 27.293776 33.09039 41.71400  91.75010 
98    22   Control 8 43.62245 25.48432 16.0188704 25.176008 39.64016 49.70537  95.49223 
99    23   Control 8 39.48536 25.47665 10.7490677 24.121527 33.90470 48.51409  91.67059 
100   24   Control 8 34.03348 17.40820 14.4552493 17.251801 35.13212 43.05961  61.88402  
Table 13B. Border Distance Moved After-Shadow Raw Data 
  Week Treatment n     mean       sd   min Q1   median Q3       max 
1 0    0.0014 8 19.18430 14.84249 -4.1542638 10.942399 21.97698 27.05075  41.19930      0.0 
2 1    0.0014 8 21.06516 15.35055  4.3478246 12.202851 19.16932 25.38005  53.87688 0.0 
3 2    0.0014 8 31.39905 21.30759  5.0728002 21.968602 29.41746 38.58487  65.23610 0.0 
4 3    0.0014 8 26.72644 16.47491  8.3970249 17.377890 21.51566 32.03920  52.13452 0.0 
5 4    0.0014 8 28.68343 23.03005  3.3162482 13.587976 22.57429 38.24031  64.33223 0.0 
6 5    0.0014 8 37.14148 22.98963 16.8551177 21.790857 29.19035 44.34290  75.80677 0.0 
7 6    0.0014 8 27.85659 21.15885  4.3696982 12.608804 24.12985 36.20910  70.71438 0.0 
8 7    0.0014 8 37.93972 21.86036 13.9270699 21.867060 34.39114 49.93053  72.75066 0.0 
9 8    0.0014 8 32.99185 21.31894 12.1992064 19.763054 27.13152 38.72041  79.95064 0.0 
10     9    0.0014 8 46.28742 17.89469 17.3490303 35.754777 49.04543 58.03863  69.26245 0.0 
11    10    0.0014 8 30.54237 15.45366 10.9123655 23.703287 28.17967 33.34398  62.49693 0.0 
12    11    0.0014 8 29.66990 21.76730  5.9973161 13.104070 25.96831 36.37604  68.56506 0.0 
13    12    0.0014 8 40.23353 25.45466 15.9454845 22.717573 28.70462 56.17810  87.16174 0.0 
14    13    0.0014 8 46.69816 17.73754 25.5367103 35.438364 42.66560 57.42554  76.75102 0.0 
15    14    0.0014 8 35.43092 15.74954 13.2934343 28.948869 36.01303 39.32317  66.73654 0.0 
16    15    0.0014 8 27.95290 21.89136  2.0355898 12.249962 25.50975 39.13671  66.59626 0.0 
17    16    0.0014 8 33.09273 17.30202 12.2228044 26.396492 29.35572 35.43274  70.76227 0.0 
18    17    0.0014 8 43.86752 33.98182  1.3627326 19.139295 44.87341 61.38911 105.63281 0.0 
19    18    0.0014 8 37.21508 15.09426 14.9841422 28.849739 32.80111 50.86036  56.47770 0.0 
20    19    0.0014 8 31.57695 24.44857  7.0827475  9.794702 28.56078 46.99829  69.71870 0.0 
21    20    0.0014 8 38.78102 31.31786  4.6441204 10.019811 43.19974 51.83236  97.54919 0.0 
22    21    0.0014 8 43.91015 30.66247 14.9615152 24.444830 33.76119 50.94015  98.44252 0.0 
23    22    0.0014 8 33.91258 25.27609  6.9945657 12.653022 28.37211 51.73294  69.43365 0.0 
24    23    0.0014 8 22.73495 18.23721  0.0376048 13.281045 18.18443 26.67003  59.44911 0.0 
25    24    0.0014 8 33.82535 22.53056 10.3493032 17.809013 29.70357 43.37248  69.97847 0.0 
    Week Treatment n     mean       sd    min Q1   median Q3    max 
26     0    0.0028 8 22.84886 14.61503  1.0584316 11.811449 25.93319 32.72059  42.95917 0.0 
27     1    0.0028 8 21.00922 19.31730  4.3140963  9.930593 16.52485 21.35469  65.98895 0.0 
28     2    0.0028 8 29.16352 12.78794 12.5976531 19.087896 29.74816 36.10893  51.04202 0.0 
195 
29     3    0.0028 8 29.05061 17.17396  6.3215306 13.094290 32.55375 42.71361  51.51642 0.0 
30     4    0.0028 8 33.85918 17.73894 10.3277489 17.793996 37.74560 42.72698  59.95172 0.0 
31     5    0.0028 8 26.05307 17.30380  1.8041199 13.613820 25.79584 37.31235  55.06170 0.0 
32     6    0.0028 8 22.20402 20.07080  3.3333272  3.580739 17.91152 36.38257  58.13651 0.0 
33     7    0.0028 8 28.99420 17.94317  5.1595986 19.246147 29.26009 37.36419  55.44643 0.0 
34     8    0.0028 8 26.21223 18.43467  3.6969796 12.921879 23.26202 42.87221  51.95888 0.0 
35     9    0.0028 8 26.40801 12.73039  7.2421621 19.618256 28.37522 32.99524  44.79624 0.0 
36    10    0.0028 8 23.22583 15.24749  2.9041083 15.279582 23.62656 32.54685  46.38829 0.0 
37    11    0.0028 8 30.88930 17.33758  3.1806540 22.525982 30.59230 34.94813  62.89710      0.0 
38    12    0.0028 8 37.95931 27.66513  2.0413624 23.400447 35.58063 46.86036  90.72176 0.0 
39    13    0.0028 8 33.03572 16.44418  9.9021072 23.099455 29.61511 42.13944  62.87089 0.0 
40    14    0.0028 8 32.16743 13.00546 11.1324898 25.765125 31.64288 40.65647  50.91951 0.0 
41    15    0.0028 8 23.25826 13.41063  5.3116253 13.931244 21.77475 32.70593  45.78548 0.0 
42    16    0.0028 8 28.61741 16.49642  1.9938074 15.201683 32.40791 39.98776  50.51073 0.0 
43    17    0.0028 8 33.55528 14.42416  6.2364941 28.280189 39.43214 43.11798  46.30435 0.0 
44    18    0.0028 8 24.10307 21.41760  1.6053824  8.108458 19.88538 34.39153  59.95038 0.0 
45    19    0.0028 8 26.03785 17.32997  4.3483347 18.164535 25.83424 30.21405  60.80655 0.0 
46    20    0.0028 8 24.24205 18.78877  0.6553242 10.286832 21.48251 34.36927  52.11103 0.0 
47    21    0.0028 8 26.18672 14.98689  3.6887143 19.165309 28.49945 32.46774  46.67491 0.0 
48    22    0.0028 8 20.07622 12.86129  6.5581709  9.744302 17.61656 28.13941  41.00212 0.0 
49    23    0.0028 8 27.75423 23.82361  1.2347925  7.014642 28.70689 35.77156  74.03722 0.0 
50    24    0.0028 8 26.89387 15.90832  1.5130536 13.591251 31.72965 39.23851  43.96606 0.0 
     Week Treatment n     mean       sd        min  Q1   median  Q3    max 
51     0     0.014 8 21.14841 17.92839  1.8739139 10.405219 14.68935 30.68197  50.49163 0.0 
52     1     0.014 8 17.32924 17.00795  0.0714364  3.750764 13.78639 24.86988  43.68726 0.0 
53     2     0.014 8 32.75239 20.05770 12.5042259 18.222016 25.23613 44.98497  68.47671 0.0 
54     3     0.014 8 33.66405 11.95496 22.4306193 25.209660 29.40930 38.25581  53.21688 0.0 
55     4     0.014 8 36.85492 21.51942 10.1904599 28.961923 32.96062 39.00183  80.84974 0.0 
56     5     0.014 8 37.60434 31.40664  4.8522030 18.237074 30.79066 45.96617 104.63996 0.0 
57     6     0.014 8 39.11565 26.18466 12.2014608 17.068680 37.92110 52.02932  88.03549 0. 0
58     7     0.014 8 48.23815 35.19865 15.5034693 18.145694 34.95850 76.39674  99.06626 0.0
59     8     0.014 8 32.57946 27.07607  4.3792444 11.255866 26.99101 47.08029  83.35649 0.0
60     9     0.014 8 38.39038 24.69047 17.4814788 23.315220 29.43658 41.22195  90.75156 0.0
61    10     0.014 8 41.56218 25.12996  2.1113433 25.372834 43.38326 61.57256  73.42563 0.0
62    11     0.014 8 42.40052 17.24980 14.9933454 34.100306 42.00379 56.42997  64.87218 0.0
63    12     0.014 8 43.05559 29.29936  4.2882777 20.245335 47.17086 56.61350  87.95387 0.0
64    13     0.014 8 48.92267 31.20916  6.7653201 28.119377 42.87372 79.39760  87.74439 0.0
65    14     0.014 8 41.79611 21.66565 11.2543318 29.632856 38.34560 52.84012  77.05818 0.0
66    15     0.014 8 40.65723 23.03931  2.6714157 32.015998 42.94113 52.97628  70.66859 0.0
67    16     0.014 8 36.24304 27.94047  0.5308512 13.938442 36.30950 56.41961  77.83147 0.0
68    17     0.014 8 47.40211 33.53017  1.4811434 31.249154 46.07764 62.62915 104.51589 0.0
69    18     0.014 8 53.57284 36.85406 15.7220897 17.213779 53.12040 77.65076 103.91698 0.0
70    19     0.014 8 41.75616 26.95811  6.7220920 27.388303 37.19927 49.67489  93.96484 0.0
71    20     0.014 8 54.29558 37.34545  2.8981118 27.534229 48.62248 94.16815  97.07645 0.0
72    21     0.014 8 37.81188 30.96329  3.5755185  9.524925 38.45922 54.90874  91.33555 0.0
73    22     0.014 8 39.10052 31.52764  0.0000000 16.751575 29.01328 64.66077  83.78098     12.5
74    23     0.014 8 49.22689 39.06712  4.0488909 15.843102 49.21881 76.48983 106.35999   0.0
75    24     0.014 8 36.04705 28.57553  1.9730262 18.948784 23.13588 59.06771  84.80876 0.0
     Week Treatment n     mean       sd        min  Q1   median  Q3    max 
196 
76     0   Control 8 18.22679 14.56822  3.2367312  6.514577 14.80409 27.50822  45.17475
77     1   Control 8 21.73662 15.87784 -1.7520375 15.043380 22.27391 30.28589  45.97966
78     2   Control 8 21.11763 14.53318  4.1503631 11.083720 19.71775 26.70077  46.44504
79     3   Control 8 25.55503 15.05342  8.8153226 11.657977 23.94502 39.33371  46.47779
80     4   Control 8 31.28436 16.02376  4.9375667 24.854574 28.55954 39.55693  58.78665
81     5   Control 8 36.35190 19.70732 -1.7555934 31.216473 37.08236 45.59154  61.18882
82     6   Control 8 44.42241 23.25510  7.0908632 31.737032 47.62999 61.50692  71.85232
83     7   Control 8 37.70382 26.51349  2.7170413 21.958871 33.67995 54.04935  79.10561
84     8   Control 8 43.14201 18.47261 24.3581484 28.452426 37.75362 53.06166  74.85628
85     9   Control 8 34.38771 20.31701 15.7058195 20.468290 24.52341 47.14800  71.06422
86    10   Control 8 42.68979 19.61665 22.8798561 24.718840 40.71541 53.91730  76.23349
87    11   Control 8 34.52646 21.20352  0.1506425 22.959762 34.61655 50.43029  60.24190
88    12   Control 8 41.54076 29.35942  8.7649498 20.443213 36.47973 54.22328  98.41676
89    13   Control 8 44.94490 24.98554  9.6429900 25.539966 48.38101 58.52625  79.36916
90    14   Control 8 26.08452 18.02888  9.3780234 12.634245 15.95325 45.11699  52.04425
91    15   Control 8 37.17437 20.49953  9.5553709 23.360248 34.56807 48.43863  71.65811
92    16   Control 8 32.43148 24.79881  7.0608798 12.483134 25.59149 49.35718  73.25807
93    17   Control 8 33.49533 22.33703  8.8273491 19.214148 27.25939 40.96388  77.48138
94    18   Control 8 34.90125 24.68621 10.6054749 16.386100 30.54461 46.84698  83.52295
95    19   Control 8 39.06463 28.58037 -1.9819435 22.734692 33.20874 55.49372  89.81949
96    20   Control 8 38.66529 24.94647  7.8478760 20.077680 34.98431 51.43902  81.68956
97    21   Control 8 35.62660 25.51010 10.9455969 20.777777 29.27916 38.44801  91.75010
98    22   Control 8 40.59309 27.64027  6.9667430 21.283159 38.35052 47.51240  95.01911
99    23   Control 8 35.24909 26.11307  9.5171585 18.682887 27.71918 44.08743  91.58154
100   24   Control 8 31.03924 18.74421 10.0020470 13.292424 31.51300 40.93093  61.66251 
Table 14B. Week 0 Distance Moved within 10-Minute Video After-Shadow Raw Data 
   Minute Treatment n      mean  sd       min   Q1    median        Q3  max 
1 0    0.0014 8 0.5137043 0.4032531 0.1588362 0.2653090 0.3948388 0.6317942  1.395175 
2 1    0.0014 8 1.0873164 1.4549588 0.0515945 0.1476953 0.6359704 1.0477178  4.320279 
3 2    0.0014 8 2.0458931 2.1816717 0.0444200 0.1097169 1.8598546 3.0360114  6.312230 
4 3    0.0014 8 2.7039812 2.5295623 0.1506484 0.6386056 2.1788478 4.2464680  7.347862 
5 4    0.0014 8 2.5266207 2.0566748 0.1732171 0.5150850 2.6054328 3.7328880  5.526165 
6 5    0.0014 8 2.7635393 1.9753915 0.1754131 1.3043867 2.1610256 4.8396733  5.315137 
7 6    0.0014 8 3.3946800 2.1926790 0.1634116 1.7720766 3.5087136 4.8001061  6.593928 
8 7    0.0014 8 3.9874954 2.1476605 0.1360641 2.7438105 4.2631773 5.3780588  7.010036 
9 8    0.0014 8 2.4838059 1.9657274 0.0986132 0.4876220 2.8761661 3.9440679  5.038659 
10 9    0.0014 8 0.7234756 0.9648850 0.0312462 0.1606175 0.3438009 0.7175360  2.797154 
   Minute Treatment n      mean  sd       min   Q1    median        Q3  max 
11 0    0.0028 8 1.2430087 0.9066041 0.2636382 0.5803727 0.9671451 1.7652499  2.691885 
12 1    0.0028 8 2.8078110 2.6667982 0.0459752 0.4660765 2.3383877 4.8485529  6.664349 
13      2    0.0028 8 3.1865129 2.5195054 0.0557998 1.3538481 2.9867598 5.2653068  6.771029 
14 3    0.0028 8 2.8213544 2.5087898 0.1906910 0.4992285 2.5919451 4.5685149  7.172895 
15 4    0.0028 8 2.5175443 1.6317778 0.3182542 1.6428182 2.4972280 3.6106864  4.544173 
16 5    0.0028 8 3.1780363 2.0443580 0.0512899 1.6603042 3.2100926 4.7851775  5.841871 
17 6    0.0028 8 2.8283411 1.9423135 0.0645744 1.7517885 3.2150677 4.0588267  5.401816 
18 7    0.0028 8 3.1823753 1.9937407 0.0933488 2.4837284 3.4388140 4.6233897  5.308898 
19 8    0.0028 8 2.9907131 1.2728591 1.0159376 2.3605711 3.1014172 3.3930375  5.370352 
20 9    0.0028 8 2.4211375 0.9895341 0.5115399 2.1440225 2.4375204 2.9007237  3.667265 
   Minute Treatment n      mean   sd       min   Q1    median        Q3  max 
197 
21 0     0.014 8 1.0511860 1.1084699 0.2422053 0.4762637 0.6028759 1.1027455  3.618459 
22 1     0.014 8 2.1390817 2.7322518 0.0490966 0.0587801 1.2738246 2.6256912  7.555901 
23 2     0.014 8 3.2696109 3.5239332 0.0943086 0.3081621 1.7059093 6.6020113  8.803994 
24 3     0.014 8 2.6498597 2.7772750 0.0481543 0.2420196 1.7657455 4.9626112  6.611284 
25 4     0.014 8 2.5788192 2.7388071 0.0459727 0.1166610 1.6582626 5.2884862  6.041494 
26 5     0.014 8 2.6541499 2.2599688 0.0615725 1.1589798 1.9529416 4.9511911  5.699501 
27 6     0.014 8 2.7887270 2.1345400 0.1918561 1.3007362 2.8190420 3.8681508  6.158312 
28 7     0.014 8 3.1043657 2.2617092 0.1558236 1.5664927 2.9438077 5.1322640  6.046632 
29 8     0.014 8 2.8648250 1.3982299 1.2710786 1.7480263 2.5930830 3.7864852  5.256899 
30 9     0.014 8 1.4564424 0.9475996 0.0358918 1.1337041 1.5243016 2.2891948  2.418221 
31 0   Control 8 2.2756940 3.7999037 0.2263035 0.3738425 0.7266651 1.7878097 11.417876 
   Minute Treatment n      mean  sd       min   Q1    median        Q3  max 
32 1   Control 8 2.4737641 2.3958189 0.0730032 0.1915707 2.3156148 3.7261582  6.244480 
33 2   Control 8 3.0751778 2.8493147 0.0581657 0.6197834 2.5507492 5.1317069  7.595394 
34 3   Control 8 2.5311409 2.6748649 0.0620684 0.1484595 1.6167830 4.8947274  6.201933 
35 4   Control 8 2.3904816 2.5715218 0.0497738 0.0593648 1.6612933 4.6378051  5.728124 
36 5   Control 8 1.4512587 1.7071711 0.0453218 0.2026166 0.8136600 2.0357340  4.371722 
37 6   Control 8 2.2302114 2.5243419 0.0395166 0.4017160 1.1351121 3.5565177  6.557135 
38 7   Control 8 2.7900044 2.5923834 0.0439355 0.4428741 2.4683055 4.7847899  6.787502 
39 8   Control 8 2.1167636 2.1568215 0.0483237 0.1640462 1.5476715 3.9849491  5.493751 
40 9   Control 8 1.1303051 1.1869318 0.0252819 0.3015784 0.6688673 1.8471762  3.391891 
Table 15B. Week 12 Distance Moved within 10-Minute Video After-Shadow Raw Data 
   Minute Treatment n     mean       sd       min Q1   median Q3       max 
1 0    0.0014 8 3.286654 2.747150 0.4397669 1.1868699 2.444543 4.913088  8.480778 
2 1    0.0014 8 4.636273 4.484206 0.0707947 1.1934964 4.172434 6.669142 13.458056 
3 2    0.0014 8 5.649273 3.323897 0.0906764 4.1634589 5.134464 7.144031 11.344310 
4 3    0.0014 8 5.447396 3.764886 1.2713599 2.5677552 4.977440 6.613972 12.796442 
5 4    0.0014 8 5.030887 3.508967 1.2262334 2.5897048 4.047548 6.527632 11.470292 
6 5    0.0014 8 3.962629 3.353551 0.0772342 1.1308738 3.910389 5.762487  9.835258 
7 6    0.0014 8 4.478143 4.022700 0.0596402 1.3597566 3.586811 7.548446  9.992603 
8 7    0.0014 8 5.123292 2.935144 0.0596503 3.6719638 5.609362 6.065402  9.943118 
9 8    0.0014 8 4.418545 3.023228 0.0699951 2.5398504 4.632418 6.507192  8.917508 
10 9    0.0014 8 2.549384 1.334580 0.0407938 2.0785303 2.561555 3.130352  4.554869 
   Minute Treatment n     mean       sd       min Q1   median Q3       max 
11      0    0.0028 8 5.217006 7.279956 0.3313978 1.6554878 2.428167 5.185290 22.483012 
12 1    0.0028 8 3.142259 3.462257 0.2230628 0.5224473 1.842073 4.549850 10.001341 
13 2    0.0028 8 4.414517 3.476144 0.0738985 1.4781848 5.035253 6.372532 10.025877 
14 3    0.0028 8 4.344615 3.052816 0.0695782 2.1876938 4.908987 6.672530  8.294196 
15 4    0.0028 8 4.459760 2.752478 0.0621279 2.5850000 5.301334 6.718247  7.257061 
16 5    0.0028 8 4.206508 2.334897 0.1686705 3.2875517 3.872681 5.461658  8.042112 
17 6    0.0028 8 4.069449 2.662646 0.0898590 2.4183832 4.281127 5.456088  8.491680 
18 7    0.0028 8 4.501379 3.711879 0.1074636 1.5874959 4.550096 6.408473  9.884040 
19 8    0.0028 8 5.093367 3.627874 0.0956114 3.0918505 5.547476 7.079465 10.478733 
20 9    0.0028 8 2.301594 1.054002 0.5660509 1.7485497 2.215694 2.946695  3.999449 
   Minute Treatment n     mean       sd       min Q1   median Q3       max 
21      0     0.014 8 3.490364 3.929623 0.2980812 0.5586596 1.648909 5.975780 11.308347 
22 1     0.014 8 5.050893 4.204596 0.1317652 1.1916598 5.881630 6.813285 12.266339 
23 2     0.014 8 5.923214 4.131622 0.1263787 2.6803125 7.737176 8.329987 11.132029 
198 
24 3     0.014 8 4.703735 4.041483 0.0932311 1.0573302 4.702553 7.296286 10.562406 
25 4     0.014 8 4.520666 3.482043 0.4060162 1.1260943 4.691988 7.604101  8.907982 
26 5     0.014 8 4.662246 2.829177 0.2536231 3.4243924 3.867777 6.506766  8.604059 
27 6     0.014 8 4.921936 3.333171 0.1067665 1.9525380 5.832987 7.261198  8.977956 
28 7     0.014 8 4.874548 3.187202 0.1054592 2.5660005 5.103637 6.469530  9.941832 
29 8     0.014 8 5.225501 2.107666 2.3919051 3.1016284 5.856687 7.050072  7.417472 
30 9     0.014 8 3.154012 1.697544 0.5445573 2.1956449 3.200846 4.297328  5.456050 
   Minute Treatment n     mean       sd       min Q1   median Q3       max 
31 0   Control 8 3.712886 4.057947 0.2649857 0.7507979 2.093177 5.569913 11.428517 
32 1   Control 8 4.098669 4.413163 0.1192832 0.7533472 2.137982 7.087789 12.152611 
33 2   Control 8 3.802771 3.707782 0.1280826 1.3583397 2.641984 5.333073 10.764408 
34 3   Control 8 4.968786 3.537940 0.0966060 2.7821268 5.215485 6.185793 11.242387 
35      4   Control 8 5.369285 2.570244 2.6930685 3.3249676 4.812323 6.939356  9.716680 
36 5   Control 8 5.515621 3.381250 0.6653254 3.5133259 5.187767 7.683385 11.232084 
37 6   Control 8 5.008714 3.360533 0.8235589 1.9016505 5.411118 7.023783 10.188721 
38 7   Control 8 5.221008 2.822826 2.2153161 3.5942326 4.311524 6.854367 10.531686 
39 8   Control 8 5.654133 2.907319 1.5410731 3.2762047 6.012552 8.501901  8.710421 
40 9   Control 8 2.862127 2.063284 0.0450794 1.7055444 2.859004 4.096805  6.046174 
Table 16B. Week 24 Distance Moved within 10-Minute Video After-Shadow Raw Data 
   Minute Treatment n      mean sd       min  Q1    median       Q3       max 
1 0    0.0014 8 3.3303720 2.793293 0.4361091 1.4776049 2.6100219 4.293708  8.358993 
2 1    0.0014 8 3.7316583 3.204992 0.2554758 1.3636824 3.2491885 5.271013  9.780455 
3 2    0.0014 8 4.2579095 3.069634 0.1106343 2.6200561 4.1469559 5.758102  8.890491 
4 3    0.0014 8 4.9144098 4.271032 0.0579101 2.1208598 4.3181151 7.017732 13.106351 
5 4    0.0014 8 4.7800453 3.289267 0.9237030 1.7771584 4.8796885 6.487819 10.360495 
6 5    0.0014 8 4.5010250 2.898466 0.0918369 2.8987102 4.1076068 6.571536  9.141458 
7  6    0.0014 8 3.3184381 2.715909 0.0792984 0.7047567 3.7149308 4.983048  7.200883 
8 7    0.0014 8 3.5342090 3.080083 0.3041930 1.4929133 2.2624050 5.193659  9.548426 
9 8    0.0014 8 2.9147210 1.808235 0.3488143 1.5298218 3.3277006 3.900924  5.676905 
10 9    0.0014 8 1.9335348 1.672532 0.1251899 0.5681013 1.8759569 2.710804  5.032352 
   Minute Treatment n      mean sd       min  Q1    median       Q3       max 
11 0    0.0028 8 3.0638037 3.361854 0.2312325 0.5835898 1.7260845 4.704192  9.998706 
12 1    0.0028 8 3.4637456 3.125396 0.0846891 0.2732047 3.6181953 5.907198  7.296838 
13 2    0.0028 8 3.1340907 2.527101 0.0878415 0.7666470 3.4414532 4.667895  6.378171 
14 3    0.0028 8 2.1874946 2.160611 0.0472111 0.1712634 2.1294397 4.142905  4.441672 
15 4    0.0028 8 2.3073683 1.608211 0.3984687 0.9040584 2.1149090 3.399403  4.559100 
16 5    0.0028 8 3.0069216 1.957864 0.0675391 1.6158965 3.1927612 4.755973  4.970692 
17 6    0.0028 8 3.1737274 2.352470 0.0946489 1.5621493 3.3466171 4.718173  6.535820 
18 7    0.0028 8 3.2096495 1.522584 0.0933353 2.6520663 3.5167489 4.233852  4.820068 
19 8    0.0028 8 3.5592047 2.533457 0.1064890 2.0709440 3.5145449 5.184079  6.911008 
20 9    0.0028 8 2.0010014 1.659946 0.0435230 0.6490326 2.0573329 2.988380  4.816319 
   Minute Treatment n      mean sd       min  Q1    median       Q3       max 
21 0     0.014 8 2.6037340 2.107971 0.3780097 1.2792829 2.2470001 3.163699  5.856196 
22 1     0.014 8 4.2791674 3.203090 0.4212191 2.0110418 3.6574114 5.886415  9.440439 
23 2     0.014 8 4.4793181 3.072594 0.4826330 2.7521367 4.1836121 6.116447 10.113512 
24 3     0.014 8 4.3864102 3.066583 0.2487340 2.6090409 3.2844781 6.764318  8.726907 
25 4     0.014 8 4.0843953 3.340610 0.2957578 1.0151080 3.5739540 7.028327  8.559031 
199 
26 5     0.014 8 3.9775145 2.949564 0.2851199 2.2895075 3.2723474 4.908268  9.754874 
27 6     0.014 8 4.6640559 3.591770 0.5688350 1.8363155 3.8729357 7.444267 10.791547 
28 7     0.014 8 4.3105228 3.362181 0.1881190 2.6443649 3.4504280 4.894375 11.307531 
29 8     0.014 8 4.1678012 3.379874 0.1927520 1.9399509 3.0988969 5.798485 10.133477 
30 9     0.014 8 2.3784949 1.701696 0.1000097 1.3557328 1.8586967 3.676949  4.812932 
   Minute Treatment n      mean sd       min  Q1    median       Q3       max 
31 0   Control 8 0.8254508 1.171158 0.0872834 0.1926676 0.2945589 0.775610  3.433109 
32 1   Control 8 1.9472696 1.528943 0.0729534 0.8077660 1.6860829 2.749246  4.642626 
33 2   Control 8 2.9019473 2.541752 0.0749503 0.1571277 3.3954368 4.338747  6.420965 
34 3   Control 8 3.7397293 2.393165 0.1362964 2.2604452 3.5453316 5.824155  6.527739 
35 4   Control 8 4.4100232 2.058960 1.2779695 3.2439961 4.7607395 5.326359  7.512492 
36 5   Control 8 4.5467044 2.370151 0.9219743 3.1873927 4.5676198 5.602777  8.530231 
37 6   Control 8 4.9197317 2.979111 1.6333851 2.9555970 4.4615209 6.144595 10.680929 
38      7   Control 8 3.9570577 3.064887 0.0685898 2.1733751 3.2565834 5.412957  8.446491 
39 8   Control 8 4.2522307 3.618337 0.0754499 1.7207927 3.0967063 7.911374  8.984988 
40 9   Control 8 2.5519448 1.719032 0.0787449 1.4235524 2.7251825 3.634326  4.852683 
Table 17B. Border Time After-Shadow Raw Data 
  Week Treatment n     mean        sd      min Q1   median       Q3  max 
1 0    0.0014 8 73.14153 24.944482 47.05570 50.39800 71.12795 97.46839 100.00000      0.0 
2 1    0.0014 8 77.67215 21.697101 33.13820 72.49762 81.47025 92.86760 100.00000      0.0 
3 2    0.0014 8 90.92058  8.114213 77.92090 83.88260 93.38855 97.44776 100.00000      0.0 
4 3    0.0014 8 86.54427 10.551113 72.84010 77.27165 87.44147 96.11332  99.18052      0.0 
5 4    0.0014 8 86.78877 16.915029 49.28000 85.56838 92.57785 97.01029 100.00000      0.0 
6 5    0.0014 8 87.36903 15.350846 62.81320 82.51435 93.33880 98.34347  99.87708      0.0 
7 6    0.0014 8 89.89733 14.650144 54.65670 90.62426 94.88393 96.47331 100.00000      0.0 
8 7    0.0014 8 87.73633 11.967299 69.47440 76.33747 94.30754 95.83675  99.19223      0.0 
9 8    0.0014 8 82.51183 16.904726 56.40700 67.71105 90.71351 94.87825  99.91805      0.0 
10     9    0.0014 8 93.17343  3.554988 86.30880 92.00421 92.71833 95.55432  97.85179      0.0 
11    10    0.0014 8 87.58781  7.738852 70.39920 87.20150 90.14869 92.02470  94.25779      0.0 
12    11    0.0014 8 90.48452  8.954306 73.15620 86.91905 92.88223 97.40985  99.14540      0.0 
13    12    0.0014 8 88.03512 12.925809 69.21100 78.39957 93.22710 98.51323  99.90635      0.0 
14    13    0.0014 8 95.12189  4.781626 85.57710 94.18608 96.65184 98.27763  99.36198      0.0 
15    14    0.0014 8 87.39463 17.200665 47.23130 85.85662 94.30169 96.27721  99.45563      0.0 
16    15    0.0014 8 91.61998  6.830095 80.00470 86.41652 95.87041 96.39429  97.00304      0.0 
17    16    0.0014 8 88.66535 10.168701 70.67260 81.51783 91.17301 95.90552  99.70148      0.0 
18    17    0.0014 8 87.30976 16.919912 56.71970 82.89187 94.44217 99.47319 100.00000      0.0 
19    18    0.0014 8 87.39307  9.223798 73.48980 80.81390 87.39715 94.16120  98.94638      0.0 
20    19    0.0014 8 77.88427 16.091286 50.94830 70.02163 75.34535 90.15160  98.93468      0.0 
21    20    0.0014 8 90.34037 11.327085 65.54090 87.46780 92.41393 98.17812 100.00000      0.0 
22    21    0.0014 8 93.45582  7.990953 77.42330 91.84005 95.40213 99.78050 100.00000      0.0 
23    22    0.0014 8 85.82226 14.237721 64.80330 74.27417 87.91267 99.51709 100.00000      0.0 
24    23    0.0014 8 69.39387 34.143439  0.55610 55.50950 78.55594 95.42847  99.10443      0.0 
25    24    0.0014 8 89.77553 14.527735 56.49150 88.97799 95.92894 97.84447  99.94732      0.0 
    Week Treatment n     mean        sd      min       Q1   median       Q3       max 
26     0    0.0028 8 78.51193 11.949521 61.47860 68.22025 79.60620 89.37567  91.68813      0.0 
27     1    0.0028 8 86.83584 20.338205 43.02190 88.41057 96.12210 97.62350 100.00000      0.0 
28     2    0.0028 8 85.53568 13.196905 60.46950 79.28725 88.02095 95.38729  99.78928      0.0 
200 
29     3    0.0028 8 87.56967 24.908648 26.09610 94.78167 95.83808 96.60355 100.00000  
30     4    0.0028 8 90.50427  9.393535 73.06840 84.86593 93.41196 97.74643  99.54343  
31     5    0.0028 8 88.70141 18.046552 45.36990 89.56920 94.95434 97.51961 100.00000  
32     6    0.0028 8 76.09749 35.317595 11.58980 68.76313 94.45666 98.51331 100.00000  
33     7    0.0028 8 85.92179  8.613464 70.76800 82.68705 83.98210 91.36621  98.12105  
34     8    0.0028 8 72.99420 31.509176 12.02880 58.58685 90.01990 93.28465  98.31421  
35     9    0.0028 8 86.05640 23.051353 30.12760 87.58050 94.56216 97.48010  98.87029  
36    10    0.0028 8 79.23954 22.315927 29.67280 73.72835 86.49320 93.50850  97.17279  
37    11    0.0028 8 91.03912  6.496013 83.13040 87.07560 89.74770 96.02845  99.84781  
38    12    0.0028 8 95.84114  4.103361 87.29810 94.45241 96.51135 98.72103  99.65465  
39    13    0.0028 8 92.73882  4.909916 86.33810 89.52970 90.86863 97.40547  99.69562  
40    14    0.0028 8 87.41951 17.216821 45.34650 90.39598 92.48712 94.62508  98.15032  
41    15    0.0028 8 90.22038 10.750449 73.83520 81.96412 94.88411 98.69908 100.00000  
42    16    0.0028 8 96.08258  2.379266 91.84617 95.10068 95.72115 97.64981  99.18637  
43    17    0.0028 8 87.12964 10.526753 69.24020 82.70753 88.05315 94.70678  99.76001  
44    18    0.0028 8 85.88176 16.021950 59.39480 83.67974 92.74739 94.73487  98.13850  
45    19    0.0028 8 85.35545 15.644470 59.94500 79.92565 94.42168 94.74801  96.93866  
46    20    0.0028 8 86.35320 11.098243 63.81990 83.26623 86.55420 92.82516 100.00000  
47    21    0.0028 8 83.19553 23.136696 33.23580 83.35138 92.68028 96.84500  99.13955  
48    22    0.0028 8 85.09423 21.826138 42.32030 84.58498 95.34360 98.11665  98.94638  
49    23    0.0028 8 93.32124  9.419512 70.70360 93.18515 96.88012 98.14299  98.95224  
50    24    0.0028 8 84.74712 16.720163 57.91720 69.86213 95.73578 95.89967  99.45566  
    Week Treatment n     mean        sd      min       Q1   median       Q3       max 
51     0     0.014 8 70.38204 28.617836 31.31590 40.24697 86.22635 90.65204  98.47543  
52     1     0.014 8 69.54095 35.077507  0.09950 64.54578 82.76455 89.45362 100.00000  
53     2     0.014 8 90.59259 10.589539 71.29310 85.25665 95.49286 97.72302 100.00000  
54     3     0.014 8 91.25204  9.619147 71.45280 88.69410 93.53196 98.87029  99.36198  
55     4     0.014 8 87.19313 13.364457 60.27040 80.42028 91.52425 96.45282  99.56682  
56     5     0.014 8 93.43740  4.900130 86.36660 89.13117 94.30461 96.59769 100.00000  
57     6     0.014 8 89.51071 10.438730 69.32800 83.69965 91.76738 98.77810  99.08101  
58     7     0.014 8 87.91266 14.856521 57.73240 83.74060 92.29104 99.42633 100.00000  
59     8     0.014 8 83.80430 18.098148 48.12100 72.59280 92.43447 96.39136 100.00000  
60     9     0.014 8 90.05410 10.067894 69.12320 86.44930 91.78178 96.82120 100.00000  
61    10     0.014 8 82.67364 30.871692  8.29430 84.39123 94.12279 98.85413 100.00000  
62    11     0.014 8 90.86645 13.918791 58.97330 89.49749 95.56310 99.92537 100.00000  
63    12     0.014 8 93.11714  7.377238 78.01450 92.19590 95.46652 97.05290  99.71318  
64    13     0.014 8 87.62512 15.051314 57.25830 81.31290 95.65968 96.98256  99.42636  
65    14     0.014 8 91.33608  8.474021 74.53170 87.97118 93.02229 97.61765  99.32100  
66    15     0.014 8 90.66524 21.405956 37.87750 96.03284 98.24689 99.67074 100.00000  
67    16     0.014 8 83.95526 22.941550 35.21040 83.05723 92.01883 99.37222 100.00000  
68    17     0.014 8 87.75490 20.920592 37.84460 86.31323 97.72887 98.65956  99.06345  
69    18     0.014 8 92.94057  9.538842 72.32340 91.62083 97.14938 99.16589  99.37954  
70    19     0.014 8 94.11731  6.085595 82.78510 89.89698 96.44989 98.63322 100.00000  
71    20     0.014 8 91.66179 10.955606 67.45490 88.55948 96.36502 98.36982  99.95317  
72    21     0.014 8 82.67896 22.656344 44.11140 70.58508 96.13380 98.62298  98.91126      0.0 
73    22     0.014 8 80.19030 34.031800  0.00000 81.94465 93.82170 98.90096 100.00000  12. 5
74    23     0.014 8 83.33748 19.982376 49.63120 79.22768 89.85601 97.17425  99.71904  0.0
75    24     0.014 8 89.31415 14.911170 61.83560 79.03065 98.67123 99.96488 100.00000  0.0
     Week Treatment n     mean        sd      min       Q1   median       Q3       max 
201 
76     0   Control 8 85.47759 14.485594 60.47180 82.03583 90.27724 94.13486  99.87706  
77     1   Control 8 86.35090 11.007432 73.91560 76.49815 86.23565 94.43193 100.00000  
78     2   Control 8 86.18936 10.640242 69.35730 78.10015 86.62195 96.14844  98.84217  
79     3   Control 8 90.98571 12.377031 63.20530 90.56867 96.13966 98.10641  99.41462  
80     4   Control 8 84.33257 17.943656 52.73360 81.03195 89.78575 96.42355  99.95317  
81     5   Control 8 92.21704  6.957913 79.13840 89.79142 92.93198 97.17279 100.00000  
82     6   Control 8 92.45087  4.387909 87.41510 89.59699 90.91548 95.59440  99.37368  
83     7   Control 8 88.38606  9.824214 70.24700 84.06548 91.81398 93.50562 100.00000  
84     8   Control 8 90.88747  8.368959 72.49310 89.05407 92.83833 96.51136  98.22056  
85     9   Control 8 89.93661 15.596683 51.48980 93.96207 95.07141 95.96991  97.93374  
86    10   Control 8 93.96577  3.653203 90.03161 91.80959 92.75025 95.40652  99.74830  
87    11   Control 8 90.39305  9.038348 71.18940 87.52778 91.74959 96.75720 100.00000  
88    12   Control 8 86.29636 16.737634 47.91030 84.83520 89.78870 97.14046  99.84781  
89    13   Control 8 88.66406 15.403119 52.90920 88.68971 94.88393 96.61379  99.52587  
90    14   Control 8 87.94704 11.135075 67.08030 83.52550 89.94380 97.60302  98.28484  
91    15   Control 8 89.32774  9.291797 72.74060 84.50302 90.04041 97.70546  98.40787  
92    16   Control 8 90.77192  6.705484 80.72470 87.93372 90.95937 94.84166 100.00000  
93    17   Control 8 86.79176 14.996517 53.20770 85.46305 91.69398 95.60115  99.67221  
94    18   Control 8 87.27348 10.310246 70.92600 83.26602 90.94474 93.07978  99.78928  
95    19   Control 8 92.34225 10.002496 72.37180 90.96523 96.58745 98.67420 100.00000  
96    20   Control 8 95.34579  4.092590 88.73210 93.05930 96.06357 98.69469 100.00000  
97    21   Control 8 92.08543 10.896032 66.72320 93.25979 96.01674 97.55180 100.00000  
98    22   Control 8 86.29713 26.048886 22.62350 91.10573 94.90752 98.47226  99.80684  
99    23   Control 8 85.27496 18.164571 48.26150 84.43133 92.95833 96.09137  98.52494  
100   24   Control 8 88.58204 10.432374 72.58840 83.19707 90.06381 96.43380 100.00000   
Table 18B. Zone Crossing After-Shadow Raw Data 
 
    Week Treatment n   mean        sd min   Q1 median    Q3 max percZero 
1 0    0.0014 8  6.500  3.891382   0 3.75    7.5  9.25  11     12.5 
2 1    0.0014 8  4.250  3.284161   0 2.50    3.5  6.25  10     12.5 
3 2    0.0014 8  6.250  4.399675   0 4.00    7.0  8.00  14     12.5 
4 3    0.0014 8 10.250  5.147815   5 5.00   10.0 13.75  18 0.0 
5 4    0.0014 8  7.625  6.345696   0 3.75    6.5  9.25  20     12.5 
6 5    0.0014 8  6.875  3.720119   2 4.50    6.5  9.00  12 0.0 
7 6    0.0014 8  7.375  4.068608   0 5.25    9.0 10.00  12     12.5 
8 7    0.0014 8  9.500  4.985694   2 6.00    9.0 13.50  16 0.0 
9 8    0.0014 8  6.875  3.226564   2 5.50    6.0  9.50  11      0.0 
10     9    0.0014 8  7.750  4.301163   3 3.75    7.5 11.50  13 0.0 
11    10    0.0014 8 20.125 23.412070   5 6.75   11.5 19.75  75 0.0 
12    11    0.0014 8  6.000  4.690416   1 2.00    5.0  8.75  14 0.0 
13    12    0.0014 8  6.875  5.718079   1 3.25    6.0  8.25  18 0.0 
14    13    0.0014 8  6.375  3.889087   2 4.50    5.5  7.00  14 0.0 
15    14    0.0014 8  6.000  2.828427   2 4.25    7.0  7.25  10 0.0 
16    15    0.0014 8  5.500  2.878492   1 3.50    6.5  7.25   9      0.0 
17    16    0.0014 8  7.625  5.829421   1 4.00    5.5 10.00  17 0.0 
18    17    0.0014 8  6.625  5.262740   0 3.50    4.5 12.00  14     12.5 
19    18    0.0014 8  5.875  4.086126   1 2.50    6.0  9.25  11 0.0 
20    19    0.0014 8  5.750  3.575712   3 3.00    4.0  7.75  12 0.0 
202 
21    20    0.0014 8  6.250  8.310922   0 0.75    4.0  7.50  25     25.0 
22    21    0.0014 8  4.625  5.125218   0 0.75    3.5  6.50  15     25.0 
23    22    0.0014 8  5.625  5.527528   0 1.50    5.5  7.25  17     25.0 
24    23    0.0014 8  6.625  3.159453   2 3.75    8.0  9.00  10 0.0 
25    24    0.0014 8  9.250  8.189715   2 3.75    6.0 12.75  26 0.0 
    Week Treatment n   mean        sd min   Q1 median    Q3 max percZero 
26     0    0.0028 8  6.625  3.113909   3 4.50    6.5  8.00  11 0.0 
27     1    0.0028 8  6.500  5.042675   0 4.75    5.0  7.00  17     12.5 
28     2    0.0028 8  6.375  2.973094   2 4.50    6.5  8.50  10 0.0 
29     3    0.0028 8  4.750  2.492847   0 3.75    5.0  7.00   7     12.5 
30     4    0.0028 8  6.875  4.389517   1 4.25    6.5  9.50  14 0.0 
31     5    0.0028 8 16.875 35.016068   0 2.25    5.0  8.25 103     25.0 
32     6    0.0028 8  2.875  2.531939   0 1.00    2.0  4.50   7     12.5 
33     7    0.0028 8  5.750  2.712405   2 3.75    6.0  7.25  10 0.0 
34     8    0.0028 8  7.250  4.301163   1 4.50    7.0 10.25  14 0.0 
35     9    0.0028 8  5.875  3.681517   1 4.75    5.5  6.00  14      0.0 
36    10    0.0028 8  7.125  3.642507   2 5.25    7.0  9.25  13 0.0 
37    11    0.0028 8  8.750  7.245688   1 5.25    8.0  9.25  25 0.0 
38    12    0.0028 8  7.750  7.106335   1 2.50    6.5 11.00  22 0.0 
39    13    0.0028 8  7.625  7.576986   3 4.00    5.0  6.50  26 0.0 
40    14    0.0028 8  6.500  2.777460   3 4.75    6.0  7.75  11 0.0 
41    15    0.0028 8  3.500  1.851640   0 2.75    4.0  4.25   6     12.5 
42    16    0.0028 8  5.625  4.596194   1 3.00    4.0  6.25  15      0.0 
43    17    0.0028 8  8.500  4.928054   2 5.00    7.5 11.25  16 0.0 
44    18    0.0028 8  8.250  9.407444   1 2.75    5.0 10.00  30 0.0 
45    19    0.0028 8  8.750  5.092010   3 5.50    7.5 11.00  18 0.0 
46    20    0.0028 8  7.125  4.580627   0 3.00    8.5 10.25  13     12.5 
47    21    0.0028 8  6.500  4.105745   2 2.75    6.5  9.25  13 0.0 
48    22    0.0028 8  5.625  4.240536   1 1.75    5.5  8.50  12 0.0 
49    23    0.0028 8  3.750  3.770184   1 1.00    2.5  4.50  12      0.0 
50    24    0.0028 8  7.125  4.323937   2 4.50    6.0 10.00  15 0.0 
    Week Treatment n   mean        sd min   Q1 median    Q3 max percZero 
51     0     0.014 8  8.375  6.390562   2 4.50    7.0  9.75  22 0.0 
52     1     0.014 8  5.000  3.464102   0 1.75    6.5  7.25   9     12.5 
53     2     0.014 8  7.125  8.475806   0 3.25    5.0  7.25  27     12.5 
54     3     0.014 8  7.750  4.949747   1 3.75    7.5 12.25  14 0.0 
55     4     0.014 8  7.125  4.969550   1 3.50    6.5 10.25  14 0.0 
56     5     0.014 8  5.625  4.340425   0 2.50    5.5  8.25  13     12.5 
57     6     0.014 8 13.125 15.338444   2 4.50    8.0 14.00  49 0.0 
58     7     0.014 8  6.375  4.749060   0 3.25    6.5  9.25  14     12.5 
59     8     0.014 8  7.750  6.041523   0 3.50    8.0  9.75  19     12.5 
60     9     0.014 8 10.000  9.258201   0 4.25    8.0 13.50  29     12.5 
61    10     0.014 8  5.125  3.870677   0 3.00    5.5  6.75  11     25.0 
62    11     0.014 8  8.000  9.942693   0 0.75    5.5  9.75  29     25.0 
63    12     0.014 8  7.250  5.338539   1 2.75    6.5 11.00  15 0.0 
64    13     0.014 8  4.875  3.522884   1 1.75    5.0  6.50  11 0.0 
65    14     0.014 8  6.375  2.722263   3 4.50    6.5  8.25  10      0.0 
66    15     0.014 8  4.375  3.583195   0 0.75    5.5  6.50   9     25.0 
67    16     0.014 8  4.000  3.854496   0 1.00    2.5  6.75  10     12.5 
203 
68    17     0.014 8  3.625  2.825269   1 1.00    3.5  4.50   9 0.0 
69    18     0.014 8  5.625  4.172615   2 2.75    4.0  7.25  13 0.0 
70    19     0.014 8  6.000  5.345225   0 2.00    5.5  7.50  17     12.5 
71    20     0.014 8  9.250  6.606274   2 2.00   10.5 13.25  18 0.0 
72    21     0.014 8  4.250  3.327376   1 1.00    4.0  6.25  10      0.0 
73    22     0.014 8  3.875  3.356763   0 1.00    3.0  7.25   8     12.5 
74    23     0.014 8 11.625 15.927851   1 3.75    7.0  9.25  50 0.0 
75    24     0.014 8  4.875  5.540436   0 0.75    2.0  9.75  13     25.0 
    Week Treatment n   mean        sd min   Q1 median    Q3 max percZero 
76     0   Control 8  9.750  8.207140   1 3.75    7.0 15.25  25 0.0 
77     1   Control 8  8.000  6.071008   0 3.50    8.0 11.50  18     12.5 
78     2   Control 8 10.375  5.578978   4 5.75    9.5 14.75  18 0.0 
79     3   Control 8  6.625  4.172615   2 3.00    6.5  8.00  14 0.0 
80     4   Control 8  7.750  4.464143   2 4.50    7.5 10.50  15 0.0 
81     5   Control 8 10.125  7.918108   0 6.25   10.0 11.25  27     12.5 
82     6   Control 8 11.375  6.069538   3 7.00   12.0 15.50  20 0.0 
83     7   Control 8  7.750  4.832923   0 4.50    8.5 10.75  14     12.5 
84     8   Control 8 10.125  2.948971   6 8.00    9.5 12.50  14 0.0 
85     9   Control 8  9.250  6.158618   1 6.75    8.5 11.50  21 0.0 
86    10   Control 8  9.000  5.014265   2 5.25    9.5 13.25  15 0.0 
87    11   Control 8  5.625  3.583195   0 3.00    6.0  8.25  10     12.5 
88    12   Control 8 10.625  7.366672   1 4.50   11.5 15.00  23 0.0 
89    13   Control 8  5.750  2.815772   2 3.00    6.0  8.25   9 0.0 
90    14   Control 8  7.500  5.631544   2 3.50    6.5  9.50  19 0.0 
91    15   Control 8  6.875  3.482097   3 4.00    6.5  8.50  13 0.0 
92    16   Control 8  8.250  7.025464   0 5.00    6.0 10.75  21     12.5 
93    17   Control 8  6.000  3.251373   1 4.50    6.5  7.00  12 0.0 
94    18   Control 8  8.875  7.827379   2 4.00    7.5  9.25  27 0.0 
95    19   Control 8  5.500  3.927922   0 2.00    6.0  7.75  11     12.5 
96    20   Control 8  7.250  4.234214   0 5.00    6.5 11.00  13     12.5 
97    21   Control 8  4.875  3.642507   0 2.75    3.5  8.25  10     12.5 
98    22   Control 8  3.750  2.314550   1 2.00    3.5  4.50   8      0.0 
99    23   Control 8  8.125  7.472569   1 3.50    6.0 10.00  24 0.0 
100   24   Control 8  5.250  4.200340   0 2.50    5.0  7.25  13     12.5  
Table 19B. Time Moving After-Shadow Raw Data 
    Week Treatment n      mean       sd       min Q1    median      Q3      max 
1 0    0.0014 8  8.530047 4.774989 0.7533376  5.829415  9.255322 11.768427 14.69265      0.0 
2 1    0.0014 8  8.279284 4.474399 1.6439744  5.249268  8.832686 11.755974 13.98399      0.0 
3 2    0.0014 8 10.697403 5.917794 1.0722501  7.628232 12.746255 15.203515 16.06736      0.0 
4 3    0.0014 8  9.585671 4.731188 3.0341016  6.441611  9.260257 12.544704 16.06778   0.0 
5 4    0.0014 8  9.969207 6.148505 1.0350644  5.352157 10.148945 13.398391 19.14429      0.0 
6      5    0.0014 8 11.230661 3.750366 7.3788563  8.234310 10.798127 12.488543 17.36439      0.0 
7 6    0.0014 8  9.419791 5.485748 2.0750707  6.060398  9.387122 12.704042 16.70519      0.0 
8 7    0.0014 8 12.136663 4.116950 5.9065415 10.453181 12.831243 14.462372 17.53001      0.0 
9 8    0.0014 8 11.054961 3.622128 4.9004505  9.327205 11.261527 13.048297 16.73500      0.0 
10     9    0.0014 8 14.255426 2.970326 8.2444646 12.474266 15.821407 16.183181 16.72864      0.0 
11    10    0.0014 8 10.474317 2.966524 5.5644018  8.778777 10.177584 13.329695 13.90927      0.0 
12    11    0.0014 8 10.526175 5.025029 3.5410505  7.325731 10.207849 15.373944 16.60519      0.0 
13    12    0.0014 8 12.974331 4.248528 7.4544450  9.501263 13.635665 15.693751 19.42915      0.0 
204 
14    13    0.0014 8 14.397163 3.017989 8.6782444 13.976506 15.075907 15.497425 18.61104     
15    14    0.0014 8 12.291070 2.417955 8.2669293 11.083075 11.622145 14.900236 14.92522     
16    15    0.0014 8  9.029479 5.326126 0.9337814  4.729682 10.796924 13.231516 14.51092     
17    16    0.0014 8 10.820265 3.790678 4.4156995  8.767570 10.950291 12.426055 16.78225     
18    17    0.0014 8 11.623806 6.425524 0.3396687 10.309118 12.917181 14.922490 18.72169     
19    18    0.0014 8 13.029095 2.554067 9.7421192 11.647505 12.878465 13.432052 18.53219     
20    19    0.0014 8 10.570174 5.497342 3.9082020  6.351789 10.231608 14.541852 18.45465     
21    20    0.0014 8 12.150277 7.512612 1.4562545  5.651112 15.860898 17.952463 19.02804     
22    21    0.0014 8 13.197836 3.860297 7.7076162 10.167510 14.127653 16.179637 17.84191     
23    22    0.0014 8 10.843091 5.127847 3.5708588  7.925055 11.071061 13.833787 18.86564     
24    23    0.0014 8  8.719664 4.372172 1.1948892  6.653220  8.623493 10.891487 15.97070     
25    24    0.0014 8 10.489231 3.118623 5.5081414  8.109626 10.973317 13.169056 13.72596     
    Week Treatment n mean       sd       min        Q1    median        Q3      max 
26     0    0.0028 8 10.376235 4.262306 5.2671531  6.311861 10.546721 14.190924 15.98951     
27     1    0.0028 8  8.719343 4.767229 2.7039600  4.653208  9.131088 11.226404 17.30574     
28     2    0.0028 8 11.563040 2.900110 7.3255714  9.589947 11.423759 13.519368 16.41645     
29     3    0.0028 8 10.707963 4.737279 4.3895368  6.271577 12.726802 13.920222 16.27417  
30     4    0.0028 8 12.798581 4.142632 5.7223711 10.034293 13.921726 15.667514 17.87381     
31     5    0.0028 8 10.727961 5.575945 0.2392407  7.736155 11.521781 15.301304 16.89994     
32     6    0.0028 8  9.026760 6.224088 1.8193244  3.091175  8.638091 15.232257 16.44689     
33     7    0.0028 8 10.994948 4.493188 3.3367474  9.330844 11.929186 14.006550 15.94642     
34     8    0.0028 8 10.153704 5.720337 2.4370754  5.521213 10.683203 14.806186 17.39761     
35     9    0.0028 8 10.415064 4.146776 4.8527452  7.754730 10.387907 12.744979 16.98150     
36    10    0.0028 8  9.505321 5.534125 2.5532563  5.194899  9.955774 12.792258 17.75029     
37    11    0.0028 8 11.320749 5.034048 1.6491680  8.551344 12.747375 14.571172 17.07340     
38    12    0.0028 8 12.253037 6.130873 0.7591916 10.648547 14.399644 16.215277 18.17412     
39    13    0.0028 8 11.681641 3.169995 6.5562761  8.757074 13.204304 14.229274 14.45028     
40    14    0.0028 8 12.042370 3.775446 5.9215306  9.837275 11.962927 14.740955 17.19097     
41    15    0.0028 8  9.414509 4.702550 2.9412305  5.986011  9.478286 11.942139 17.51278     
42    16    0.0028 8  9.583846 5.015368 0.8112934  5.941023 10.859099 12.688112 15.99866     
43    17    0.0028 8 12.634341 4.117957 4.7263397 10.880549 13.759618 14.469787 18.68728     
44    18    0.0028 8  8.867316 6.058113 0.8977748  4.284450  9.349358 13.302802 17.23573     
45    19    0.0028 8  9.674743 4.270260 1.9399939  8.792066 10.649274 11.086640 16.38577     
46    20    0.0028 8 10.763550 5.497523 0.1795267  8.419192 12.143656 13.375678 17.90168  
47    21    0.0028 8 10.004853 4.407451 2.3604898  8.384504 10.768981 13.527553 14.46062     
48    22    0.0028 8  7.880975 3.311408 3.4610173  5.792993  7.238948  9.921987 13.18298     
49    23    0.0028 8  9.120651 5.502038 0.1651195  4.756200 11.242162 12.479829 16.18681     
50    24    0.0028 8  9.822306 5.349191 0.8836494  7.173400  8.974927 14.268125 16.40266     
    Week Treatment n mean       sd       min Q1    median   Q3      max 
51     0     0.014 8  8.793984 5.477024 1.6497104  5.789606  7.353097 12.604893 16.93098      0.0 
52     1     0.014 8  7.269321 5.900150 0.1056918  1.822062  8.007352 10.353396 15.60833      0.0 
53     2     0.014 8 11.783867 4.906795 5.5964845  8.271044 10.938189 16.573722 17.91665      0.0 
54     3     0.014 8 12.746268 2.452824 9.9212651 11.050981 12.550471 14.002742 17.26640      0.0 
55     4     0.014 8 12.095808 3.764097 5.0743733 11.278133 12.236235 13.171585 18.56921      0.0 
56     5     0.014 8 11.528212 5.796729 1.6321301  8.458974 11.360883 16.103137 19.59797      0.0 
57     6     0.014 8 12.326543 4.744477 5.6476503  8.836824 13.512515 14.635420 19.79449      0.0 
58     7     0.014 8 13.602713 5.168432 6.8045446  9.812528 13.449264 18.199234 19.62613      0.0 
59     8     0.014 8 11.299112 6.391792 1.4894842  5.961316 12.447387 16.063759 19.15835      0.0 
60     9     0.014 8 13.748247 4.312356 6.8214427 11.236444 13.449065 16.910378 19.29661      0.0 
205 
61    10     0.014 8 12.795481 5.758415 2.2936282 10.209540 12.762718 16.383178 19.88538     
62    11     0.014 8 13.728025 3.528320 7.7028855 11.707405 13.391913 16.974395 17.76753     
63    12     0.014 8 12.316995 6.116221 1.2825825  8.334211 14.712740 16.367932 18.85782     
64    13     0.014 8 13.422619 5.577979 2.8417313 11.030565 13.734128 17.511047 19.65296     
65    14     0.014 8 13.301217 4.721530 4.5275744 11.209893 13.148099 16.801997 19.42172     
66    15     0.014 8 12.323099 5.894164 0.8877782 10.977817 14.062188 16.035178 17.81682     
67    16     0.014 8 11.226660 7.087440 0.1857998  7.278868 12.884153 16.134893 19.60507     
68    17     0.014 8 13.035000 6.534670 0.2079693 10.358113 15.987566 16.780530 18.88465     
69    18     0.014 8 14.158962 5.569578 6.1880613  8.585526 16.265075 18.967639 19.58573     
70    19     0.014 8 12.875149 4.769545 2.5630478 11.249141 14.359772 15.187107 18.01602     
71    20     0.014 8 13.594088 6.373944 0.9300036 11.037231 15.658681 17.748765 20.52491     
72    21     0.014 8 11.351286 5.782522 2.7974031  6.310311 12.829429 15.829552 17.90928     
73    22     0.014 8 12.306494 6.496112 0.1308972  9.922752 11.127379 17.801158 20.64618     
74    23     0.014 8 13.421608 6.628946 2.3593147  8.945430 14.558920 19.262647 19.91075     
75    24     0.014 8 11.411440 5.995793 0.0000000  9.480359 10.567553 16.181794 18.54326
    Week Treatment n mean       sd       min        Q1    median        Q3      max 
76     0   Control 8  7.192873 4.558929 0.2456019  4.159513  7.253286 10.049985 14.45793     
77     1   Control 8  8.241746 4.724776 1.7805378  4.304039  9.753360 11.471825 14.39606     
78     2   Control 8  8.169676 4.267165 3.7158051  5.123563  6.475975 10.740846 14.94567     
79     3   Control 8  8.884184 4.828234 1.5838650  5.274416  9.291294 12.880152 14.92642  
80     4   Control 8 10.866135 4.104591 3.3063437 10.031818 11.448662 12.646035 16.68659     
81     5   Control 8 11.601902 4.323061 2.3968801 10.588933 12.076683 13.905357 16.22816     
82     6   Control 8 12.896377 4.681779 5.6563834 11.039913 14.568105 16.058161 17.71424     
83     7   Control 8 11.426759 5.711758 1.7403689  8.759702 12.478086 15.387871 17.60600     
84     8   Control 8 13.045004 3.310039 8.3839076 10.646771 13.127161 14.772237 18.72690     
85     9   Control 8 10.868988 5.228521 3.3288812  7.548838 10.937502 14.009936 18.47915     
86    10   Control 8 12.505652 4.186055 4.9458857 11.093891 12.555760 14.733761 18.07504     
87    11   Control 8 13.589397 4.306544 7.4393268 10.514315 13.018424 16.968874 19.92826     
88    12   Control 8 11.919069 4.869967 4.6877464  8.371304 11.609728 15.687977 18.02213     
89    13   Control 8 13.124963 4.807192 4.8227036 10.928507 14.903560 16.699347 17.59277     
90    14   Control 8  9.039681 4.503977 3.0747304  5.562178  8.665352 12.902351 14.76861     
91    15   Control 8 12.040303 4.733335 4.5532023  9.130973 13.407307 14.662679 17.53384     
92    16   Control 8 10.021823 5.482568 4.0236248  4.622108  9.963920 15.158000 16.32615      0.0 
93    17   Control 8 10.733485 4.193694 5.6864327  7.393320 10.317713 13.714343 17.70377      0.0 
94    18   Control 8 11.146819 4.498912 5.3088974  7.676075 11.343796 13.955853 18.16220      0.0 
95    19   Control 8 12.220150 5.849189 0.4337213 10.289258 12.008570 17.002032 18.43866      0.0 
96    20   Control 8 12.941330 4.865383 4.0323875 10.442839 13.460484 16.332125 19.18751      0.0 
97    21   Control 8 11.733562 4.935594 4.3329305  8.458899 10.709559 16.204221 18.65562      0.0 
98    22   Control 8 12.802572 3.868531 5.3016981 11.863535 12.036629 15.261267 17.49029      0.0 
99    23   Control 8 11.154568 4.113435 5.9981557  7.679226 10.878005 13.853902 17.94990    0.0 
100   24   Control 8 10.510968 3.541118 5.1870085  8.103018 10.251330 12.680435 16.12902      0.0  
Table 20B. Border Time Moving After-Shadow Raw Data 
    week treatment n     mean        sd      min       Q1   median       Q3      max 
1 0    0.0014 8 73.97271 21.514345 41.88175 61.35816 76.05156 91.87457 96.98417      0.0 
2 1    0.0014 8 74.99117 20.248068 46.62557 61.86770 75.42736 93.39949 98.62287      0.0 
3 2    0.0014 8 81.17406 17.037343 48.52725 71.24234 85.73901 93.87836 99.02980      0.0 
4 3    0.0014 8 80.64386 16.801571 48.52725 72.15203 85.73989 93.80535 96.24762      0.0 
5 4    0.0014 8 84.42724 16.188613 48.47680 82.77777 90.16224 94.37283 96.50135      0.0 
206 
6 5    0.0014 8 88.14344 10.313626 72.49107 82.53884 91.05865 95.65855 98.51448   
7 6    0.0014 8 87.63502  9.964811 72.09387 81.94959 91.13446 94.87732 98.13410   
8 7    0.0014 8 90.19646  7.958315 73.62030 88.13429 91.19317 96.98178 97.09387   
9 8    0.0014 8 86.90922  9.423265 70.54733 83.19405 88.40788 93.24926 97.23515   
10     9    0.0014 8 86.82528  9.618441 70.54733 82.00368 89.48885 93.46858 96.87918   
11    10    0.0014 8 85.84383 10.761733 66.59690 81.85815 86.28335 94.94022 97.63330   
12    11    0.0014 8 89.51211  6.104553 79.35265 86.67191 88.83473 95.28871 96.41210   
13    12    0.0014 8 85.28491 10.458018 68.15457 80.61302 87.49120 93.85591 95.71662   
14    13    0.0014 8 81.92350 17.440632 43.15458 80.90117 86.43712 93.25426 96.35143   
15    14    0.0014 8 77.06507 24.337222 23.16860 70.64982 87.57309 92.01032 95.32600   
16    15    0.0014 8 70.41459 24.737031 25.00000 59.07557 73.95181 91.18576 96.13707   
17    16    0.0014 8 73.28107 19.480252 43.20915 63.37477 73.92855 91.47669 94.53580   
18    17    0.0014 8 70.89044 21.009785 42.08675 53.29807 70.70358 92.41694 94.31970   
19    18    0.0014 8 68.66936 13.528542 47.77972 65.35882 68.81548 70.24863 95.51045   
20    19    0.0014 8 68.04689 19.642412 46.57572 50.46770 68.14996 76.05208 97.08330   
21    20    0.0014 8 66.57339 15.594423 45.86180 57.43146 69.56621 71.22107 95.60125   
22    21    0.0014 8 71.79553 16.612583 47.79393 63.42748 73.03231 82.10988 93.75983   
23    22    0.0014 8 76.33869 15.163927 47.68785 71.29809 76.25850 88.72736 94.03158   
24    23    0.0014 8 78.09191 17.027448 49.51093 67.05459 80.37798 90.95658 98.31968   
25    24    0.0014 8 80.63692 19.690903 42.76240 71.27237 88.36050 95.71365 97.35443   
    week treatment n     mean        sd      min       Q1   median       Q3      max 
26     0    0.0028 8 73.79268 19.240905 39.97512 64.82091 70.76149 92.21027 95.12273   
27     1    0.0028 8 74.40935 17.554542 48.37228 63.66344 72.33609 91.17973 95.11758   
28     2    0.0028 8 78.94351 19.744285 48.37228 65.72898 88.67135 92.58777 96.56472   
29     3    0.0028 8 71.15487 27.241505 25.00000 60.04219 76.91325 93.74948 96.48403   
30     4    0.0028 8 71.12947 25.579279 25.00000 56.48672 76.89550 91.40244 97.08365   
31     5    0.0028 8 65.42567 34.366665  0.00000 43.63224 76.51590 92.00444 97.55410   
32     6    0.0028 8 68.43132 28.514065 21.02250 43.97231 80.32545 89.23252 98.41215   
33     7    0.0028 8 70.04307 32.911155 19.31915 50.31216 87.07367 93.07148 97.12687   
34     8    0.0028 8 70.48982 27.887295 21.02250 55.82856 77.30184 94.10991 96.83310   
35     9    0.0028 8 73.18830 26.928926 21.02250 62.32726 83.54958 94.26113 94.69460   
36    10    0.0028 8 71.97656 28.676722 13.00220 65.14151 83.59780 91.69105 94.04507   
37    11    0.0028 8 77.72132 24.939433 33.41002 69.96432 90.16702 94.06867 96.32197   
38    12    0.0028 8 76.63122 13.727940 56.19915 69.71290 73.89734 87.74546 94.84900   
39    13    0.0028 8 74.88329 14.594621 56.19915 64.55583 71.90264 84.59977 96.24920   
40    14    0.0028 8 75.68451 17.398983 43.19695 69.72724 74.93590 87.20956 98.69650   0. 0
41    15    0.0028 8 69.93944 24.199871 22.78912 58.13090 75.74796 85.99884 95.01490   0.0
42    16    0.0028 8 69.95103 34.566089  0.00000 65.74292 82.34310 93.89192 96.29963     12.5 
43    17    0.0028 8 67.26093 28.812853 24.16668 50.62304 77.34628 87.97989 95.25498      0.0 
44    18    0.0028 8 64.79893 35.902702  0.00000 46.20046 79.97004 90.56743 96.92488     12.5 
45    19    0.0028 8 64.91197 28.945957 15.36885 46.27776 71.88270 88.70811 97.53262      0.0 
46    20    0.0028 8 67.45087 23.569582 28.40673 58.22053 73.47414 78.36174 97.81580      0.0 
47    21    0.0028 8 71.98071 18.853255 50.00000 58.64274 66.53158 88.46560 97.36170      0.0 
48    22    0.0028 8 77.61139 12.088275 64.94830 69.71571 73.31334 84.02587 97.46150      0.0 
49    23    0.0028 8 70.35844 16.767049 45.08160 59.25594 70.96655 77.14696 95.32915      0.0 
50    24    0.0028 8 73.63715 10.877674 62.64635 68.08806 69.16795 75.06572 95.37748      0.0 
    week treatment n     mean        sd      min       Q1   median       Q3      max 
51     0     0.014 8 69.58241 26.028272 18.39080 59.97590 74.73781 87.52830 95.93070      0.0 
52     1     0.014 8 76.10483 17.409389 42.80175 69.01072 76.57690 87.33309 97.03345      0.0 
207 
53     2     0.014 8 85.69563 10.050537 67.73795 82.29087 88.54847 92.31786 95.57180   
54     3     0.014 8 84.91017 10.146748 68.75803 80.67531 87.64957 91.59305 95.61940   
55     4     0.014 8 88.77398  7.874927 72.16430 86.59683 91.14168 92.86209 97.97338   
56     5     0.014 8 83.69387 12.364536 66.01945 73.65739 86.19027 93.38893 98.72860   
57     6     0.014 8 83.12275 12.102171 67.29825 71.89824 84.06719 93.96918 97.26422   
58     7     0.014 8 81.07312 14.913442 62.14240 69.02019 81.21204 94.97733 97.63535   
59     8     0.014 8 72.62949  7.940361 61.93388 69.10184 72.10773 74.40454 88.03498   
60     9     0.014 8 73.26456  5.194090 65.23960 70.80511 72.60035 74.82839 80.85345   
61    10     0.014 8 76.54626  9.512496 67.60802 70.64418 73.51355 80.54152 96.71658   
62    11     0.014 8 78.00813 11.270406 63.39713 70.76484 75.74969 83.87600 97.49315   
63    12     0.014 8 83.70908 18.358115 41.20050 80.66961 90.57211 93.79122 97.09155   
64    13     0.014 8 81.39363 19.636819 41.20050 78.97299 89.31556 93.86800 96.07410   
65    14     0.014 8 75.78247 26.890624 16.20050 66.15185 87.21120 93.93268 95.13367   
66    15     0.014 8 76.37039 25.350723 25.00000 62.21251 89.15651 93.63957 97.57070   
67    16     0.014 8 75.23628 19.768562 47.51310 60.91597 76.89166 92.77662 98.04082   
68    17     0.014 8 77.66375 19.284398 47.51310 63.85277 83.97111 93.49089 98.02343   
69    18     0.014 8 78.54133 16.555650 47.51310 71.16352 77.38634 93.08688 97.42758   
70    19     0.014 8 72.59909 22.412250 22.51310 71.35083 74.69241 83.32511 94.82425   
71    20     0.014 8 70.66266 30.389015  0.00000 72.72080 75.93717 82.12052 97.05218   
72    21     0.014 8 66.56401 27.528754  2.23750 70.42536 73.04444 75.03897 96.49107   
73    22     0.014 8 65.52487 22.734666 25.19575 54.29214 66.17817 81.51294 97.92533   
74    23     0.014 8 60.08063 23.221759 25.00000 43.88376 65.12559 69.55013 97.66697   
75    24     0.014 8 65.76660 25.837077 18.39080 57.25920 66.05785 85.54769 96.96375   
    week treatment n     mean        sd      min       Q1   median       Q3      max 
76     0   Control 8 75.45818 21.903130 44.34582 57.96377 82.84547 91.93706 98.57812   
77     1   Control 8 78.64042 17.473398 46.52490 67.23538 83.12364 91.25566 98.48090   
78     2   Control 8 81.36949 18.175307 44.03750 77.07419 88.11886 92.45464 98.19745   
79     3   Control 8 85.28918 17.484006 44.03750 85.80441 91.52556 93.97006 98.21213   
80     4   Control 8 85.72945 17.137614 44.89753 88.13628 90.91694 93.62575 99.15670   
81     5   Control 8 88.64189 12.019260 61.04102 88.69634 92.70334 94.05049 99.53550   
82     6   Control 8 88.59249 11.805984 61.99923 88.01152 92.08966 94.66244 99.34275   
83     7   Control 8 90.23186  5.065557 86.29320 86.42179 88.78249 90.88074 99.52380   
84     8   Control 8 90.02339  5.979108 81.66480 86.63909 88.15568 93.48931 99.52380   
85     9   Control 8 86.71904 10.954168 67.70328 80.35356 87.02720 97.55494 97.86450      0.0 
86    10   Control 8 87.05391 11.260756 67.38800 82.43276 87.01868 97.35559 98.99770      0.0 
87    11   Control 8 88.99437  9.331304 71.14315 86.45828 90.54864 96.59127 97.80673      0.0 
88    12   Control 8 83.19560 11.932970 67.92710 70.83862 87.24084 92.45401 96.48705      0.0 
89    13   Control 8 85.67313 10.787344 65.57592 83.39338 89.93654 93.27517 94.06923      0.0 
90    14   Control 8 79.19641 18.431210 47.08430 66.25929 89.59623 91.96700 95.05728    0.0 
91    15   Control 8 76.91885 21.715652 37.73265 60.32011 89.20190 92.69531 94.21560      0.0 
92    16   Control 8 81.89825 13.466915 60.99475 75.45246 86.67831 91.43381 95.19855      0.0 
93    17   Control 8 79.51931 15.187773 54.91580 69.98499 85.23198 90.39581 94.99617      0.0 
94    18   Control 8 80.25832 11.027311 65.36435 72.58363 79.07579 87.64829 95.24870      0.0 
95    19   Control 8 82.78314 11.630069 64.74045 73.51583 83.90374 92.68779 97.01883      0.0 
96    20   Control 8 80.97518 16.702421 49.84027 72.05029 85.05630 94.32206 98.24887      0.0 
97    21   Control 8 77.62676 23.970362 25.00000 71.93528 84.72526 94.62653 97.59203      0.0 
98    22   Control 8 77.10294 19.068132 46.68572 66.94402 85.13542 90.77383 94.81713      0.0 
99    23   Control 8 72.65493 27.009020 25.00000 62.46610 83.70520 91.33266 96.89878      0.0 
100   24   Control 8 71.33827 25.938084 21.98640 57.99663 81.34975 88.75170 96.70305    0.0  
208 
Table 21B. Week 0 Time Moving within 10-Minute Video After-Shadow Raw Data 
   Minute Treatment n      mean        sd      min        Q1    median        Q3     max 
1 1    0.0014 8  7.054583  8.812522  2.34790  3.463065  3.779835  5.257257  28.6826      0.0 
2 2    0.0014 8 20.549537 24.842612  0.00000  0.000000 14.597600 26.907225  62.1032     37.5 
3 3    0.0014 8 34.578154 32.442030  0.00000  1.793422 31.383900 68.488975  72.4995     25.0 
4 4    0.0014 8 45.676674 33.354063  0.00000 18.810098 51.725300 74.766975  81.6487     12.5 
5 5    0.0014 8 44.932199 33.895655  0.00000 10.719547 58.178550 69.608475  85.1972     12.5 
6 6    0.0014 8 48.272112 27.594810  0.00000 29.293850 55.510650 72.056000  76.8106     12.5 
7 7    0.0014 8 59.404356 32.352793  1.39025 35.246050 70.285800 80.846200  96.4966      0.0 
8 8    0.0014 8 59.930363 32.933226  0.00000 42.101525 64.567100 86.125275  98.6097     12.5 
9  9    0.0014 8 40.811138 35.463670  0.00000 12.887625 37.967050 63.430600  90.4351     25.0 
10     10    0.0014 8 25.570914 34.405434  0.00000  2.754863 10.121030 35.097200  80.3953     25.0 
   Minute Treatment n      mean  sd      min  Q1    median        Q3      max 
11 1    0.0028 8 23.335822 18.441127  3.47256 11.923680 17.498900 33.134200  54.2859      0.0 
12 2    0.0028 8 47.975134 38.571128  0.00000 13.374168 49.296900 83.177950  94.2162     12.5 
13 3    0.0028 8 53.221869 36.746644  0.00000 27.763262 64.186350 86.000200  87.0588     12.5 
14 4    0.0028 8 46.092076 37.485057  0.00000  8.714153 53.695500 72.236725  95.1619     12.5 
15 5    0.0028 8 54.156453 36.912326  1.94635 25.416493 64.237500 81.765750  96.9971      0.0 
16 6    0.0028 8 57.137563 31.620256  0.00000 35.471300 65.810300 79.963125  95.6624     12.5 
17 7    0.0028 8 53.577413 35.648335  0.00000 36.212025 66.154150 73.894950  91.6585     25.0 
18 8    0.0028 8 63.121662 37.150171  0.00000 55.067900 74.975500 83.724225  97.6644     12.5 
19 9    0.0028 8 61.178362 18.575846 27.74940 51.608025 63.685800 74.469000  83.4838      0.0 
20     10    0.0028 8 72.550313 25.432095 19.98740 70.433525 79.555000 84.728300 100.0000      0.0 
   Minute Treatment n      mean        sd      min        Q1    median        Q3      max 
21 1     0.014 8 12.419956 15.132710  2.35177  4.315688  5.773840 11.258598  45.6179      0.0 
22 2     0.014 8 33.066412 35.852242  0.00000  0.000000 26.344550 51.882775  93.8961     37.5 
23 3     0.014 8 44.291050 39.649154  0.00000 11.457600 36.848250 81.148250  94.7171     25.0 
24 4     0.014 8 42.307636 42.748130  0.00000  3.890760 32.233955 82.163750  97.5532     12.5 
25 5     0.014 8 38.673113 39.763295  0.00000  0.000000 30.641100 81.838675  84.1512     37.5 
26 6     0.014 8 46.543850 35.443297  0.00000 24.055175 43.343900 79.459950  87.9089     12.5 
27 7     0.014 8 49.589245 32.266275  4.33758 24.047445 58.607700 76.355825  82.7053      0.0 
28 8     0.014 8 57.678799 37.131930  0.00000 38.482098 66.182550 89.624050  92.8263     12.5 
29 9     0.014 8 60.607613 25.188314 25.58840 45.600175 58.896450 75.763875  95.3844      0.0 
30     10     0.014 8 57.049550 39.549311  0.00000 31.491225 70.196350 84.729650 100.0000     25.0 
   Minute Treatment n      mean  sd      min  Q1    median        Q3    max 
31 1   Control 8 16.655685 14.161272  3.44582  8.194220 13.949150 19.133875  48.5133      0.0 
32 2   Control 8 45.163575 37.244351  0.00000  7.163775 52.370000 77.283350  90.7263     25.0 
33 3   Control 8 49.842100 38.090579  0.00000 17.288775 61.817100 81.250200  87.4877     25.0 
34 4   Control 8 34.462987 35.988064  0.00000  0.000000 25.525000 69.220525  80.2612     37.5 
35 5   Control 8 36.164675 39.331405  0.00000  0.000000 31.530850 67.801150  87.9855     50.0 
36 6   Control 8 24.786143 31.972564  0.00000  4.587825 12.484420 29.778425  89.6009     25.0 
37 7   Control 8 35.787650 38.372690  0.00000  0.000000 24.347850 66.828600  90.7687     37.5 
38 8   Control 8 47.400238 41.715628  0.00000  0.000000 60.454700 80.286225  95.3288     37.5 
39 9   Control 8 34.672500 42.485179  0.00000  0.000000 11.212000 76.560425  98.1093     37.5 
40     10   Control 8 37.745615 36.998946  0.00000  5.989590 30.379200 66.684925  94.4315     25.0  
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Table 22B. Week 12 Time Moving within 10-Minute Video After-Shadow Raw Data    
Minute Treatment n     mean       sd      min        Q1   median       Q3      max 
1 1    0.0014 8 36.36104 32.58626  4.20434 11.863725 29.00345 46.86162  99.8263      0.0 
2 2    0.0014 8 57.65826 42.34018  0.00000 21.479325 71.09600 93.52140 100.0000     25.0 
3 3    0.0014 8 74.34790 31.75954  0.00000 78.435850 85.93070 88.29412  99.4439     12.5 
4 4    0.0014 8 70.83855 28.58130 18.81210 49.995300 81.03840 93.00708 100.0000      0.0 
5 5    0.0014 8 67.58962 27.61899 15.35880 49.960250 75.16350 88.41925  95.7180      0.0 
6 6    0.0014 8 51.58225 39.70022  0.00000 16.271950 59.57150 87.65460  89.4660     12.5 
7 7    0.0014 8 57.99855 41.00043  0.00000 27.262725 70.84190 92.13502  98.9990     25.0 
8 8    0.0014 8 71.58460 32.12694  0.00000 67.004675 82.05920 93.64652  95.7736     12.5 
9 9    0.0014 8 62.28615 37.35540  0.00000 37.834725 77.39450 91.76968  97.6088     12.5 
10     10    0.0014 8 75.75408 34.88185  0.00000 70.888450 89.12290 99.76435 100.0000     12.5 
   Minute Treatment n     mean       sd      min Q1   median       Q3      max 
11 1    0.0028 8 44.73887 36.40359  6.19182 14.270430 40.54075 66.18555  96.3371      0.0 
12 2    0.0028 8 45.47970 36.64340  1.66830 13.672797 43.98615 75.87323  94.9395      0.0 
13 3    0.0028 8 54.88839 37.94208  0.00000 25.922250 73.87650 81.56530  89.2673     25.0 
14      4    0.0028 8 60.27560 39.92678  0.00000 34.796025 82.89195 88.80850  91.2136     25.0 
15 5    0.0028 8 71.36415 36.09955  0.00000 66.714125 87.12490 92.21457 100.0000     12.5 
16 6    0.0028 8 75.30585 30.91284  3.78148 75.666725 78.65100 96.39925 100.0000      0.0 
17 7    0.0028 8 65.81514 35.93327  0.00000 44.352975 84.00555 91.43620  96.0517     12.5 
18 8    0.0028 8 62.22656 43.36756  0.00000 26.980650 87.01780 94.87920  97.3863     25.0 
19 9    0.0028 8 70.29863 43.62754  0.00000 64.735875 90.92895 96.59390  99.8332     25.0 
20     10    0.0028 8 77.57694 24.99697 19.94000 75.177125 83.01180 94.64822  96.5295      0.0 
   Minute Treatment n     mean       sd      min Q1   median       Q3      max 
21 1     0.014 8 31.84817 30.65249  4.69143  7.906038 18.65165 51.38595  86.8606      0.0 
22 2     0.014 8 54.16842 38.21324  0.00000 20.087747 68.50355 85.44742  92.1590     12.5 
23 3     0.014 8 64.82900 39.17505  0.00000 60.367922 80.54445 89.82340  94.6058     12.5 
24 4     0.014 8 52.58785 38.88828  0.00000 18.390975 66.10705 85.52953  92.8263     25.0 
25 5     0.014 8 59.11440 38.97619  2.84660 30.810025 63.12395 94.21447  98.2205      0.0 
26 6     0.014 8 64.62014 32.06784  2.60318 47.035475 70.28695 90.56020  96.4729      0.0 
27 7     0.014 8 72.34064 36.03901  0.00000 69.961375 85.27520 96.85805  98.4110     12.5 
28 8     0.014 8 71.63491 32.41526  0.00000 67.644225 87.90480 90.05973  92.6039     12.5 
29 9     0.014 8 71.45652 20.60266 43.93970 51.863750 79.28530 87.83530  93.7717    0.0 
30     10     0.014 8 78.34029 28.35708 19.67070 64.273925 93.63800 96.45642 100.0000      0.0 
   Minute Treatment n     mean       sd      min        Q1   median       Q3      max 
31 1   Control 8 37.12422 29.73121  4.41799 14.248690 32.35075 56.86475  87.9583      0.0 
32 2   Control 8 43.91965 36.38915  0.00000 13.123975 36.06310 82.24058  86.8204     12.5 
33 3   Control 8 46.99340 35.83948  0.00000 19.501250 43.44595 72.84838  99.7484     12.5 
34 4   Control 8 55.73476 31.62832  0.00000 35.344100 58.36790 81.71630  95.0507     12.5 
35 5   Control 8 68.37911 19.55959 38.87410 57.511925 69.98655 84.64108  89.5453      0.0 
36      6   Control 8 65.81011 30.78739  9.78736 52.779800 72.47305 88.51845  98.6654      0.0 
37 7   Control 8 62.24046 28.93150 26.34050 34.088225 62.12300 89.92465  97.4419      0.0 
38 8   Control 8 73.72725 20.04755 49.17250 53.636425 77.05155 89.62875  97.3307      0.0 
39 9   Control 8 73.11689 25.76753 24.75420 62.219125 80.28625 91.11630  98.3873      0.0 
40     10   Control 8 67.16084 41.94856  0.00000 57.275700 89.40965 90.56640 100.0000     25.0  
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   Minute Treatment n     mean       sd      min  Q1   median Q3      max 
1 1    0.0014 8 42.71644 26.34695  5.60885 20.7467000 44.54990 61.56995  79.7437 
2 2    0.0014 8 49.62593 30.67773  4.78246 26.5008000 50.54810 78.83310  86.7780 
3 3    0.0014 8 53.40280 34.83598  0.00000 31.4507250 55.17970 84.78338  93.1044 
4 4    0.0014 8 46.18308 33.07806  0.00000 24.7021250 43.99275 73.71228  90.6019 
5 5    0.0014 8 63.63340 26.96963 27.08480 44.9573500 60.14885 88.33378  95.3844 
6 6    0.0014 8 66.17321 32.16921  0.00000 56.4202000 71.38865 91.49165  96.7746 
7 7    0.0014 8 59.10482 36.98236  0.00000 36.9164750 64.57645 87.00585 100.0000 
8 8    0.0014 8 55.91090 23.58413 28.54660 38.7310000 48.45500 71.99568  92.7151 
9 9    0.0014 8 62.20931 25.50118 25.81080 46.5255500 58.67515 87.98825  92.1034 
10     10    0.0014 8 69.07805 33.98542  5.12091 58.2248750 80.63315 93.01448 100.0000 
   Minute Treatment n     mean       sd      min Q1   median Q3      max 
11 1    0.0028 8 35.71439 38.49012  0.00000  6.2261425 17.31881 66.86052  98.3317 
12 2    0.0028 8 45.30261 41.29431  0.00000  0.0000000 52.19660 71.85738 100.0000 
13 3    0.0028 8 55.59774 39.18504  0.00000 24.1903725 64.49435 88.65552 100.0000  
14 4    0.0028 8 52.81327 43.74314  0.00000  5.9641725 67.85880 86.22057 100.0000 
15 5    0.0028 8 56.36301 35.31205 10.78830 23.9427250 59.48675 86.26435 100.0000 
16 6    0.0028 8 62.03397 35.43682  0.00000 38.4523750 70.94785 89.61095 100.0000 
17 7    0.0028 8 63.93328 41.34348  0.00000 44.9012250 82.11480 91.87682 100.0000 
18 8    0.0028 8 66.46055 31.56446  0.00000 57.3205750 72.10770 85.88882 100.0000 
19 9    0.0028 8 59.48247 38.69676  0.00000 39.6279675 63.65225 94.34165 100.0000 
20     10    0.0028 8 53.46015 41.26088  0.00000 16.2901500 64.42600 88.25485 100.0000 
   Minute Treatment n     mean       sd      min Q1   median Q3      max 
21 1     0.014 8 38.27962 28.11205  2.13597 23.2525250 37.95270 45.21845  93.4113 
22 2     0.014 8 59.21075 31.07936  5.00490 37.6764500 67.05110 77.67588  94.7462 
23 3     0.014 8 62.77901 29.72384 12.67910 48.5150250 66.24335 88.75880  94.0762 
24 4     0.014 8 60.99425 31.18656  0.38927 46.9527250 65.41190 81.63685  94.2166 
25 5     0.014 8 54.93073 36.59075  0.00000 21.3707750 64.37905 82.98337  98.2761 
26 6     0.014 8 65.34574 29.97214  9.12004 49.3182000 72.55650 87.70628 100.0000 
27 7     0.014 8 63.02430 29.12341 21.35420 47.0830250 63.82840 83.73405  99.2771      0.0 
28 8     0.014 8 57.33521 33.33947  0.00000 42.7906250 57.45175 76.58818 100.0000     12.5 
29 9     0.014 8 58.49511 33.47726  0.00000 41.8484500 54.72570 89.89288  96.6078     12.5 
30     10     0.014 8 60.69216 33.91295  0.00000 39.9346750 65.05890 89.12620  98.4258     12.5 
   Minute Treatment n     mean       sd      min Q1   median Q3      max 
31 1   Control 8 13.08912 16.32935  0.00000  1.7803100  7.86073 18.34255  48.5007     12.5 
32 2   Control 8 32.96247 21.34599  0.00000 20.2069250 31.38520 47.31683  63.1862     12.5 
33 3   Control 8 41.93490 38.38064  0.00000  0.2721225 49.72195 63.01608  97.7200     25.0 
34 4   Control 8 59.42983 34.88685  0.00000 39.2699000 67.75805 83.02697 100.0000     12.5 
35 5   Control 8 69.53101 25.48676 31.53090 46.3780750 78.89600 88.62772 100.0000      0.0 
36 6   Control 8 67.38709 25.91689 12.58110 68.9557250 79.29465 82.10750  83.3726      0.0 
37 7   Control 8 67.16827 24.30426 31.11790 45.4328250 74.60740 87.16003  92.8819      0.0 
38 8   Control 8 55.35547 34.07239  0.00000 32.9911750 67.47360 77.30120  95.8293     12.5 
39 9   Control 8 55.16604 36.25839  0.00000 32.1344750 62.12685 82.67340  97.2195     12.5 
40     10   Control 8 68.99095 30.94909  0.00000 69.4370000 74.79060 82.57375  98.3704     12.5  
Table 23B. Week 24 Time Moving within 10-Minute Video After-Shadow Raw Data 
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APPENDIX C: Threat Avoidance Behavior 
Fig. 1C. Control Group Threat Avoidance Behavior 
212 
Fig. 2C. 0.0014 ppm Mn2+ Treatment Threat Avoidance Behavior 
213 
Fig. 3C. 0.0028 ppm Mn2+ Treatment Threat Avoidance Behavior 
214 
Fig. 4C. 0.014 ppm Mn2+ Treatment Threat Avoidance Behavior 
215 
Table 1C. Matrix of Threat Avoidance Response 
Control 0.0014 ppm 0.0028 ppm 0.014 ppm
Week Defensive Tailflip Tailflip (Multiple) Flee Freeze Startle Week Defensive Tailflip Tailflip (Multiple) Flee Freeze Startle Week Defensive Tailflip Tailflip (Multiple) Flee Freeze Startle Week Defensive Tailflip Tailflip (Multiple) Flee Freeze Startle
0 1 7 0 2 6 0 1 1 1 5 0 2 6
1 2 1 5 1 1 1 6 1 1 1 1 1 4 1 1 2 5
2 1 1 1 5 2 2 1 5 2 1 1 6 2 1 7
3 1 1 1 1 4 3 1 1 6 3 3 1 4 3 8
4 2 1 5 4 1 1 6 4 1 1 6 4 1 1 6
5 2 6 5 3 5 5 2 2 4 5 2 1 1 4
6 1 1 1 1 4 6 1 1 1 5 6 1 2 5 6 8
7 1 1 6 7 1 2 5 7 1 7 7 1 1 1 1 4
8 1 3 2 2 8 1 1 6 8 1 1 2 4 8 3 1 4
9 1 1 1 5 9 1 1 6 9 2 2 4 9 1 2 1 2 2
10 1 1 2 4 10 1 1 6 10 2 1 5 10 2 1 5
11 1 1 3 3 11 3 5 11 2 2 4 11 1 7
12 1 1 1 1 4 12 1 1 1 5 12 3 1 2 2 12 3 5
13 2 1 2 3 13 1 1 6 13 1 1 6 13 1 1 6
14 1 1 6 14 2 2 4 14 4 1 3 14 1 2 5
15 1 2 5 15 1 1 6 15 1 3 4 15 2 1 3 2
16 2 1 3 2 16 1 1 6 16 1 1 6 16 1 7
17 1 1 3 3 17 3 2 2 1 17 2 2 4 17 2 1 1 4
18 1 3 4 18 2 1 1 4 18 1 3 4 18 1 2 2 3
19 1 2 5 19 1 2 5 19 2 1 3 2 19 1 3 4
20 1 1 1 3 2 20 1 1 2 4 20 1 1 4 2 20 1 1 1 5
21 1 1 3 3 21 1 2 5 21 3 5 21 2 6
22 5 3 22 1 3 4 22 1 5 2 22 1 2 5
23 1 1 2 4 23 2 2 4 23 2 5 1 23 2 1 2 3
24 5 3 24 1 2 1 4 24 2 3 3 24 5 3
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 Table 2C. Threat Avoidance Behavior Kruskal Wallis P-values 
General Antipredator Behavior (defensive, stopping, escape) 
Week 0 Week 1 Binned Weeks 1-4 Binned Weeks 9-12 Binned Weeks 21-
24 
0.28 0.93 0.19 0.96 0.70 
Subcategorized Antipredator Behavior (defensive, startle, freeze, flee, tail-flip, and multiple 
tail-flip) 
Week 0 Week 1 Binned 
Weeks 1-4 
Binned Weeks 9-12 Binned Weeks 21-
24 
0.22 0.81 0.29 0.64 0.31 
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Table 3C. Kruskal Wallis and Post-hoc P-values for Individual Threat Avoidance Behavior 








0.73 0.64 0.33 0.37 0.14 
Freeze 0.37 0.11 0.78 0.037* 0.059 
Defensive 0.44 0.39 0.1 0.39 N/A 
Flee 0.31 0.39 0.56 1 0.32 
Tail-flip 0.31 0.87 0.28 0.74 0.52 
Multiple 
tail-flip 
0.39 N/A 0.26 0.32 0.39 
*Dunn’s Test Multiple Pairwise Comparison P-values (Kruskal Wallis Post hoc)
Comparison  Z P.unadj P.adj
0.0014ppm - 0.0028ppm  2.2589109  0.023888926  0.11944463 
0.0014ppm - 0.014ppm  1.1294555  0.258705747  0.77611724 
0.0028ppm - 0.014ppm  1.1294555  0.258705747  0.51741149 
0.0014ppm – Control  2.6353961  0.008403915  0.05042349 
0.0028ppm – Control  0.3764852  0.706556250  0.70655625 
0.014ppm – Control  1.5059406  0.132082418  0.52832967 
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Table 4C. Friedman Test (Repeated Measures) P-values for Threat Avoidance Behavior 
General Antipredator Behavior (defensive, stopping, escape) 
Control 0.0014 ppm Mn2+ 0.0028 ppm Mn2+ 0.014 ppm Mn2+ 
0.87 0.37 0.15 0.06 
Subcategorized Antipredator Behavior (defensive, startle, freeze, flee, tail-flip, and multiple 
tail-flip) 
Control 0.0014 ppm Mn2+ 0.0028 ppm Mn2+ 0.014 ppm Mn2+ 
0.44 0.79 0.04* 0.01* 
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Table 5C. Tail-flip Latency in Seconds (*grey represents multiple-flexions) 
Week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Control
#7A 0.034 0.367 -0.134 0.034 -0.2 -0.133 0.201 0.033 0.3 -0.1 0.267 0.034 -0.067 0.067 0




#17 0.033 0.333 -0.034 0.067 0.1 0.267 0.1 0.233
week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
0.0014 ppm
#2 0.067
#8 -0.033 0.034 0.033 0.033 0.101
#9 -0.175 0.234 -0.103 -0.067 0.1 0.1
#20 0.033 0.1 0.034
#24 0.2 0.101 0.033 0.033
#25A 0 0 0 0.067 0.034 -0.067 -0.034 0 0 0.1
#14B 0 -0.034 0.067 0.1 0.067 0.101 0.067
week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
0.0028 ppm
#23 0.033 0.1 0.233 0.1 0
#29 0.067 0.067
#32 -0.033 0.066 0.1 0.067 0.067
#3A 0 0.067 -0.267 -0.034 0.067 0 0.06
#1A 0.134 0.2 0.133 0.1
#4A -0.101 0.034 0.1 0.067 0.033
#13A 0.1 0.1
#18C 0.067
week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
0.014 ppm
#10 0 0.201 0.233
#15 0 0.067 0.033 0.033 -0.034
#22 0.467 0.034 0.1
#28 0.067 -0.167 0 0.133 0.101 0.033 0.033 0.1
#30 0.033
#31A 0.033 0.033 0.067
#26A 0
